ticlopidine has been researched along with Blood Clot in 938 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 9.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "The aim of this study was the identification of the optimal cutoff value of high residual platelet reactivity (HRPR) assessed by light transmission aggregometry (LTA) in the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) patient cohort to discriminate patients with and without major adverse cardiac events (MACE) and cardiac death at 2 years." | 9.20 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st ( Abbate, R; Antoniucci, D; Cantini, G; Capodanno, D; Carrabba, N; De Luca, G; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Paniccia, R; Parodi, G; Valenti, R, 2015) |
| "Diabetes mellitus (DM) is associated with impaired platelet response to clopidogrel." | 9.19 | Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. ( Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2014) |
| " In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) reduced the primary composite end point of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding." | 9.16 | Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L, 2012) |
| "In this prospective, randomized trial in patients with acute myocardial infarction (AMI) admitted for primary percutaneous coronary intervention (PPCI), loaded with 600 mg clopidogrel, we hypothesized that eptifibatide administered downstream of the coronary occlusion leads to a lower degree of microvascular obstruction compared with no additional eptifibatide." | 9.16 | Microvascular effect of intracoronary eptifibatide in acute myocardial infarction. ( Bondor, CI; Cadiş, H; Iancu, A; Ober, C, 2012) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 9.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "Clopidogrel low-responsiveness assessed with multiple electrode platelet aggregometry (MEA) has been shown to be a strong and independent predictor of early stent thrombosis (ST) after coronary stenting." | 9.14 | Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N, 2010) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 9.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 9.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding." | 9.13 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008) |
| "It was the objective of this study to compare the antithrombotic effects and bleeding profiles of the oral direct thrombin inhibitor ximelagatran, an anticoagulant, and the antiplatelet agent clopidogrel on top of steady-state acetylsalicylic acid (ASA) in a human arterial thrombosis model." | 9.12 | Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. ( Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K, 2006) |
| "The VERIfy Thrombosis risk ASsessment (VERITAS) was a prospective study designed to measure platelet response to clopidogrel therapy in subjects with multiple risk factors or history of vascular disease using this novel point-of-care assay." | 9.12 | Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. ( Atar, D; Defranco, A; Mahmud, E; Malinin, A; Pokov, A; Schwartz, D; Schwartz, K; Serebruany, V; Spergling, M, 2007) |
| " Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months." | 9.12 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 9.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "Six months of clopidogrel and aspirin and a reduction in re-stenting for patients with in-stent restenosis treated with gamma-radiation is well tolerated and associated with a reduction in the late thrombosis rate compared with a similar cohort treated with only 1 month of clopidogrel and aspirin." | 9.09 | Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). ( Ajani, AE; Bui, AB; Dieble, R; Gruberg, L; Kent, KK; Lindsay, J; Mintz, GS; Pichard, AD; Pinnow, E; Satler, LF; Taaffe, M; Waksman, R; White, RL, 2001) |
| "In this multicenter trial 169 patients with chronic intermittent claudication due to obstructive peripheral vascular disease were randomized in a double-blind fashion into two parallel groups receiving either 250 mg ticlopidine or placebo, twice daily." | 9.06 | Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. ( Arcan, JC; Blanchard, J; Boissel, JP; Destors, JM; Panak, E, 1988) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 8.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 8.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well." | 8.88 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 8.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| " The drug is widely used in combination with aspirin for the prevention of atherothrombosis after placement of intravascular stents, and available data suggest that this combination is as effective as ticlopidine plus aspirin for this indication." | 8.80 | Clopidogrel: a review of its use in the prevention of atherothrombosis. ( Jarvis, B; Simpson, K, 2000) |
| "The present case demonstrates that both diabetes mellitus and carriage of CYP2C19*2 allele are associated with a reduced response to clopidogrel in the setting of this standard dose of clopidogrel and a high risk of stent thrombosis." | 7.96 | Subacute stent thrombosis in a patient with type 2 diabetes and clopidogrel resistance: A case report . ( Cao, SP; Zheng, P; Zhong, HL; Zhou, MC, 2020) |
| "The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown." | 7.88 | Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. ( Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E, 2018) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)." | 7.83 | Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016) |
| "Stent thrombosis (ST) is considered as a multifactorial problem which is mostly occurs due to clopidogrel resistance." | 7.83 | Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. ( Avcilar, T; Cetin, SE; Emre, A; Erdem, A; Guney, AI; Isbir, T; Kaspar, EC; Kirac, D; Terzi, S; Yazici, S; Yesilcimen, K, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 7.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice." | 7.80 | In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. ( Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y, 2014) |
| "Ticagrelor has been promoted to reduce the rate of definite stent thrombosis compared to clopidogrel from the The Platelet Inhibition and Patient Outcomes (PLATO) trial." | 7.79 | Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports. ( Biondi-Zoccai, G; Dinicolantonio, JJ, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 7.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel." | 7.79 | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 7.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| " This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery." | 7.78 | Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012) |
| "Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far." | 7.78 | Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. ( Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T, 2012) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 7.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| "This case report describes recurrent drug-eluting stent thrombosis with documented laboratory hyporesponsiveness to clopidogrel." | 7.78 | Failure of high-dose clopidogrel in recurrent stent thrombosis. ( Chan, MY; Li, Y, 2012) |
| "Our data on the inhibitory effect of rivaroxaban alone or with DAT are consistent with the ATLAS 2 trial findings, and support its potential use for preventing stent thrombosis after stent deployment." | 7.78 | Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. ( Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E, 2012) |
| "Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis." | 7.77 | Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( Byron, KA; Dear, AE; Dick, RJ, 2011) |
| "Ticagrelor has been shown to be superior to clopidogrel in patients presenting with acute myocardial infarction who undergo early invasive treatment." | 7.77 | The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. ( Chauhan, A; More, RS; Morgan, KP, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention with the deployment of a coronary stent." | 7.77 | [Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?]. ( Ardissino, D; Conte, G; Demola, MA; Giacalone, R; Mantovani, F; Marziliano, N; Notarangelo, MF, 2011) |
| "The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI." | 7.76 | Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 7.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "The new P2Y(12) antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding." | 7.75 | Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. ( Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC, 2009) |
| "The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST)." | 7.75 | Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N, 2009) |
| " In rat and dog models of thrombosis/hemostasis, there was greater separation between doses that provided antithrombotic effect and those that increased bleeding for ticagrelor compared with clopidogrel and compound 072, a chemical compound indistinguishable from the prasugrel parent compound." | 7.75 | Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. ( Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H, 2009) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 7.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent (DES) implantation." | 7.74 | Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. ( Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2008) |
| "We describe a case of fatal stent thrombosis after Carbostent implantation and clopidogrel alone antiplatelet therapy in a patient affected by rectal cancer who does not tolerate aspirin." | 7.74 | A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy? ( Altamura, L; Crea, F; De Vita, M; Ferrante, G; Fusco, B; Leone, AM; Niccoli, G; Rebuzzi, AG; Siviglia, M, 2007) |
| "To evaluate the effect of clopidogrel on the rate of thrombosis in a rat model for venous microvascular failure." | 7.74 | Clopidogrel (Plavix) reduces the rate of thrombosis in the rat tuck model for microvenous anastomosis. ( Deschler, DG; Moore, MG, 2007) |
| "Nonresponsiveness to clopidogrel is a strong independent predictor of stent thrombosis in patients receiving sirolimus- or paclitaxel-eluting stents." | 7.74 | Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Gori, AM; Marcucci, R; Migliorini, A; Moschi, G; Paniccia, R; Santini, A, 2007) |
| "The incidence of stent thrombosis was evaluated in 1,029 patients receiving ticlopidine and aspirin after SES deployment." | 7.74 | Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation. ( Fujimoto, Y; Himi, T; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T, 2008) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 7.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "The pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on acute thrombosis and chronic neointima formation after vascular injury have been investigated." | 7.73 | Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice. ( Hayashi, K; Kawasaki, T; Moritani, Y; Nagai, K; Saito, T; Shigenaga, T; Takamatsu, H; Takasaki, J; Taniguchi, M; Uemura, T, 2005) |
| "Of 33 arteries, 19 (58%) in the control group developed complete thrombosis by the end of the period compared with only 6 (19%) of 32 arteries in the group that received clopidogrel." | 7.73 | Clopidogrel use for reducing the rate of thrombosis in a rat model of microarterial anastomosis. ( Deschler, DG; Nayak, VK, 2005) |
| " All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy." | 7.73 | [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006) |
| "Dual antiplatelet therapy with aspirin and clopidogrel decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)." | 7.72 | Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. ( Besta, F; Gawaz, M; Massberg, S; Müller, I; Schönig, A; Schulz, C, 2003) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 7.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 7.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "Ticlopidine (250 mg twice daily) was administered to human volunteers for seven days and the response of their heparinized platelet-rich plasma to SKNMC (ADP-dependent) human neuroblastoma cells was examined." | 7.67 | Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. ( Almirall, L; Bastida, E; Escolar, G; Ordinas, A, 1986) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 6.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 6.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Cangrelor is an intravenous, reversibly-binding platelet P2Y12 receptor antagonist with ultra-rapid onset and offset of action that is approved in Europe and United States for use in patients undergoing PCI." | 6.53 | Cangrelor for the management and prevention of arterial thrombosis. ( Sinha, A; Storey, RF, 2016) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 6.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| " Long-term administration of clopidogrel was associated with a modest but statistically significant advantage over aspirin in reducing adverse cardiovascular outcomes in patients with established cardiovascular disease in the CAPRIE trial." | 6.44 | Clopidogrel: a review of its use in the prevention of thrombosis. ( Lyseng-Williamson, KA; Plosker, GL, 2007) |
| "Ticagrelor is an adenosine diphosphate (ADP) receptor antagonist antithrombotic that can inhibit ADP-dependent platelet activation and aggregation." | 5.62 | The effect of ticagrelor on microarterial thrombosis in an experimental model. ( Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A, 2021) |
| " Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents." | 5.46 | In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. ( Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M, 2017) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 5.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| " However, unlike other medications, subtle differences in clopidogrel bioavailability may lead to acute consequences including stent thrombosis (ST)." | 5.40 | Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. ( Baber, U; Badimon, JJ; Hulot, JS; Kini, A; Kovacic, JC; Krishnan, P; Li, JR; Mehran, R; Moreno, P; Sharma, SK; Sweeny, J, 2014) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 5.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective." | 5.40 | Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014) |
| "Obesity is associated with a prothrombotic state resulting from increased thrombin generation, platelet hyper-reactivity, and decreased fibrinolysis." | 5.39 | Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. ( Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S, 2013) |
| "Dyspnea was diagnosed in 157 (4." | 5.35 | Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. ( Atar, D; Kuliczkowski, W; Pokov, I; Serebruany, V; Vahabi, J, 2008) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 5.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| "Ferric chloride has been widely used to induce arterial thrombosis in a variety of species." | 5.33 | An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. ( Wang, X; Xu, L, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Clopidogrel reduces arterial thrombus cohesion by an effect that correlates with inhibition of ADP-induced platelet aggregation." | 5.32 | Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. ( Bal dit Sollier, C; Berge, N; Bergmann, JF; Drouet, L; Mahé, I; Simoneau, G, 2003) |
| "The process of thrombus formation was investigated by electron microscopic study." | 5.28 | Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. ( Iwamoto, M; Kumada, T; Morishita, K; Tanaka, T; Tomikawa, M; Wada, M, 1991) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| "In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly patients increased the risk of bleeding, without affording a significant prevention of ischaemic events." | 5.24 | Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. ( Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S, 2017) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 5.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "A total of 55 patients with a history of thrombosis and SPS phenotype were prospectively studied before and after treatment with aspirin and/or clopidogrel." | 5.20 | Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome. ( García-Chavez, J; Hernández-Reyes, J; Rosales-Padrón, J; Ruiz-Arguelles, A; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vargas-Espinosa, J; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G, 2015) |
| "The aim of this study was the identification of the optimal cutoff value of high residual platelet reactivity (HRPR) assessed by light transmission aggregometry (LTA) in the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) patient cohort to discriminate patients with and without major adverse cardiac events (MACE) and cardiac death at 2 years." | 5.20 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st ( Abbate, R; Antoniucci, D; Cantini, G; Capodanno, D; Carrabba, N; De Luca, G; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Paniccia, R; Parodi, G; Valenti, R, 2015) |
| "Previous studies evaluating correlates of stent thrombosis (ST) have included mostly patients with bare metal stents and early-generation drug-eluting stents (DES) and have not systematically evaluated the role of intravascular ultrasound-guided stenting and high platelet reactivity on clopidogrel." | 5.20 | Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. ( Brodie, BR; Garg, A; Kirtane, AJ; Maehara, A; Mehran, R; Metzger, DC; Neumann, FJ; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2015) |
| "Diabetes mellitus (DM) is associated with impaired platelet response to clopidogrel." | 5.19 | Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. ( Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2014) |
| "(1) PF4/H antibody-positive patients suffered a significantly higher incidence of thrombosis than those who were antibody-negative; (2) PF4/H antibody-positive patients who survived a thrombosis manifested a significantly longer bleeding time and decreased maximum percentage of platelet aggregation inhibition; (3) aspirin and clopidogrel decreased the incidence of thrombosis in PF4/H antibody-positive patients by inhibiting platelet activation." | 5.19 | Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients. ( Chen, G; Kong, D; Ma, L; Qi, K; Shan, F; Wang, C; Yang, Y, 2014) |
| "Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding." | 5.19 | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW, 2014) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| "Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding." | 5.17 | Effect of platelet inhibition with cangrelor during PCI on ischemic events. ( Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P, 2013) |
| "The results indicate that tirofiban and warfarin combined with aspirin and clopidogrel could reduce the rates of MACCE and bleeding, and it could prevent non-acute stent thrombosis safely and effectively after percutaneous coronary intervention with DES." | 5.17 | [Prevention of non-acute stent thrombosis after drug-eluting stent implantation]. ( Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291)." | 5.17 | Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. ( Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L, 2013) |
| "Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and currently used for prevention of stent thrombosis." | 5.16 | The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. ( Azarpira, N; Khalili, A; Kojuri, J; Namazi, S, 2012) |
| "A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
| "In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common." | 5.16 | A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC ( Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U, 2012) |
| "Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 5.16 | The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. ( de la Peña, NC; Isordia-Salas, I; Olalde-Román, MJ; Santiago-Germán, D; Valencia-Sánchez, JS, 2012) |
| " In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) reduced the primary composite end point of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding." | 5.16 | Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L, 2012) |
| "In this prospective, randomized trial in patients with acute myocardial infarction (AMI) admitted for primary percutaneous coronary intervention (PPCI), loaded with 600 mg clopidogrel, we hypothesized that eptifibatide administered downstream of the coronary occlusion leads to a lower degree of microvascular obstruction compared with no additional eptifibatide." | 5.16 | Microvascular effect of intracoronary eptifibatide in acute myocardial infarction. ( Bondor, CI; Cadiş, H; Iancu, A; Ober, C, 2012) |
| " Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard-dose clopidogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis." | 5.15 | Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. ( Angiolillo, DJ; Aragon, JR; Berger, PB; Bertrand, OF; Cannon, CP; Garratt, KN; Kandzari, DE; Lee, MS; Manoukian, SV; Price, MJ; Puri, S; Robbins, M; Schork, NJ; Spriggs, D; Stillablower, ME; Stillabower, ME; Stinis, CT; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 5.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "The goal of this study was to investigate whether omega-3 polyunsaturated fatty acids (n-3 PUFA) are able to alter plasma fibrin clot properties and reduce thrombin formation in stable coronary artery disease patients undergoing percutaneous coronary intervention (PCI)." | 5.15 | Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). ( Gajos, G; Nessler, J; Piwowarska, W; Rostoff, P; Undas, A; Zalewski, J, 2011) |
| "In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce cardiovascular events compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention, defined as OTR ≥230 P2Y12 reaction units according to the VerifyNow P2Y12 platelet function test." | 5.15 | Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. ( Angiolillo, DJ; Berger, PB; Cannon, CP; Lillie, E; Manoukian, SV; Price, MJ; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011) |
| " The elderly have an increased risk of (temporary) discontinuation of clopidogrel, which is associated with a higher risk of developing stent thrombosis (ST)." | 5.15 | Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients. ( Beijk, M; Damman, P; de Winter, RJ; Iñiguez, A; Klomp, M; Ribeiro, EE; Silber, S; Sim, KH; Suryapranata, H; Tijssen, JG; Woudstra, P, 2011) |
| "This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications." | 5.14 | The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting." | 5.14 | Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009) |
| "Thirty-two high risk acute coronary syndrome patients were randomised to bivalirudin and provisional GPIIb/IIIa inhibition (GPIIb/IIIa) or unfractionated heparin (UFH) and mandatory GPIIb/IIIa." | 5.14 | A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu ( Bett, N; Juneja, M; Ray, MJ; Walters, DL, 2009) |
| "Clopidogrel low-responsiveness assessed with multiple electrode platelet aggregometry (MEA) has been shown to be a strong and independent predictor of early stent thrombosis (ST) after coronary stenting." | 5.14 | Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N, 2010) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 5.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 5.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding." | 5.13 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008) |
| "1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study." | 5.13 | Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. ( Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2008) |
| "Intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel." | 5.13 | Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi ( Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD, 2008) |
| "Clopidogrel reduces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proportion of fistulas that become suitable for dialysis." | 5.13 | Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. ( Allon, M; Beck, GJ; Braden, GL; Davidson, IJ; Delmez, JA; Dember, LM; Dixon, BS; Feldman, HI; Gassman, JJ; Greenberg, A; Greene, T; Himmelfarb, J; Ikizler, TA; Kaufman, JS; Kusek, JW; Meyers, CM; Radeva, MK; Rocco, MV; Vazquez, MA, 2008) |
| "It was the objective of this study to compare the antithrombotic effects and bleeding profiles of the oral direct thrombin inhibitor ximelagatran, an anticoagulant, and the antiplatelet agent clopidogrel on top of steady-state acetylsalicylic acid (ASA) in a human arterial thrombosis model." | 5.12 | Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. ( Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K, 2006) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "The VERIfy Thrombosis risk ASsessment (VERITAS) was a prospective study designed to measure platelet response to clopidogrel therapy in subjects with multiple risk factors or history of vascular disease using this novel point-of-care assay." | 5.12 | Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. ( Atar, D; Defranco, A; Mahmud, E; Malinin, A; Pokov, A; Schwartz, D; Schwartz, K; Serebruany, V; Spergling, M, 2007) |
| " Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months." | 5.12 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "Low-response to the P2Y12 adenosine diphosphate (ADP)-receptor antagonist clopidogrel was suggested to correspond to a higher incidence of stent thrombosis (ST)." | 5.12 | The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. ( Blindt, R; de Taeye, A; Hoffmann, R; Kelm, M; Kiefer, P; Müller, R; Stellbrink, K; Weber, C; Yagmur, E, 2007) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Clopidogrel combined to aspirin reduces the early risk of stent thrombosis and a clopidogrel pre-treatment strategy is associated with a better outcome." | 5.11 | Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bernardo, E; Escaned, J; Fernandez-Ortiz, A; Hernández-Antolín, R; Macaya, C; Moreno, R; Ramírez, C; Sabaté, M, 2004) |
| "The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study was designed to evaluate the efficacy and safety of clopidogrel plus aspirin versus placebo plus aspirin in patients with established coronary, cerebral, or peripheral arterial disease or in patients with multiple risk factors for atherothrombosis who have not yet sustained an ischemic event." | 5.11 | Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. ( Bhatt, DL; Topol, EJ, 2004) |
| "Measuring clopidogrel responsiveness may overestimate the risk of stent thrombosis in nonresponders with low pretreatment reactivity and underestimate risk in those responders who remain with high posttreatment platelet reactivity." | 5.11 | The difference between clopidogrel responsiveness and posttreatment platelet reactivity. ( Bliden, KP; Gurbel, PA; Samara, WM; Tantry, US, 2005) |
| "Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate." | 5.11 | Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 5.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure." | 5.09 | Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999) |
| "Combined therapy with abciximab and ticlopidine has a prolonged inhibitory effect on mural thrombosis formation relative to either treatment alone." | 5.09 | Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. ( Effron, MB; Fredrickson, BJ; Graziadei, N; Kleiman, NS; Maresh, K; Mascelli, MA; McIntire, LV; Turner, NA, 2000) |
| "We conducted a double-blind, randomized, crossover study to assess the antithrombotic effects of the combination of aspirin (acetylsalicylic acid, ASA) and clopidogrel, with or without a loading dose, versus ASA alone in a model of arterial thrombosis in humans." | 5.09 | Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. ( Boneu, B; Bossavy, JP; Cadroy, Y; Sagnard, L; Sakariassen, K; Thalamas, C, 2000) |
| "Six months of clopidogrel and aspirin and a reduction in re-stenting for patients with in-stent restenosis treated with gamma-radiation is well tolerated and associated with a reduction in the late thrombosis rate compared with a similar cohort treated with only 1 month of clopidogrel and aspirin." | 5.09 | Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). ( Ajani, AE; Bui, AB; Dieble, R; Gruberg, L; Kent, KK; Lindsay, J; Mintz, GS; Pichard, AD; Pinnow, E; Satler, LF; Taaffe, M; Waksman, R; White, RL, 2001) |
| "Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present." | 5.08 | Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. ( Albiero, R; Blengino, S; Colombo, A; Ferraro, M; Hall, P; Itoh, A; Martini, G; Nakamura, S, 1997) |
| "As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone." | 5.08 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998) |
| "EMATAP, a randomized stratified, placebo-controlled double-blind multicentre trial was performed in Argentina in order to confirm the effect of ticlopidine in the prevention of thrombotic events in patients with intermittent claudication." | 5.07 | Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. ( Blanchard, J; Carreras, LO; Kindermans, M, 1994) |
| "In this multicenter trial 169 patients with chronic intermittent claudication due to obstructive peripheral vascular disease were randomized in a double-blind fashion into two parallel groups receiving either 250 mg ticlopidine or placebo, twice daily." | 5.06 | Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. ( Arcan, JC; Blanchard, J; Boissel, JP; Destors, JM; Panak, E, 1988) |
| " A 5-day course of ticlopidine HCl immediately before surgery results in a significant reduction in the thrombopenia usually observed and attributed to platelet aggregation and adhesion to the apparatus." | 5.05 | [Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)]. ( Curtet, JM; Guilmet, D; Renner, C, 1980) |
| " The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events." | 4.95 | The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017) |
| "The purpose of this review is to update our current knowledge and understanding of the pharmacogenetic basis for poor clopidogrel responsiveness in patients undergoing CAS and endovascular interventions as well as to explore usefulness of genotyping to reduce the rate of procedure-related thrombosis that results in ischemic complications." | 4.95 | Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. ( Duconge, J; Hernandez-Suarez, DF, 2017) |
| "Despite the demonstrated benefits of Prasugrel, a new generation thienopyridine, in the prevention of thrombotic complications after percutaneous coronary interventions (PCI) for Acute Coronary Syndromes (ACS), its use is still precluded to those many patients arriving to the cath lab pre-treated with Clopidogrel." | 4.93 | Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. ( Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M, 2016) |
| "High on-clopidogrel platelet reactivity (HcPR) during dual-antiplatelet therapy is a marker of vascular risk, in particular stent thrombosis, in patients with acute coronary syndromes (ACS)." | 4.93 | On-treatment platelet reactivity: State of the art and perspectives. ( Giusti, B; Grifoni, E; Marcucci, R, 2016) |
| " Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes." | 4.93 | The pharmacodynamics of antiplatelet compounds in thrombosis treatment. ( Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 4.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 4.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "Based on this meta-analysis, we did not find any difference in the risk of the primary composite efficacy endpoint of all-cause death, ischaemia-driven revascularisation, and myocardial infarction at 48hours between cangrelor and clopidogrel use." | 4.90 | Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis. ( Aryal Pandit, A; Aryal, MR; Hakim, FA; Jalota, L; Lee, HR; Mookadam, F; Pandit, A; Tleyjeh, IM, 2014) |
| "Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel." | 4.90 | Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014) |
| "Clopidogrel is one of the most commonly prescribed medications and is currently recommended along with aspirin as treatment to be used for 1 year in all patients without contraindications following an acute coronary syndrome." | 4.89 | Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review. ( Finkel, JB; Marhefka, GD; Weitz, HH, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Clopidogrel is an oral tyenopiridin with a central role in the management of acute coronary syndromes and after stent implantation." | 4.89 | What's new about clopidogrel. ( Biasucci, LM; Camaioni, C; Cialdella, P; Gustapane, M, 2013) |
| " The platelet inhibitory effect of the thienopyridine clopidogrel varies widely among individuals, and high on-treatment platelet reactivity has been associated with a substantial hazard for post-PCI cardiovascular events, including stent thrombosis." | 4.89 | Platelet function monitoring and clopidogrel. ( Harper, AR; Price, MJ, 2013) |
| "Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients." | 4.89 | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013) |
| "Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well." | 4.88 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| " Premature withdrawal of dual antiplatelet therapy carries a substantial risk of stent thrombosis but perioperative continuation of dual antiplatelet therapy is associated with an increased risk of bleeding, particularly in patients treated with the new potent drugs prasugrel and ticagrelor." | 4.88 | [Platelet function: new drugs, new assays : possible impacts on operative medicine?]. ( Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F, 2012) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events." | 4.87 | Clopidogrel withdrawal: is there a "rebound" phenomenon? ( Curzen, N; Sambu, N; Warner, T, 2011) |
| " The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality." | 4.87 | Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011) |
| "Clopidogrel has been used (alone or in association with aspirin) to prevent vascular complications in atherothrombotic patients, to prevent stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI) and as a long-term prevention of cardiovascular and cerebrovascular events." | 4.87 | Genetic determinants of on-clopidogrel high platelet reactivity. ( Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Miccoli, M; Monti, M; Tebaldi, M; Valgimigli, M, 2011) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 4.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "The optimal length of clopidogrel therapy in patients with acute coronary syndromes or in those who have undergone percutaneous coronary intervention (PCI) remains controversial." | 4.87 | Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. ( Gaglia, MA; Waksman, R, 2011) |
| "Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included." | 4.87 | CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. ( Casas, JP; Hingorani, AD; Holmes, MV; Perel, P; Shah, T, 2011) |
| "The patients at greatest risk, when discontinuing clopidogrel therapy, are those with drug eluting stents who may be at risk of stent thrombosis." | 4.87 | Clopidogrel dilemma for orthopaedic surgeons. ( Bell, G; Fletcher, JP; Fox, JS; Grigg, LE; Steele, MJ, 2011) |
| "Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)." | 4.86 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. ( Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "The administration of dual antiplatelet therapy with aspirin and a thienopyridine for the prevention of thrombosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention is proven to reduce mortality." | 4.86 | A comparison of the metabolism of clopidogrel and prasugrel. ( Laizure, SC; Parker, RB, 2010) |
| "Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis." | 4.86 | Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. ( Anderson, JL; Antman, EM; Bliden, K; Cannon, CP; Collet, JP; Danchin, N; Giusti, B; Gurbel, P; Horne, BD; Hulot, JS; Kastrati, A; Mega, JL; Montalescot, G; Neumann, FJ; Sabatine, MS; Shen, L; Sibbing, D; Simon, T; Steg, PG; Trenk, D; Wiviott, SD, 2010) |
| "Clopidogrel plus aspirin is considered the antiplatelet treatment of choice in patients with acute coronary syndrome, whether or not they are undergoing a percutaneous coronary intervention (PCI)." | 4.86 | Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies? ( Lettino, M, 2010) |
| "Dual antiplatelet therapy with a thienopyridine (ticlopidine or clopidogrel) and aspirin is used to reduce the risk of late stent thrombosis and complications (myocardial infarction [MI] and death) after placement of a drug-eluting stent (DES)." | 4.86 | Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. ( Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA, 2010) |
| " The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel in decreasing the risk of adverse events in coronary heart disease patients has been well established in the past 20 years." | 4.85 | Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working ( Arnesen, H; Budaj, A; De Caterina, R; Filipiak, K; Golanski, J; Gorski, J; Huber, K; Kristensen, SD; Kuliczkowski, W; Opolski, G; Polonski, L; Pregowski, J; Sitkiewicz, D; Watala, C; Witkowski, A; Zembala, M, 2009) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| " The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial demonstrated a similar ischemic event rate to 30 days with a significantly lower bleeding event rate (enhanced net clinical benefit) in favor of bivalirudin monotherapy (with provisional platelet glycoprotein [GP] IIb/IIIa receptor blockade) in comparison with unfractionated heparin plus GP IIb/IIIa blockade in patients undergoing primary PCI for STEMI." | 4.85 | Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. ( Kereiakes, DJ, 2009) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention." | 4.85 | Prasugrel: Clinical development and therapeutic application. ( Guerra, DR; Tcheng, JE, 2009) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is currently the standard therapy after coronary stent implantation to prevent a life-threatening stent thrombosis." | 4.84 | Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. ( Gawaz, M; Geisler, T; May, AE, 2008) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| "The use of ticlopidine in association with aspirin has reduced the incidence of subacute stent thrombosis to currently < 1% after coronary stent implantation." | 4.82 | [Should we use clopidogrel instead of ticlopidine in elective coronary angioplasty?]. ( Baralis, G; Dellavalle, A; La Scala, E; Steffenino, G; Uslenghi, E, 2003) |
| " Clopidogrel, a potent new antiplatelet compound, is the first clinical alternative to aspirin for long-term oral treatment and prevention of arterial thrombosis." | 4.82 | Antithrombotic drugs in vascular medicine: a historical perspective. ( Schrör, K, 2003) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "The work of many investigators since adenosine diphosphate (ADP) was recognized as a platelet aggregating agent in 1961 has led to an appreciation of the important part that ADP plays in hemostasis and thrombosis." | 4.82 | Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. ( Mustard, JF; Packham, MA, 2005) |
| "Adenosine diphosphate (ADP) and adenosine triphosphate (ATP) play a crucial role in hemostasis and thrombosis, and their receptors are potential targets for antithrombotic drugs." | 4.82 | The platelet P2 receptors in thrombosis. ( Gachet, C; Hechler, B, 2005) |
| " In addition to aspirin, whose benefit has been clearly demonstrated in all forms of ischemic heart disease, clopidogrel, given before and after cardiac catheterization, also reduces the rate of thrombosis after stent placement." | 4.82 | [Advances in adjunctive pharmacological therapy for percutaneous coronary interventions]. ( Benito, B; Betriu, A; Masotti, M, 2005) |
| "The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists." | 4.82 | Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005) |
| " In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel." | 4.81 | Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002) |
| " The drug is widely used in combination with aspirin for the prevention of atherothrombosis after placement of intravascular stents, and available data suggest that this combination is as effective as ticlopidine plus aspirin for this indication." | 4.80 | Clopidogrel: a review of its use in the prevention of atherothrombosis. ( Jarvis, B; Simpson, K, 2000) |
| "Inflammation increases the risk of thrombosis in coronary artery disease (CAD) patients and affects the antiplatelet efficacy of clopidogrel." | 4.12 | Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy. ( Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y, 2022) |
| "The present case demonstrates that both diabetes mellitus and carriage of CYP2C19*2 allele are associated with a reduced response to clopidogrel in the setting of this standard dose of clopidogrel and a high risk of stent thrombosis." | 3.96 | Subacute stent thrombosis in a patient with type 2 diabetes and clopidogrel resistance: A case report . ( Cao, SP; Zheng, P; Zhong, HL; Zhou, MC, 2020) |
| "The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown." | 3.88 | Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. ( Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E, 2018) |
| " Due to previous atrial fibrillation and ischaemic heart disease, this patient was treated with both dabigatran and clopidogrel." | 3.88 | Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel. ( Fredgart, M; Gill, S, 2018) |
| " However, the risk of rebleeding remains high, especially in patients with chronic ICH and those pretreated with clopidogrel." | 3.85 | Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage. ( Baschin, M; Greinacher, A; Kohlmann, T; Schroeder, HW; Selleng, S; Thiele, T; Westphal, A; Zeden, JP, 2017) |
| "Stent thrombosis (ST) remains a thorny issue in spite of dual antiplatelet treatment with aspirin plus clopidogrel after stent-assisted coiling (SAC)." | 3.85 | Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report. ( Ding, L; Fang, Y; Gu, Z; Li, Y; Wang, R, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Prasugrel has proved its superiority over clopidogrel for reducing ischemic events among patients with ST elevation myocardial infarction (STEMI) undergoing urgent percutaneous coronary intervention (PCI)." | 3.83 | In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. ( Arad, J; Gilutz, H; Lerman, TT; Reitblat, O; Shimony, A; Zahger, D, 2016) |
| "Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)." | 3.83 | Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016) |
| "Stent thrombosis (ST) is considered as a multifactorial problem which is mostly occurs due to clopidogrel resistance." | 3.83 | Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. ( Avcilar, T; Cetin, SE; Emre, A; Erdem, A; Guney, AI; Isbir, T; Kaspar, EC; Kirac, D; Terzi, S; Yazici, S; Yesilcimen, K, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| " The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding." | 3.83 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "The recently published, largest trial with cangrelor, the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PHOENIX, suggested that the experimental agent significantly reduced the rate of stent thrombosis (ST) and myocardial infarction (MI) during PCI at 48 hours (h) and 30 days." | 3.80 | Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. ( DiNicolantonio, JJ; Fortmann, SD; Pokov, AN; Serebruany, VL, 2014) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is used to lower the risk of arterial thrombosis." | 3.80 | The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. ( Grybauskas, P; Gustiene, O; Jankauskiene, L; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 3.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice." | 3.80 | In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. ( Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y, 2014) |
| "Patients on aspirin therapy for 1 week or longer with known or suspected coronary artery disease undergoing nonurgent cardiac catheterization (n=1172), of whom 924 were on aspirin and clopidogrel therapy, were studied." | 3.80 | Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. ( Bliden, KP; Franzese, C; Gurbel, PA; Jeong, YH; Kang, K; Lev, EI; Pandya, S; Tantry, US, 2014) |
| "Using an anaesthetized dog model of thrombosis, the effects of aspirin (50mg/kg) in addition to clopidogrel and ticagrelor were evaluated at two levels of P2Y12 inhibition, maximal (≥96%) and sub-maximal (~80%), as assessed by ex vivo ADP-induced whole blood impedence aggregometry." | 3.79 | High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. ( Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H, 2013) |
| "Ticagrelor has been promoted to reduce the rate of definite stent thrombosis compared to clopidogrel from the The Platelet Inhibition and Patient Outcomes (PLATO) trial." | 3.79 | Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports. ( Biondi-Zoccai, G; Dinicolantonio, JJ, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 3.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "Consecutive patients with acute ST-segment elevation myocardial infarction who were treated by primary angioplasty within 12 hours of the onset of symptoms received bivalirudin plus clopidogrel (Group A) or bivalirudin plus prasugrel (Group B)." | 3.79 | A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. ( Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F, 2013) |
| "Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel." | 3.79 | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013) |
| "The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel." | 3.79 | Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. ( Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G, 2013) |
| "Patients with atrial fibrillation (AF) often receive, in addition to warfarin, antithrombotic drugs to manage other comorbid conditions." | 3.79 | The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. ( Azoulay, L; Dell'Aniello, S; Renoux, C; Simon, T; Suissa, S, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 3.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| "Clopidogrel use after drug-eluting stent (DES) coronary artery implantation is essential for the prevention of early in-stent thrombosis, but clopidogrel use among older DES recipients has not been widely studied." | 3.78 | Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent. ( Malenka, DJ; Morden, NE; Roth, GA; Skinner, J; Zhou, W, 2012) |
| "Variants in ABCB1 and CYP2C19 have been identified as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI)." | 3.78 | Predicting clopidogrel response using DNA samples linked to an electronic health record. ( Basford, MA; Bowton, E; Cleator, JH; Crawford, DC; Delaney, JT; Denny, JC; Jahangir, E; Masys, DR; Oetjens, M; Pulley, JM; Ramirez, AH; Ritchie, MD; Roden, DM; Schildcrout, JS; Shi, Y; Xu, H; Zink, R, 2012) |
| " Phenotyping of platelet response to clopidogrel was a better predictor of stent thrombosis than genotyping." | 3.78 | Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. ( Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM, 2012) |
| " We examined the effects on thrombosis and haemostasis in PAR₄ -/- mice (platelets unresponsive to thrombin) treated with therapeutic doses of either aspirin or clopidogrel." | 3.78 | Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. ( Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012) |
| " This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery." | 3.78 | Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012) |
| "Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far." | 3.78 | Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. ( Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T, 2012) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 3.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| " In particular, an herbal combination including Tribulus terrestris (TT), Avena sativa (AS), and Panax Ginseng (PG), which may be effective in treatment of atherosclerosis and thrombosis, is used by patients with coronary artery disease." | 3.78 | [Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?]. ( Erdoğan, E; Göktekin, Ö; Tasal, A; Vatankulu, MA, 2012) |
| "This case report describes recurrent drug-eluting stent thrombosis with documented laboratory hyporesponsiveness to clopidogrel." | 3.78 | Failure of high-dose clopidogrel in recurrent stent thrombosis. ( Chan, MY; Li, Y, 2012) |
| "Our data on the inhibitory effect of rivaroxaban alone or with DAT are consistent with the ATLAS 2 trial findings, and support its potential use for preventing stent thrombosis after stent deployment." | 3.78 | Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. ( Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E, 2012) |
| "A 59-year-old man underwent spinal decompression and fusion for neurogenic claudication with lumbar spinal stenosis and spondylolisthesis while managed on clopidogrel for prevention of thrombosis after cardiac stent placement." | 3.77 | A case of late epidural hematoma in a patient on clopidogrel therapy postoperatively: when is it safe to resume antiplatelet agents? ( Carragee, EJ; Golish, SR; Scuderi, GJ, 2011) |
| "Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis." | 3.77 | Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( Byron, KA; Dear, AE; Dick, RJ, 2011) |
| "Stent thrombosis occurs frequently within the first weeks after cessation of longterm clopidogrel therapy." | 3.77 | Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2011) |
| "Clopidogrel discontinuation after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation has been reported to correlate with stent thrombosis." | 3.77 | Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. ( Ben-Dor, I; Bonello, L; Collins, SD; de Labriolle, A; Lemesle, G; Maluenda, G; Pichard, AD; Satler, LF; Syed, AI; Torguson, R; Waksman, R; Xue, Z, 2011) |
| "One possible cause of stent thrombosis is an insufficient effect of clopidogrel." | 3.77 | Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. ( Behr, T; Behr, W; Kuch, B; von Scheidt, W, 2011) |
| "This study demonstrates that high on treatment platelet reactivity with aspirin and/or clopidogrel is common amongst patients who develop stent thrombosis." | 3.77 | High on treatment platelet reactivity and stent thrombosis. ( French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I, 2011) |
| "Although clopidogrel pretreatment benefits patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes, these benefits are less well established among patients undergoing elective PCI--in particular, when they are treated with the direct thrombin inhibitor, bivalirudin." | 3.77 | Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). ( Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN, 2011) |
| "Thienopyridines, specifically clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents." | 3.77 | Use of prasugrel in a patient with clopidogrel hypersensitivity. ( Beddingfield, R; Held-Godgluck, BM; Peppard, SR, 2011) |
| "Ticagrelor has been shown to be superior to clopidogrel in patients presenting with acute myocardial infarction who undergo early invasive treatment." | 3.77 | The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. ( Chauhan, A; More, RS; Morgan, KP, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention with the deployment of a coronary stent." | 3.77 | [Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?]. ( Ardissino, D; Conte, G; Demola, MA; Giacalone, R; Mantovani, F; Marziliano, N; Notarangelo, MF, 2011) |
| " clopidogrel) is known to be essential in patients in whom percutaneous coronary intervention with stent implantation has been performed in order to prevent stent thrombosis and its fatal consequences." | 3.77 | [Diagnostic laparoscopy under dual antiplatelet therapy with clopidogrel and aspirin]. ( Buerke, M; Mannes, F; Plehn, A; Schlitt, A; Vogt, A; Werdan, K; Wolf, HH, 2011) |
| "This case-control study identified 3 genes (CYP2C19, ABCB1, and ITGB3) and 2 clopidogrel-related factors (loading dose and proton pump inhibitors) that were independently associated with early stent thrombosis." | 3.77 | Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. ( Allanic, F; Barthélémy, O; Beygui, F; Cayla, G; Collet, JP; de la Briolle, A; Gruel, Y; Huerre, Y; Hulot, JS; Montalescot, G; O'Connor, SA; Pathak, A; Scott, SA; Silvain, J; Vignalou, JB, 2011) |
| "In patients with coronary stents, the risks of halting clopidogrel therapy in the perioperative period are potentially life-threatening and include stent thrombosis and myocardial infarction." | 3.77 | Clopidogrel therapy in ophthalmic procedures: a survey of subspecialty ophthalmologists and review of current guidelines. ( Hess, TM; Liu, ES, 2011) |
| " A 35-year-old lady with ES taking aspirin with clopidogrel for thrombo-prophylaxis presented with massive epistaxis." | 3.77 | Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum. ( Liu, A; Pusalkar, P; Saman, H, 2011) |
| "Platelet hyperreactivity in MEA might be a better risk predictor for stent thrombosis than the assessment of the specific clopidogrel effect with the VASP phosphorylation assay." | 3.76 | Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. ( Christ, G; Delle-Karth, G; Huber, K; Jilma, B; Lang, IM; Siller-Matula, JM, 2010) |
| "The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI." | 3.76 | Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| " An increased risk of thrombosis after coronary stenting for ACS patients treated with aspirin and clopidogrel has been linked to high platelet reactivity and, for certain patients, poor drug response." | 3.76 | VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. ( Bidet, A; Coste, P; Jais, C; Jakubowski, J; Nurden, A; Nurden, P; Puymirat, E, 2010) |
| "The antithrombotic effect of Danggui and Honghua, herbs commonly used in Traditional Chinese medicine to treat the syndrome corresponding to vascular thrombosis, and their potential interactions with clopidogrel were investigated." | 3.76 | Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. ( Li, Y; Wang, N, 2010) |
| " Carriers of this polymorphism have a higher incidence of stent thrombosis and cardiovascular death, whilst on the thienopyridine clopidogrel." | 3.76 | Prasugrel, Māori, and personalised medicine in New Zealand. ( Gladding, P; Webster, M; White, H, 2010) |
| " Here, we investigated the potential synergy of a potent factor Xa/prothrombinase inhibitor, TAK-442, plus aspirin or clopidogrel in preventing arterial thrombosis and whole blood coagulation." | 3.76 | Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. ( Hiroe, K; Kawamura, M; Konishi, N, 2010) |
| "Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention." | 3.76 | Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 3.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "To determine whether the 681 G>A (*2) polymorphism of cytochrome P450 (CYP2C19) is related to suboptimal reperfusion and mortality in patients with acute myocardial infarction (AMI) pretreated with clopidogrel." | 3.76 | Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. ( Kostrzewa, G; Kruk, M; Kłopotowski, M; Małek, LA; Przyłuski, J; Płoski, R; Rużyłło, W; Spiewak, M; Witkowski, A, 2010) |
| "The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coronary intervention (PCI) and stent implantation." | 3.76 | Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. ( Brozovic, I; Farhan, S; Geppert, A; Huber, K; Jarai, R; Siller-Matula, J; Smetana, P; Tentzeris, I; Wojta, J, 2010) |
| "Among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers." | 3.75 | Cytochrome p-450 polymorphisms and response to clopidogrel. ( Antman, EM; Brandt, JT; Braunwald, E; Close, SL; Hockett, RD; Macias, W; Mega, JL; Sabatine, MS; Shen, L; Walker, JR; Wiviott, SD, 2009) |
| "The new P2Y(12) antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding." | 3.75 | Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. ( Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC, 2009) |
| " Clopidogrel (Plavix), a selective P(2)Y(12) antagonist, prevents platelets from clotting but thereby increases the risk of severe or fatal bleeding." | 3.75 | Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ( Andrésson, T; Bjarnadottir, M; Bjornsson, JM; Fabre, JE; Gurney, ME; Hategen, G; Kiselyov, A; Magnusson, O; Mishra, R; Onua, E; Polozov, A; Ramírez, JL; Sigthorsson, G; Singh, J; Stefansson, K; Thorsteinsdottir, M; Yu, P; Zeller, W; Zembower, D; Zhang, J; Zhou, N, 2009) |
| "The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST)." | 3.75 | Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N, 2009) |
| "This study sought to investigate the incidence of stent thrombosis (ST) in patients treated with drug-eluting stents (DES) and clearly defined short-term dual antiplatelet therapy (DAT) for three or six months for sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES), respectively." | 3.75 | Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. ( Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C, 2009) |
| " In rat and dog models of thrombosis/hemostasis, there was greater separation between doses that provided antithrombotic effect and those that increased bleeding for ticagrelor compared with clopidogrel and compound 072, a chemical compound indistinguishable from the prasugrel parent compound." | 3.75 | Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. ( Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H, 2009) |
| "Clopidogrel as a sole anti-platelet treatment after coronary stenting resulted in a relatively high percentage of subacute stent thrombosis." | 3.75 | Coronary artery stenting in patients treated by clopidogrel without aspirin. ( Amit, G; Leibowitz, D; Rott, D; Weiss, AT; Zahger, D, 2009) |
| "In the case of stent thrombosis and resistance to clopidogrel, choices of an alternative drug remain limited." | 3.74 | Repeated high doses of clopidogrel in 2 cases of pharmacological resistance. ( Cayla, G; Leclercq, F; Macia, JC; Piot, C; Rabesendratana, H; Roubille, F; Schved, JF, 2008) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 3.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent (DES) implantation." | 3.74 | Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. ( Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2008) |
| "We describe a case of fatal stent thrombosis after Carbostent implantation and clopidogrel alone antiplatelet therapy in a patient affected by rectal cancer who does not tolerate aspirin." | 3.74 | A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy? ( Altamura, L; Crea, F; De Vita, M; Ferrante, G; Fusco, B; Leone, AM; Niccoli, G; Rebuzzi, AG; Siviglia, M, 2007) |
| "To evaluate the effect of clopidogrel on the rate of thrombosis in a rat model for venous microvascular failure." | 3.74 | Clopidogrel (Plavix) reduces the rate of thrombosis in the rat tuck model for microvenous anastomosis. ( Deschler, DG; Moore, MG, 2007) |
| "Nonresponsiveness to clopidogrel is a strong independent predictor of stent thrombosis in patients receiving sirolimus- or paclitaxel-eluting stents." | 3.74 | Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Gori, AM; Marcucci, R; Migliorini, A; Moschi, G; Paniccia, R; Santini, A, 2007) |
| "Therapy with acetylsalicylic acid (ASA) and/or clopidogrel is used to achieve prophylactic inhibition of platelet aggregation in patients with arterial thrombosis." | 3.74 | [Modified platelet aggregation test in patients on ASA and/or clopidogrel]. ( Eder, C; Funke, U; Lutze, G; Prasse, T; Schulze, M; Töpfer, G; Zimmermann, M, 2007) |
| "The authors present a fatal case of late thrombosis of paclitaxel-eluting stent implanted in the left main stem occurring 6 months after the procedure and 3 weeks after the cessation of clopidogrel." | 3.74 | The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. ( Bystron, M; Cervinka, P; Jakabcin, J; Kala, P; Kvasnak, M; Malý, J; Spacek, R; Veselka, J, 2008) |
| " Fibrin(ogen) deposition, light transmittance aggregometry (LTA; collagen, U46619, and ADP), and bleeding time (BT) were also evaluated." | 3.74 | A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. ( Badimon, L; Casaní, L; Vilahur, G, 2007) |
| " The patient experienced a coronary stent thrombosis possibly due to discontinuation of clopidogrel prior to urologic surgery." | 3.74 | Late coronary stent thrombosis complicating urologic surgery. ( de Korte, FI; Ten Berg, JM; van Werkum, JW; Vijverberg, PL, 2008) |
| "The incidence of stent thrombosis was evaluated in 1,029 patients receiving ticlopidine and aspirin after SES deployment." | 3.74 | Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation. ( Fujimoto, Y; Himi, T; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T, 2008) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 3.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination." | 3.74 | Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. ( Baxi, S; Karnicki, K; Leadley, RJ; McBane, RD; Peterson, T; Wysokinski, W, 2008) |
| "The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors." | 3.74 | What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008) |
| " Moreover, in a mouse model of thrombosis, administration of Gas6 or Sky blocking antibodies resulted in a decrease in thrombus weight similar to clopidogrel but, unlike clopidogrel, produced no increase in template bleeding." | 3.73 | Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. ( Baxi, SM; Gould, WR; Leadley, RJ; Peng, YW; Perrin, LA; Peterson, JT; Schroeder, R, 2005) |
| "The pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on acute thrombosis and chronic neointima formation after vascular injury have been investigated." | 3.73 | Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice. ( Hayashi, K; Kawasaki, T; Moritani, Y; Nagai, K; Saito, T; Shigenaga, T; Takamatsu, H; Takasaki, J; Taniguchi, M; Uemura, T, 2005) |
| "Of 33 arteries, 19 (58%) in the control group developed complete thrombosis by the end of the period compared with only 6 (19%) of 32 arteries in the group that received clopidogrel." | 3.73 | Clopidogrel use for reducing the rate of thrombosis in a rat model of microarterial anastomosis. ( Deschler, DG; Nayak, VK, 2005) |
| "The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin." | 3.73 | The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. ( Jönsson, B; Lindgren, P; Ringborg, A, 2005) |
| " aspirin (4-30 mg/kg), heparin (100-500 U/kg), enoxaparin (4-30 mg/kg) and clopidogrel (10-20 mg/kg) were studied in a rat Folts-like preparation of carotid arterial thrombosis." | 3.73 | Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. ( Daykin, HJ; Jones, C; Sturgeon, SA; Wright, CE, 2006) |
| " All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy." | 3.73 | [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006) |
| "Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis." | 3.73 | Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. ( Bach, RG; Cohen, DJ; Decker, C; Jones, PG; Kettelkamp, R; Khanal, S; Krumholz, HM; Messenger, JC; Peterson, ED; Rumsfeld, JS; Spertus, JA; Vance, C, 2006) |
| "Thrombotic events still occur in aspirin-treated patients with coronary artery disease." | 3.73 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006) |
| "Dual antiplatelet therapy with aspirin and clopidogrel decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)." | 3.72 | Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. ( Besta, F; Gawaz, M; Massberg, S; Müller, I; Schönig, A; Schulz, C, 2003) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 3.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| " Thus, we have determined the effects of thrombopoietin, on its own and in combination with ticlopidine, an anti-platelet drug, on platelet activation, thrombosis formation and survival of irradiated C57BL6/J mice." | 3.71 | Ticlopidine inhibits the prothrombotic effects of thrombopoietin and ameliorates survival after supralethal total body irradiation. ( Gaugler, MH; Gourmelon, P; Mouthon, MA; Van der Meeren, A; Vandamme, M; Wagemaker, G, 2002) |
| "The antiplatelet and antithrombotic effects of the oral combination treatment of ticlopidine and Ginkgo biloba extract (EGb 761) were studied in normal and thrombosis-induced rats." | 3.70 | Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (EGb 761). ( Hahn, BS; Kim, YS; Park, KM; Park, PH; Pyo, MK; Wu, SJ; Yun-Choi, HS, 1998) |
| "The effects of clopidogrel and aspirin have been compared, singly and in combination, for measurements of 111In-labeled platelets and 125I-labeled fibrin deposition in baboon models of arterial thrombosis and related to platelet aggregation and expression of activation epitopes induced by ADP, collagen, and thrombin receptor agonist peptide (TRAP) and to template bleeding times (BTs)." | 3.70 | Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. ( Chronos, NR; Hanson, SR; Harker, LA; Herbert, JM; Kelly, AB; Marzec, UM; Sundell, IB, 1998) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 3.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "Combination antiplatelet therapy using aspirin and ticlopidine has been the standard of care for prevention of subacute thrombosis following coronary stent implantation." | 3.70 | Combination therapy with clopidogrel and aspirin after coronary stenting. ( Curran, SC; Herrmann, HC; Hirshfeld, JW; Klugherz, BD; Kolansky, DM; Magness, K; Wilensky, RL, 2000) |
| "Combination antiplatelet agents, particularly aspirin and ticlopidine, have found increased use in the prevention of arterial thrombosis." | 3.70 | A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. ( Fiore, L; Hasbargen, JA; Kaufman, JS; O'Connor, TZ; Perdriset, G, 2000) |
| "The effects of a new antithrombotic compound, PCA-4230, versus ticlopidine were investigated using an experimental thrombosis and vascular endothelial injury model in rats." | 3.68 | Interaction of platelets with subendothelium in rats treated with PCA-4230, a new antithrombotic agent. Effect of PCA-4230 on experimental thrombosis. ( Gutiérrez Díaz, JA; Ortega, MP; Priego, JG; Sunkel, C; Tolón, RM, 1992) |
| "A series of 1,4-dihydropyridines (DHP) bound to 1,2-benzisothiazol-3-ones were synthesized and evaluated for their ability to inhibit platelet aggregation induced by collagen in human platelet-rich plasma (PRP) and to protect mice against experimental thrombosis." | 3.67 | Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. ( Cillero, FJ; Fau de Casa-Juana, M; Ortega, MP; Priego, JG; Sunkel, CE, 1988) |
| "The relative importance of ADP, arachidonic acid metabolites and serotonin as thrombogenic factors was evaluated in rats by comparing, after oral administration, the effects of two inhibitors of ADP-induced platelet aggregation (ticlopidine and PCR 4099), three cyclo-oxygenase inhibitors (aspirin, triflusal and indobufen) and a selective serotonin 5HT2 receptor antagonist (ketanserin) on platelet aggregation, in four platelet-dependent thrombosis models and on bleeding time." | 3.67 | ADP plays a key role in thrombogenesis in rats. ( Bernat, A; Cazenave, JP; Defreyn, G; Delebassée, D; Gordon, JL; Maffrand, JP, 1988) |
| "Ticlopidine (250 mg twice daily) was administered to human volunteers for seven days and the response of their heparinized platelet-rich plasma to SKNMC (ADP-dependent) human neuroblastoma cells was examined." | 3.67 | Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. ( Almirall, L; Bastida, E; Escolar, G; Ordinas, A, 1986) |
| "Tiny cerebral aneurysms can be safely and effectively treated with appropriate endovascular approaches based on aneurysm specific morphology, especially neck size and neck-to-dome ratio." | 2.87 | Tiny Cerebral Aneurysms Can Be Treated Safely and Effectively with Low-Profile Visualized Intraluminal Support Stent-Assisted Coiling or Coiling Alone. ( Gao, BL; Li, L; Li, TX; Xu, GQ; Yang, BW, 2018) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 2.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| "Residual intra-stent thrombus was quantified by optical coherence tomography using both the number of cross-sections with thrombus area more than 10% and thrombus volume." | 2.82 | Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. ( Cattabiani, MA; Di Vito, L; Gatto, L; Limbruno, U; Marco, V; Micari, A; Pawlowski, T; Prati, F; Romagnoli, E; Trivisonno, A; Versaci, F, 2016) |
| "The highest incidence of intra-stent thrombus was observed in tertile 1 followed by tertiles 2 and 3 in LOF carriers, whereas there was no such difference in non-carriers." | 2.78 | Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers. ( Hariki, H; Hiranuma, N; Hirata, K; Inoue, T; Iwasaki, M; Kinutani, H; Konishi, A; Kuroda, M; Nakagawa, M; Nishio, R; Osue, T; Otake, H; Shinke, T; Taniguchi, Y, 2013) |
| " Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up." | 2.78 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013) |
| "Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels." | 2.76 | Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. ( Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 2.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| " A clopidogrel maintenance dosage of 150 mg daily for 1 week resulted in greater platelet inhibition than 75 mg daily (50 +/- 28% vs." | 2.73 | The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. ( Armstrong, G; Dahl, ML; El-Jack, S; Farrell, H; Gladding, P; Gunes, A; Kay, P; Ormiston, J; Ruygrok, P; Scott, D; Stewart, J; Webster, M; Zeng, I, 2008) |
| " The dose-dependent effect was confirmed by the absolute and relative increase in platelet aggregation after resuming standard dosing (p < 0." | 2.73 | Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Desai, B; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Macaya, C; Palazuelos, J; Weisberg, I; Zenni, MZ, 2008) |
| "Dialysis fistula thrombosis is the most common and dangerous complication which prevents proper dialysis therapy." | 2.71 | Preventive administration of Clopidogrel after restoring patency of acute dialysis fistula with surgical thrombectomy. ( Bojarska-Szmygin, A; Gieryng, J; Janicka, L; Janicki, K; Orłowska, A; Pietura, R, 2003) |
| "Arterial thrombus formation was induced ex vivo by exposing a collagen-coated surface in a parallel-plate perfusion chamber to native blood for 3 min (arterial wall shear rate 2600 s(-1))." | 2.71 | Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. ( Boneu, B; Cadroy, Y; Sakariassen, K; Thalamas, C, 2005) |
| "In contrast, platelet thrombus formation was blocked by more than 90% in volunteers treated by aspirin + ticlopidine (P < ." | 2.69 | A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. ( Barret, A; Boneu, B; Bossavy, JP; Cadroy, Y; Sagnard, L; Sakariassen, K; Thalamas, C, 1998) |
| " These results suggest that while waiting for the technological advancements of stents, postprocedural treatment that includes a low dosage of ticlopidine, aspirin, and low-molecular-weight heparin is a very effective alternative to conventional poststenting therapy." | 2.68 | Intracoronary stenting without coumadin: one month results of a French multicenter study. ( Benveniste, E; Biron, Y; Bourdonnec, C; Faivre, R; Fajadet, J; Gaspard, P; Glatt, B; Joly, P; Morice, MC; Zemour, G, 1995) |
| "Clopidogrel ingestion reduced the thrombus volume significantly (p < 0." | 2.67 | Clopidogrel--a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. ( Barstad, RM; Dickinson, JP; Kieffer, G; Kierulf, P; Roald, HE; Sakariassen, KS; Skjørten, F, 1994) |
| "Ticlopidine is an effective inhibitor of platelet aggregation." | 2.66 | Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. ( Gröntoft, KC; Gutierrez, A; Mulec, H; Olander, R, 1985) |
| "Cangrelor is an intravenous, reversibly-binding platelet P2Y12 receptor antagonist with ultra-rapid onset and offset of action that is approved in Europe and United States for use in patients undergoing PCI." | 2.53 | Cangrelor for the management and prevention of arterial thrombosis. ( Sinha, A; Storey, RF, 2016) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Arterial thrombosis is a major component of vascular disease, especially myocardial infarction (MI) and stroke." | 2.49 | Pharmacogenomics of anti-platelet and anti-coagulation therapy. ( Fisch, AS; Horenstein, RB; Perry, CG; Shuldiner, AR; Stephens, SH, 2013) |
| " A "one size fits all" approach to clopidogrel dosing is probably flawed." | 2.49 | Clopidogrel "resistance": where are we now? ( Hobson, AR; Qureshi, Z, 2013) |
| " The comparator was standard dosage of clopidogrel." | 2.49 | Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. ( Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013) |
| " The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)." | 2.47 | Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. ( Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011) |
| "Platelet-mediated thrombosis is a dreaded clinical event and is the primary cause of acute coronary syndromes and post-percutaneous intervention (PCI) ischaemic events." | 2.47 | Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. ( Gurbel, PA; Tantry, US, 2011) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 2.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| " Currently, efficiency, dosing and indications of established antiplatelet substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibition of platelet activity come up front." | 2.44 | Antiplatelet drugs in cardiological practice: established strategies and new developments. ( Klauss, V; Krötz, F; Sohn, HY, 2008) |
| " Long-term administration of clopidogrel was associated with a modest but statistically significant advantage over aspirin in reducing adverse cardiovascular outcomes in patients with established cardiovascular disease in the CAPRIE trial." | 2.44 | Clopidogrel: a review of its use in the prevention of thrombosis. ( Lyseng-Williamson, KA; Plosker, GL, 2007) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| " Despite the unambiguous clinical benefit associated with clopidogrel, accumulating experience with this drug has also led to identification of some of its drawbacks, which are related to inadequate platelet inhibition with standard dosage regimens as well as to its irreversible antiplatelet effects." | 2.44 | ADP receptor antagonism: what's in the pipeline? ( Angiolillo, DJ, 2007) |
| "Atherothrombosis is a generalized and progressive process with an inflammatory component." | 2.44 | Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. ( Ellahham, S, 2008) |
| " In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable responsiveness/hyporesponsiveness to platelet inhibition." | 2.44 | Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. ( Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S, 2008) |
| " However, since ASS does not influence the mortality but is significantly increasing the risk for bleeding, careful risk stratification is indispensable prior to preventive chronic administration of the drug." | 2.43 | [Oral antithrombotic therapy in primary and secondary prevention]. ( Elsässer, A; Hamm, CW; Möllmann, H, 2005) |
| "We report a case of multiple coronary thrombosis involving the left anterior descending artery and circumflex artery and stent implantation to the subtotally stenotic right renal artery in a women with unstable angina pectoris, essential thrombocytosis and previous history of renal artery trombosis." | 2.43 | Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. ( Bugra, Z; Ekmekci, A; Meric, M; Ozben, B; Umman, S, 2006) |
| " Intravenous glycoprotein IIb/IIIa inhibitors effectively prevent periprocedural thrombotic complications, but their short duration of action and parenteral dosing don't allow for long-term protection." | 2.42 | What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? ( Berger, P; Steinhubl, S, 2003) |
| "ticlopidine 0." | 2.41 | Clopidogrel and coronary stenting: what is the next question? ( Moore, SA; Steinhubl, SR, 2000) |
| "Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined." | 2.41 | Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002) |
| "Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy." | 2.40 | Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. ( Schafer, AI, 1997) |
| "Removal of the thrombus and maze procedure were performed at the same time." | 2.40 | [A case of mobile left atrial thrombus without mitral valve disease]. ( Asada, K; Hasegawa, Y; Kodama, T; Kondou, K; Matsuyama, N; Minohara, S; Okamoto, J; Okamoto, K; Sasaki, S; Sawada, Y, 1997) |
| "This may reflect a reduction in restenosis, although this remains to be proven." | 2.40 | Pharmacologic prevention of acute ischemic complications of coronary angioplasty. ( Cumberland, D; Wheeldon, N, 1997) |
| "Ticlopidine has become an established therapy in patients with stroke, and during stenting in patients with coronary artery disease." | 2.40 | Clopidogrel: the future choice for preventing platelet activation during coronary stenting? ( Cummings, CC; Gurbel, PA; O'Connor, CM; Serebruany, VL, 1999) |
| "Ticagrelor is an adenosine diphosphate (ADP) receptor antagonist antithrombotic that can inhibit ADP-dependent platelet activation and aggregation." | 1.62 | The effect of ticagrelor on microarterial thrombosis in an experimental model. ( Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A, 2021) |
| "Device-related thrombus remains a major concern because it may result in recurrent embolic events." | 1.46 | WATCHMAN device-related thrombus successfully treated with apixaban: A case report. ( Chan, PH; Kwok, OH; Lam, CC; Lam, YY; Siu, CW; Wong, CK, 2017) |
| " Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents." | 1.46 | In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. ( Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M, 2017) |
| "Platelet-covered area, individual thrombus size, and the average thrombus size were assessed morphometrically." | 1.46 | Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate. ( Calmer, S; Echtermeyer, F; Jahn, K; Johanning, K; Küster, U; Sahlmann, B; Schäfer, A; Suchodolski, K; Theilmeier, G, 2017) |
| "ESSENTIALS: Cancer patients have a high rate of venous thrombosis (VT) but the underlying mechanisms are unknown." | 1.43 | Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. ( Bergmeier, W; Boulaftali, Y; Cooley, BC; Dee, R; Fuentes, R; Geddings, JE; Getz, TM; Hisada, Y; Key, NS; Mackman, N; Whelihan, M; Wolberg, AS, 2016) |
| "The total thrombus-formation analysis system (T-TAS) was developed for quantitative analysis of platelet thrombus formation by the use of microchips with thrombogenic surfaces (collagen, platelet chip [PL-chip]; collagen plus tissue factor, atherome chip [AR-chip])." | 1.43 | Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. ( Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Kaikita, K; Kojima, S; Nakagawa, K; Ogawa, H; Oimatsu, Y; Sakamoto, K; Sueta, D; Tsujita, K, 2016) |
| "In the moderate injury, thrombus formation peaked at approximately 1min after injury and resolved within 3min, with the mean AUC (area under the curve) of 165." | 1.43 | Standardization of a well-controlled in vivo mouse model of thrombus formation induced by mechanical injury. ( Chi, Q; Gachet, C; Huang, L; Lei, D; Mangin, PH; Tang, C; Wang, G; Wang, Y; Zheng, Y; Zhu, L, 2016) |
| "Measuring platelet thrombus formation (PTF) for evaluating antiplatelet effects was assessed." | 1.43 | Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. ( Hosokawa, K; Kawashima, A; Kitagawa, K; Ohnishi, T; Okada, Y; Uchiyama, S; Yamaguchi, K; Yamazaki, M; Yoneyama, T, 2016) |
| "We observed that pancreatic cancer cell derived microparticles expressed TF, its inhibitor tissue factor pathway inhibitor (TFPI) as well as the integrins αvβ1 and αvβ3." | 1.42 | Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. ( Darbousset, R; Dignat-George, F; Dubois, C; Mezouar, S; Panicot-Dubois, L, 2015) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 1.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| " Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database." | 1.42 | Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. ( Abe, J; Hara, H; Kinosada, Y; Miyamura, N; Nakamura, M; Nishibata, Y; Sekiya, Y; Suzuki, H; Suzuki, Y; Tsuchiya, T; Umetsu, R; Uranishi, H, 2015) |
| "Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality." | 1.42 | Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. ( Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015) |
| " Since the bioavailability of 30d was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, 45)." | 1.42 | 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in ( Caroff, E; Gnerre, C; Hess, P; Hilpert, K; Hubler, F; Meyer, E; Renneberg, D; Rey, M; Riederer, MA; Steiner, B; Treiber, A, 2015) |
| " However, unlike other medications, subtle differences in clopidogrel bioavailability may lead to acute consequences including stent thrombosis (ST)." | 1.40 | Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. ( Baber, U; Badimon, JJ; Hulot, JS; Kini, A; Kovacic, JC; Krishnan, P; Li, JR; Mehran, R; Moreno, P; Sharma, SK; Sweeny, J, 2014) |
| "Human atherosclerotic plaques produced PGE2, which facilitated platelet aggregation in human blood and rescued the function of P2Y12-blocked platelets." | 1.40 | Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. ( Charles, AL; Fabre, JE; Geny, B; Gross, S; Gurney, ME; Ludwig, S; Meilhac, O; Slimani, F; Stefansson, K; Tilly, P, 2014) |
| "Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects." | 1.40 | Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; Darlington, A; Degroat, C; Desai, B; Ferrante, E; Ferreiro, J; Franchi, F; Guzman, LA; Muniz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2014) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 1.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "T2DM was associated with increased thrombus [14861 (8003 to 30161) vs 8908 (6812 to 11996), μ(2)/mm, median (IQR), p=0." | 1.40 | Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Viswanathan, GN; Zaman, AG, 2014) |
| "In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective." | 1.40 | Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014) |
| " However, no data are available regarding its impact on adverse clinical outcomes in patients undergoing percutaneous coronary intervention (PCI)." | 1.39 | Comparison of clinical efficacy and safety of clopidogrel resinate with clopidogrel bisulfate in patients undergoing percutaneous coronary intervention. ( Chang, K; Cho, JS; Chung, WS; Her, SH; Jeong, SH; Kim, CJ; Kim, PJ; Park, MW; Seung, KB; Yim, HW, 2013) |
| "Platelet thrombus formation was analysed by measuring flow pressure changes due to the occlusion of micro-capillaries and was quantified by calculating AUC 10 (area under the flow pressure curve." | 1.39 | Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. ( Hosokawa, K; Ito, T; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H, 2013) |
| "Obesity is associated with a prothrombotic state resulting from increased thrombin generation, platelet hyper-reactivity, and decreased fibrinolysis." | 1.39 | Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. ( Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S, 2013) |
| "Stent thrombosis is not unusual in a post-operative setting." | 1.38 | Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. ( Agnani, S; Akkus, NI; Rajpal, S, 2012) |
| "We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0." | 1.38 | Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012) |
| "In vivo, thrombosis was virtually abolished in arterioles and arteries of CalDAG-GEFI(-/-) mice, while small, hemostatically active thrombi formed in venules." | 1.37 | The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. ( Bergmeier, W; Chavez, M; Diamond, SL; Greene, T; Hirsch, J; Maloney, SF; Ouellette, TD; Poncz, M; Roden, RC; Stefanini, L; Stolla, M; Woulfe, DS, 2011) |
| "Left ventricular thrombus (LVT) and rupture are important mechanical complications following myocardial infarction (MI) and are believed to be due to unrelated mechanisms." | 1.37 | Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. ( Dart, AM; Du, XJ; Gao, XM; Head, GA; Kiriazis, H; Liu, Y; Lobo, A; Shan, L, 2011) |
| "Cerebral infarction associated with ulcerative colitis is particularly rare, but clinically important because of its high morbidity and mortality." | 1.37 | Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a). ( Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P, 2011) |
| "Essential hypertension is associated with increased risk of arterial thrombotic disease." | 1.36 | Platelet activation in essential hypertension: implications for antiplatelet treatment. ( Douma, S; Ferro, A; Gkaliagkousi, E; Passacquale, G; Zamboulis, C, 2010) |
| "Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation." | 1.36 | Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). ( Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2010) |
| "Arterial thrombosis was induced by insertion of a silk thread (thrombogenic substrate) into an extracorporeal shunt." | 1.36 | Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. ( Calmettes, Y; Le Grand, B; Leparq-Panissié, A; Létienne, R; Nadal-Wollbold, F; Perez, M, 2010) |
| "Thrombosis is still the first cause of microsurgery failure." | 1.36 | [Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers]. ( Dumont, LA; Gangloff, D; Garrido-Stowhas, I; Rongières, M; Tchénio, P, 2010) |
| "We describe a patient with terminal renal cell carcinoma who developed late iliac artery stent thrombosis despite dual chronic antiplatelet therapy with aspirin and clopidogrel." | 1.36 | Late common iliac artery stent thrombosis in a patient with terminal malignancy. ( Akgün, T; Can, MM; Karabay, CY; Kaymaz, C; Ozveren, O; Serebruany, V; Tanboğa, IH; Tokgöz, HC; Türkyilmaz, E, 2010) |
| "This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment." | 1.36 | Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010) |
| "Dyspnea was diagnosed in 157 (4." | 1.35 | Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. ( Atar, D; Kuliczkowski, W; Pokov, I; Serebruany, V; Vahabi, J, 2008) |
| "Isolated splenic infarction as a complication of the procedure is extreme rare." | 1.35 | Athero-embolic isolated splenic infarction following left cardiac catheterization. ( Hussein, A; Irani, F; Kasmani, R; Mohan, G, 2009) |
| "Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent." | 1.35 | Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009) |
| " HCPR as measured with the novel INNOVANCE P2Y cartridge was associated with clinical determinants such as BMI, female gender, impaired LVEF (left ventricular ejection fraction), renal failure and dosing of clopidogrel." | 1.35 | The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. ( Berg, JM; Bouman, HJ; Elsenberg, EH; Hackeng, CM; van de Wal, RM; van Werkum, JW; Verheugt, FW; Zomer, AC, 2009) |
| "Stent thrombosis is a rare but devastating complication of coronary stent implantation." | 1.35 | Stent thrombosis: a poor man's disease? ( Danenberg, HD; Lotan, C; Marincheva, G; Nassar, H; Varshitzki, B, 2009) |
| "Aspirin pre-treatment at the dose tested did not influence either endothelial injury or platelet thrombus growth, while clopidogrel pretreatment significantly inhibited 3D growth and prolonged occlusion time up to 64." | 1.35 | Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries. ( Eguchi, Y; Goto, S; Ishida, H; Kawamura, Y; Takahari, Y; Tamura, N; Urano, T, 2009) |
| "Antiplatelet and antithrombotic activity of multiple oral dosing of prasugrel were evaluated in several animal species." | 1.35 | Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. ( Asai, F; Hashimoto, M; Isobe, T; Jakubowski, JA; Niitsu, Y; Ogawa, T; Otsuguro, K; Sugidachi, A, 2008) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 1.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| "In a rat model of a platelet-rich thrombus induced by vessel injury with FeCl(2), both BX 667 and clopidogrel exhibited higher levels of thrombus inhibition after oral administration compared to their potency in the A-V shunt model." | 1.34 | A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. ( Alexander, S; Bryant, J; Buckman, BO; da Cunha, V; Dole, WP; Fitch, RM; Islam, I; Mallari, C; Martin-McNulty, B; Morser, J; Post, JM; Subramanyam, B; Sullivan, ME; Vergona, R; Vincelette, J; Wang, YX; Yuan, S, 2007) |
| "Ferric chloride has been widely used to induce arterial thrombosis in a variety of species." | 1.33 | An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. ( Wang, X; Xu, L, 2005) |
| "Stent thrombosis is associated with considerable morbidity and mortality." | 1.33 | Stent thrombosis is associated with an impaired response to antiplatelet therapy. ( Dörffler-Melly, J; Haeberli, A; Hess, OM; Imboden, K; Meier, B; Togni, M; Wenaweser, P; Windecker, S, 2005) |
| "To review a pediatric experience with the antiplatelet agent clopidogrel and suggest a dosage regimen." | 1.33 | Clopidogrel use in children. ( Avner, M; Benson, LN; Finkelstein, Y; Koren, G; Nurmohamed, L, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "Acute in-stent thrombosis is a well-known complication of carotid angioplasty and stenting (CAS) and often due to resistance to or inadequate treatment with platelet-inhibiting agents." | 1.33 | Late in-stent thrombosis following carotid angioplasty and stenting. ( Buhk, JH; Knauth, M; Wellmer, A, 2006) |
| "Pump thrombus is a potentially serious complication with few available treatment options." | 1.33 | An alternative treatment strategy for pump thrombus in the DeBakey VAD Child: use of clopidogrel as a thrombolytic agent. ( Carberry, KE; Chang, AC; Dreyer, WJ; Kennedy, CE; McKenzie, ED; Moffett, BS; Morales, DL; Price, JF; Studer, MA; Teitel, ER, 2006) |
| "Pretreatment with parecoxib (20 mg/kg) almost doubled shear stress-induced platelet aggregation (188% vs." | 1.33 | Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. ( Borgdorff, P; Paulus, WJ; Tangelder, GJ, 2006) |
| "Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition." | 1.33 | Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006) |
| "The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention." | 1.32 | Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003) |
| "Arterial thrombosis was induced in one mesenteric arteriole of a mouse using FeCl3, while venous thrombosis was studied in a Wessler model adapted to rats." | 1.32 | Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. ( Cazenave, JP; Freund, M; Gachet, C; Lenain, N; Léon, C, 2003) |
| "Clopidogrel reduces arterial thrombus cohesion by an effect that correlates with inhibition of ADP-induced platelet aggregation." | 1.32 | Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. ( Bal dit Sollier, C; Berge, N; Bergmann, JF; Drouet, L; Mahé, I; Simoneau, G, 2003) |
| " To evaluate possible pharmacokinetic determinants of this response variability, we developed a sensitive and specific liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of unmodified inactive clopidogrel, its inactive carboxyl metabolite, and its active thiol metabolite in plasma." | 1.32 | Pharmacokinetics of clopidogrel after administration of a high loading dose. ( Gorchakova, O; Harlfinger, S; Kastrati, A; Lazar, A; Schömig, A; Schömig, E; Taubert, D; von Beckerath, N, 2004) |
| " This rabbit model with a high dosage of clopidogrel and aspirin, and a short-time exposure of the heart valve leaflets to rabbit blood under laminar flow, should be further evaluated with respect to whether it can give information about antithrombotic regimens in patients after mechanical heart valve replacement." | 1.31 | Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. ( Bickel, C; Buerke, M; Hauroeder, B; Hundt, F; Meyer, J; Peetz, D; Rupprecht, HJ; Schlitt, A; Victor, A, 2002) |
| "5." | 1.31 | The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. ( Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A, 2000) |
| "Microthrombus formation within the glomeruli was assessed by a semiquantitative immunohistochemical analysis of fibrinogen/fibrin deposits." | 1.31 | Radiation-induced glomerular thrombus formation and nephropathy are not prevented by the ADP receptor antagonist clopidogrel. ( Dewit, LG; Stewart, FA; te Poele, JA; van der Wal, AF; van Kleef, EM, 2001) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| "In ticlopidine pretreated rats the thrombogenic effect of streptokinase was eliminated, and its thrombolytic potency intensified." | 1.30 | Effect of ticlopidine on streptokinase-induced thrombolysis in rats. ( Gryglewski, RJ; Korbut, R; Swies, J; Uracz, W, 1999) |
| "or more) also suppressed the thrombus formation by single administration." | 1.29 | Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. ( Doi, H; Kaburaki, M; Murata, S; Narita, H; Yasoshima, A, 1995) |
| "Treatment with aspirin inhibited spontaneous platelet aggregation but had little effect on the activated platelet profile." | 1.29 | Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. ( Bihour, C; Nurden, AT; Nurden, P; Raymond, JM; Smith, M, 1996) |
| "However, their effects on thrombus formation have rarely been evaluated in experimental animals in vivo." | 1.29 | In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. ( Iwamoto, Y; Naritomi, H; Nishimura, H; Sugita, M; Tachibana, H, 1996) |
| "Ticlopidine was administered orally to rats alone or in combination with aspirin and the efficacy of the association was determined in several experimental models." | 1.29 | The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. ( Bernat, A; Herbert, JM; Maffrand, JP; Samama, M, 1996) |
| "He-Ne laser-induced thrombus formation in arterioles and in venules was significantly inhibited by 100 mg/kg ticlopidine." | 1.28 | Antithrombotic effect of ticlopidine on He-Ne laser-induced thrombus formation in rat mesenteric microvessels. ( Ando, E; Ishii, I; Matsuda, T; Nagamatsu, Y; Sasaki, Y; Yamamoto, J, 1992) |
| "The composition of the thrombus is analyzed by double isotope labeling of platelets and fibrinogen." | 1.28 | [Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats]. ( Cazenave, JP; Freund, M; Mantz, F, 1991) |
| "Ticlopidine was significantly effective only at 100 mg/kg p." | 1.28 | Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. ( Hara, H; Kitajima, A; Shimada, H; Tamao, Y, 1991) |
| "The process of thrombus formation was investigated by electron microscopic study." | 1.28 | Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. ( Iwamoto, M; Kumada, T; Morishita, K; Tanaka, T; Tomikawa, M; Wada, M, 1991) |
| "With regard to thrombus dimensions, 1 patient treated with ticlopidine showed a decrease in thrombus size associated with a reduction of the scintigraphic activity." | 1.28 | Left ventricular thrombi: changes in size and in platelet deposition during treatment with indobufen and ticlopidine. ( Bellotti, P; Chiarella, F; Claudiani, F; Domenicucci, S; Lupi, G; Mazzotta, G; Scopinaro, G; Strada, P; Vecchio, C, 1990) |
| "The dry weight of thrombus in the graft in group B and group D was 39 +/- 3 mg and 30 +/- 2 mg, respectively on day 28." | 1.28 | The pathogenesis of thrombosis in venous prostheses. ( Itoh, T; Kambayashi, J; Kawasaki, T; Mori, T; Sakon, M; Shiba, E; Watase, M, 1990) |
| "The decrease in thrombus formation, and the diminished size of platelet aggregates, clearly indicated that ticlopidine impaired platelet-platelet interaction in this experimental flowing system." | 1.27 | Ticlopidine inhibits platelet thrombus formation studied in a flowing system. ( Bastida, E; Castillo, R; Escolar, G; Ordinas, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (4.37) | 18.7374 |
| 1990's | 83 (8.85) | 18.2507 |
| 2000's | 350 (37.31) | 29.6817 |
| 2010's | 456 (48.61) | 24.3611 |
| 2020's | 8 (0.85) | 2.80 |
| Authors | Studies |
|---|---|
| Sunkel, CE | 1 |
| Fau de Casa-Juana, M | 1 |
| Cillero, FJ | 1 |
| Priego, JG | 2 |
| Ortega, MP | 2 |
| Kirac, D | 2 |
| Yaman, AE | 1 |
| Doran, T | 1 |
| Mihmanli, M | 1 |
| Keles, EC | 1 |
| Zhao, Z | 1 |
| Ma, M | 1 |
| Huang, X | 1 |
| Sun, T | 1 |
| Han, K | 1 |
| Yang, S | 1 |
| Zhou, Y | 1 |
| Jain, N | 2 |
| Corken, A | 1 |
| Arthur, JM | 1 |
| Ware, J | 1 |
| Arulprakash, N | 1 |
| Dai, J | 1 |
| Phadnis, MA | 1 |
| Davis, O | 1 |
| Rahmatallah, Y | 1 |
| Mehta, JL | 1 |
| Hedayati, SS | 2 |
| Smyth, S | 1 |
| Jin, H | 1 |
| Song, J | 1 |
| Shen, X | 1 |
| Liang, Q | 1 |
| Sun, G | 1 |
| Yu, Y | 1 |
| Zhou, MC | 1 |
| Cao, SP | 1 |
| Zhong, HL | 1 |
| Zheng, P | 1 |
| Wang, L | 2 |
| Di, Y | 1 |
| Guo, T | 1 |
| Ming, JE | 1 |
| Kong, F | 1 |
| Yin, H | 1 |
| Zhang, L | 2 |
| Xie, F | 1 |
| Yang, N | 1 |
| Ping, C | 1 |
| Li, Y | 10 |
| Hou, J | 1 |
| Stefanini, GG | 1 |
| Vicenzi, M | 1 |
| Okur, Mİ | 1 |
| Çetinbaş, A | 1 |
| Altun, S | 1 |
| Öztan, M | 1 |
| Yıldız Altun, A | 1 |
| Özercan, İ | 1 |
| Wu, X | 1 |
| Liu, G | 1 |
| Lu, J | 1 |
| Zheng, XX | 1 |
| Cui, JG | 1 |
| Zhao, XY | 2 |
| Huang, XH | 1 |
| Rodés-Cabau, J | 1 |
| Masson, JB | 1 |
| Welsh, RC | 4 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 2 |
| Al-Qoofi, F | 1 |
| Généreux, P | 3 |
| Maluenda, G | 4 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Graham, BR | 1 |
| Menon, BK | 1 |
| Uzu, K | 1 |
| Shinke, T | 7 |
| Otake, H | 6 |
| Takaya, T | 3 |
| Osue, T | 5 |
| Iwasaki, M | 4 |
| Kinutani, H | 5 |
| Konishi, A | 5 |
| Kuroda, M | 3 |
| Takahashi, H | 4 |
| Terashita, D | 3 |
| Hirata, KI | 2 |
| Saito, S | 1 |
| Nakamura, M | 3 |
| Shite, J | 5 |
| Akasaka, T | 1 |
| Ramotowski, B | 1 |
| Żuk, A | 1 |
| Budaj, A | 3 |
| Yee, J | 1 |
| Kumar, V | 1 |
| Anuwatworn, A | 1 |
| Petrasko, M | 1 |
| Stys, A | 1 |
| Baschin, M | 1 |
| Selleng, S | 1 |
| Zeden, JP | 1 |
| Westphal, A | 1 |
| Kohlmann, T | 1 |
| Schroeder, HW | 1 |
| Greinacher, A | 1 |
| Thiele, T | 1 |
| Koltai, K | 1 |
| Kesmarky, G | 1 |
| Feher, G | 2 |
| Tibold, A | 1 |
| Toth, K | 1 |
| Spartalis, M | 1 |
| Tzatzaki, E | 1 |
| Spartalis, E | 1 |
| Damaskos, C | 1 |
| Athanasiou, A | 1 |
| Moris, D | 1 |
| Politou, M | 1 |
| Tilemann, L | 1 |
| Mohr, SK | 1 |
| Preusch, M | 1 |
| Chorianopoulos, E | 1 |
| Giannitsis, E | 2 |
| Katus, HA | 2 |
| Müller, OJ | 1 |
| Kounis, NG | 1 |
| Koniari, I | 1 |
| Tsigkas, G | 1 |
| Chourdakis, E | 1 |
| Roumeliotis, A | 1 |
| Patsouras, N | 1 |
| Soufras, G | 1 |
| Hahalis, G | 1 |
| Rubboli, A | 5 |
| Joo, HJ | 1 |
| Ahn, SG | 1 |
| Park, JH | 2 |
| Park, JY | 1 |
| Hong, SJ | 1 |
| Kim, SY | 1 |
| Choi, W | 1 |
| Gwon, H | 1 |
| Lim, YH | 1 |
| Kim, W | 2 |
| Kang, WC | 1 |
| Cho, YH | 1 |
| Kim, YH | 8 |
| Yoon, J | 3 |
| Shin, W | 1 |
| Hong, MK | 7 |
| Garg, S | 1 |
| Jang, Y | 3 |
| Lim, DS | 3 |
| Consolo, F | 1 |
| Pozzi, L | 1 |
| Sferrazza, G | 1 |
| Della Valle, P | 1 |
| D'Angelo, A | 1 |
| Slepian, MJ | 1 |
| Pappalardo, F | 1 |
| Wong, CK | 1 |
| Chan, PH | 1 |
| Lam, CC | 1 |
| Kwok, OH | 1 |
| Lam, YY | 1 |
| Siu, CW | 1 |
| Ding, L | 1 |
| Gu, Z | 1 |
| Wang, R | 1 |
| Fang, Y | 1 |
| Gao, BL | 1 |
| Li, TX | 1 |
| Li, L | 4 |
| Xu, GQ | 1 |
| Yang, BW | 1 |
| Godschalk, TC | 2 |
| Gimbel, ME | 1 |
| Nolet, WW | 1 |
| van Kessel, DJ | 1 |
| Amoroso, G | 1 |
| Dewilde, WJ | 1 |
| Wykrzykowska, JJ | 1 |
| Janssen, PW | 2 |
| Bergmeijer, TO | 2 |
| Kelder, JC | 8 |
| Heestermans, T | 1 |
| Ten Berg, JM | 12 |
| Ju, L | 1 |
| McFadyen, JD | 1 |
| Al-Daher, S | 1 |
| Alwis, I | 1 |
| Chen, Y | 1 |
| Tønnesen, LL | 1 |
| Maiocchi, S | 1 |
| Coulter, B | 1 |
| Calkin, AC | 1 |
| Felner, EI | 1 |
| Cohen, N | 1 |
| Yuan, Y | 1 |
| Schoenwaelder, SM | 1 |
| Cooper, ME | 1 |
| Zhu, C | 2 |
| Jackson, SP | 2 |
| Regev, E | 2 |
| Asher, E | 4 |
| Fefer, P | 2 |
| Beigel, R | 4 |
| Mazin, I | 3 |
| Matetzky, S | 4 |
| Fredgart, M | 1 |
| Gill, S | 1 |
| Brunner, S | 1 |
| Rizas, K | 1 |
| Hamm, W | 1 |
| Mehr, M | 1 |
| Lackermair, K | 1 |
| Toba, T | 1 |
| Sugizaki, Y | 1 |
| Takeshige, R | 1 |
| Onishi, H | 1 |
| Nagasawa, A | 1 |
| Tsukiyama, Y | 1 |
| Yanaka, K | 1 |
| Nagano, Y | 1 |
| Yamamoto, H | 2 |
| Kawamori, H | 2 |
| Matsuura, A | 2 |
| Ishihara, T | 1 |
| Matsumoto, D | 1 |
| Igarashi, N | 1 |
| Hayashi, T | 1 |
| Yasaka, Y | 1 |
| Kadotani, M | 1 |
| Fujii, T | 1 |
| Okada, M | 1 |
| Sakakibara, T | 1 |
| Wiersema, AM | 1 |
| Vos, JA | 1 |
| Bruijninckx, CMA | 1 |
| van Delden, OM | 1 |
| Reijnen, MMPJ | 1 |
| Vahl, A | 1 |
| Zeebregts, CJ | 1 |
| Moll, FL | 1 |
| Björkman, JA | 2 |
| Zachrisson, H | 2 |
| Forsberg, GB | 1 |
| von Bahr, H | 1 |
| Hansson, GI | 1 |
| Warner, TD | 2 |
| Nylander, S | 1 |
| Lanzillo, C | 1 |
| Di Roma, M | 1 |
| Sciahbasi, A | 2 |
| Minati, M | 1 |
| Maresca, L | 1 |
| Pendenza, G | 1 |
| Romagnoli, E | 2 |
| Summaria, F | 1 |
| Patrizi, R | 1 |
| Di Luozzo, M | 1 |
| Preziosi, P | 1 |
| Lioy, E | 1 |
| Romeo, F | 1 |
| Helft, G | 4 |
| Le Feuvre, C | 3 |
| Georges, JL | 1 |
| Carrie, D | 1 |
| Leclercq, F | 2 |
| Eltchaninoff, H | 1 |
| Furber, A | 1 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 2 |
| Cayla, G | 4 |
| Vicaut, E | 2 |
| Metzger, JP | 2 |
| Finkel, JB | 1 |
| Marhefka, GD | 1 |
| Weitz, HH | 1 |
| Lange, RA | 1 |
| Hillis, LD | 1 |
| Bhatt, DL | 20 |
| Stone, GW | 8 |
| Mahaffey, KW | 2 |
| Gibson, CM | 5 |
| Steg, PG | 13 |
| Hamm, CW | 6 |
| Price, MJ | 6 |
| Leonardi, S | 2 |
| Gallup, D | 1 |
| Bramucci, E | 2 |
| Radke, PW | 2 |
| Widimský, P | 3 |
| Tousek, F | 1 |
| Tauth, J | 1 |
| Spriggs, D | 2 |
| McLaurin, BT | 1 |
| Angiolillo, DJ | 24 |
| Liu, T | 2 |
| Prats, J | 2 |
| Todd, M | 2 |
| Skerjanec, S | 2 |
| White, HD | 4 |
| Harrington, RA | 7 |
| Theidel, U | 1 |
| Asseburg, C | 1 |
| Katus, H | 2 |
| Xie, X | 1 |
| Ma, YT | 1 |
| Yang, YN | 1 |
| Li, XM | 1 |
| Ma, X | 1 |
| Fu, ZY | 1 |
| Zheng, YY | 1 |
| Chen, BD | 1 |
| Liu, F | 2 |
| James, SK | 3 |
| Pieper, KS | 1 |
| Cannon, CP | 10 |
| Storey, RF | 9 |
| Becker, RC | 4 |
| Wallentin, L | 4 |
| Karathanos, A | 1 |
| Geisler, T | 3 |
| Park, J | 1 |
| Shin, DH | 1 |
| Kim, BK | 1 |
| Her, AY | 1 |
| Choi, HH | 1 |
| Kim, JS | 2 |
| Ko, YG | 2 |
| Choi, D | 2 |
| Kremke, M | 1 |
| Tang, M | 1 |
| Bak, M | 1 |
| Kristensen, KL | 1 |
| Hindsholm, K | 1 |
| Andreasen, JJ | 1 |
| Hjortdal, V | 1 |
| Jakobsen, CJ | 1 |
| Gao, YX | 1 |
| Yu, XZ | 1 |
| Yuan, YQ | 1 |
| Sun, TW | 1 |
| Dinicolantonio, JJ | 2 |
| Biondi-Zoccai, G | 2 |
| Baber, U | 3 |
| Bander, J | 1 |
| Karajgikar, R | 1 |
| Yadav, K | 1 |
| Hadi, A | 1 |
| Theodoropolous, K | 1 |
| Gukathasan, N | 1 |
| Roy, S | 1 |
| Sayeneni, S | 1 |
| Scott, SA | 2 |
| Kovacic, JC | 2 |
| Yu, J | 1 |
| Sartori, S | 1 |
| Mehran, R | 8 |
| Uribarri, J | 1 |
| Badimon, JJ | 9 |
| Muntner, P | 1 |
| Moreno, P | 2 |
| Kini, AS | 1 |
| Sharma, SK | 2 |
| Rouine-Rapp, K | 1 |
| McDermott, MW | 1 |
| Seivani, Y | 1 |
| Abdel-Wahab, M | 1 |
| Geist, V | 1 |
| Richardt, G | 2 |
| Sulimov, DS | 1 |
| El-Mawardy, M | 1 |
| Toelg, R | 1 |
| Akin, I | 2 |
| Riezebos, RK | 1 |
| Verheugt, FW | 7 |
| Wessel, DL | 1 |
| Berger, F | 1 |
| Li, JS | 2 |
| Dähnert, I | 1 |
| Rakhit, A | 1 |
| Fontecave, S | 1 |
| Newburger, JW | 1 |
| Fisch, AS | 1 |
| Perry, CG | 1 |
| Stephens, SH | 1 |
| Horenstein, RB | 1 |
| Shuldiner, AR | 2 |
| Park, MW | 1 |
| Jeong, SH | 1 |
| Her, SH | 1 |
| Kim, PJ | 1 |
| Cho, JS | 1 |
| Kim, CJ | 1 |
| Chung, WS | 3 |
| Seung, KB | 4 |
| Yim, HW | 1 |
| Chang, K | 2 |
| Huang, KN | 1 |
| Grandi, SM | 1 |
| Filion, KB | 2 |
| Eisenberg, MJ | 2 |
| Leoncini, M | 1 |
| Toso, A | 1 |
| Maioli, M | 1 |
| Giusti, B | 8 |
| Marcucci, R | 11 |
| Abbate, R | 9 |
| Bellandi, F | 1 |
| DePaula, KM | 1 |
| deLaorcade, AM | 1 |
| King, RG | 1 |
| Hughs, H | 1 |
| Boudrieau, RJ | 1 |
| Wong, BY | 1 |
| Davlouros, P | 2 |
| Gizas, V | 1 |
| Stavrou, K | 1 |
| Raptis, G | 1 |
| Alexopoulos, D | 2 |
| Francis, DO | 1 |
| Dang, JH | 1 |
| Fritz, MA | 1 |
| Garrett, CG | 1 |
| Díaz DE LA Llera, LS | 1 |
| Cubero Gómez, JM | 1 |
| Rangel, D | 1 |
| Parejo, J | 1 |
| Acosta, J | 1 |
| Fernández-Cisnal, A | 1 |
| Zafra, F | 1 |
| Benezet, J | 1 |
| Tanguay, JF | 4 |
| Bell, AD | 1 |
| Ackman, ML | 2 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 1 |
| Wong, G | 1 |
| Mehta, SR | 3 |
| Velázquez-Sánchez-de-Cima, S | 1 |
| Zamora-Ortiz, G | 1 |
| Hernández-Reyes, J | 1 |
| Vargas-Espinosa, J | 1 |
| García-Chavez, J | 1 |
| Rosales-Padrón, J | 1 |
| Ruiz-Delgado, GJ | 1 |
| Ruiz-Arguelles, A | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Mogabgab, O | 1 |
| Wiviott, SD | 10 |
| Sloan, S | 1 |
| Sabatine, MS | 3 |
| Antman, EM | 7 |
| Braunwald, E | 9 |
| Giugliano, RP | 1 |
| Aradi, D | 5 |
| Komócsi, A | 4 |
| Trenk, D | 3 |
| Gulba, D | 1 |
| Kiss, RG | 3 |
| Husted, S | 4 |
| Bonello, L | 5 |
| Sibbing, D | 15 |
| Collet, JP | 7 |
| Huber, K | 11 |
| Nishio, R | 4 |
| Nakagawa, M | 3 |
| Inoue, T | 5 |
| Hariki, H | 3 |
| Taniguchi, Y | 3 |
| Hiranuma, N | 2 |
| Hirata, K | 5 |
| Pandit, A | 1 |
| Aryal, MR | 1 |
| Aryal Pandit, A | 1 |
| Jalota, L | 1 |
| Hakim, FA | 1 |
| Mookadam, F | 1 |
| Lee, HR | 1 |
| Tleyjeh, IM | 1 |
| Robier, C | 2 |
| Stettin, M | 1 |
| Neubauer, M | 2 |
| Feres, F | 1 |
| Costa, RA | 1 |
| Abizaid, A | 1 |
| Leon, MB | 5 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 1 |
| Negoita, M | 1 |
| Liu, M | 1 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 2 |
| Brener, SJ | 1 |
| LaSalle, L | 1 |
| Cialdella, P | 1 |
| Gustapane, M | 1 |
| Camaioni, C | 1 |
| Biasucci, LM | 1 |
| Sweeny, J | 1 |
| Li, JR | 1 |
| Krishnan, P | 1 |
| Hulot, JS | 4 |
| Kini, A | 1 |
| Serebruany, VL | 7 |
| Pokov, AN | 1 |
| Fortmann, SD | 1 |
| Tilly, P | 1 |
| Charles, AL | 1 |
| Ludwig, S | 1 |
| Slimani, F | 1 |
| Gross, S | 1 |
| Meilhac, O | 1 |
| Geny, B | 1 |
| Stefansson, K | 2 |
| Gurney, ME | 2 |
| Fabre, JE | 2 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Rollini, F | 3 |
| Franchi, F | 2 |
| Cho, JR | 2 |
| Degroat, C | 2 |
| Bhatti, M | 2 |
| Ferrante, E | 1 |
| Patel, R | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 4 |
| Desai, B | 4 |
| Ferreiro, J | 1 |
| Muniz-Lozano, A | 1 |
| Zenni, MM | 2 |
| Guzman, LA | 3 |
| Bass, TA | 6 |
| Tatarunas, V | 2 |
| Jankauskiene, L | 1 |
| Kupstyte, N | 2 |
| Skipskis, V | 2 |
| Gustiene, O | 2 |
| Grybauskas, P | 1 |
| Lesauskaite, V | 2 |
| Daali, Y | 1 |
| Reny, JL | 1 |
| Fontana, P | 2 |
| Tornyos, A | 1 |
| Pintér, T | 2 |
| Vorobcsuk, A | 3 |
| Kónyi, A | 2 |
| Faluközy, J | 1 |
| Veress, G | 1 |
| Magyari, B | 2 |
| Horváth, IG | 3 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 1 |
| Samoš, M | 1 |
| Šimonová, R | 1 |
| Kovář, F | 1 |
| Duraj, L | 1 |
| Fedorová, J | 1 |
| Galajda, P | 1 |
| Staško, J | 1 |
| Fedor, M | 1 |
| Kubisz, P | 1 |
| Mokáň, M | 1 |
| Viswanathan, GN | 2 |
| Marshall, SM | 2 |
| Balasubramaniam, K | 2 |
| Zaman, AG | 3 |
| Dalén, M | 2 |
| Sartipy, U | 1 |
| Corbascio, M | 1 |
| Lund, LH | 1 |
| Grinnemo, KH | 1 |
| Holm, M | 1 |
| Tornvall, P | 1 |
| van der Linden, J | 2 |
| Kleiman, NS | 4 |
| Parodi, G | 3 |
| De Luca, G | 6 |
| Bellandi, B | 1 |
| Comito, V | 1 |
| Valenti, R | 3 |
| Carrabba, N | 2 |
| Migliorini, A | 4 |
| Ramazzotti, RN | 1 |
| Gensini, GF | 7 |
| Antoniucci, D | 5 |
| Gabrielli, A | 1 |
| Bouatou, Y | 1 |
| Saudan, P | 1 |
| Yang, Y | 1 |
| Kong, D | 2 |
| Wang, C | 1 |
| Chen, G | 1 |
| Shan, F | 1 |
| Qi, K | 1 |
| Ma, L | 1 |
| Murray, AM | 1 |
| Keville, N | 1 |
| Gray, S | 1 |
| Oran, I | 1 |
| Cinar, C | 1 |
| Bozkaya, H | 1 |
| Korkmaz, M | 1 |
| Loh, JP | 1 |
| Torguson, R | 4 |
| Pendyala, LK | 1 |
| Omar, A | 1 |
| Chen, F | 2 |
| Satler, LF | 9 |
| Pichard, AD | 7 |
| Waksman, R | 9 |
| Lai, YS | 1 |
| Yang, LT | 1 |
| Kao Yang, YH | 1 |
| Liu, PY | 1 |
| Chen, J | 2 |
| Meng, H | 1 |
| Xu, L | 2 |
| Liu, J | 2 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 2 |
| Li, C | 1 |
| Eikelboom, JW | 6 |
| Mezouar, S | 1 |
| Darbousset, R | 1 |
| Dignat-George, F | 1 |
| Panicot-Dubois, L | 1 |
| Dubois, C | 1 |
| Cavalli, G | 1 |
| Sallemi, C | 1 |
| Berti, A | 1 |
| Komiya, R | 1 |
| Kamintani, K | 1 |
| Kubo, E | 1 |
| Hattori, M | 1 |
| Kataoka, H | 1 |
| Iwase, Y | 1 |
| Miyoshi, H | 1 |
| Minami, M | 1 |
| Kato, S | 1 |
| Arai, R | 1 |
| Yoshida, H | 1 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 3 |
| Tremoli, E | 1 |
| Bagai, A | 1 |
| Wang, Y | 2 |
| Wang, TY | 1 |
| Curtis, JP | 1 |
| Gurm, HS | 1 |
| Shah, B | 1 |
| Cheema, AN | 1 |
| Peterson, ED | 2 |
| Saucedo, JF | 2 |
| Granger, CB | 3 |
| Roe, MT | 1 |
| McNamara, RL | 1 |
| Alexander, KP | 1 |
| Moeckel, D | 1 |
| Jeong, SS | 1 |
| Sun, X | 2 |
| Broekman, MJ | 1 |
| Nguyen, A | 1 |
| Drosopoulos, JH | 1 |
| Marcus, AJ | 1 |
| Robson, SC | 1 |
| Chen, R | 1 |
| Abendschein, D | 1 |
| Wu, H | 1 |
| Wang, Q | 1 |
| Zhou, J | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Mayer, K | 2 |
| Bernlochner, I | 4 |
| Braun, S | 6 |
| Schulz, S | 6 |
| Orban, M | 2 |
| Morath, T | 6 |
| Cala, L | 1 |
| Hoppmann, P | 1 |
| Schunkert, H | 2 |
| Laugwitz, KL | 1 |
| Kastrati, A | 17 |
| Sorich, MJ | 2 |
| Rowland, A | 1 |
| McKinnon, RA | 1 |
| Wiese, MD | 2 |
| Almendro-Delia, M | 2 |
| Blanco Ponce, E | 1 |
| Gomez-Domínguez, R | 1 |
| Gonzalez-Matos, C | 1 |
| Lobo-Gonzalez, M | 1 |
| Caballero-Garcia, A | 1 |
| Hidalgo-Urbano, R | 2 |
| Cruz-Fernandez, MJ | 1 |
| Garcia-Rubira, JC | 1 |
| Tantry, US | 15 |
| Gesheff, M | 1 |
| Bliden, KP | 6 |
| Gurbel, PA | 20 |
| Lev, EI | 3 |
| Jeong, YH | 4 |
| Pandya, S | 1 |
| Kang, K | 1 |
| Franzese, C | 1 |
| Colombo, A | 6 |
| Chieffo, A | 1 |
| Mauri, L | 3 |
| Kereiakes, DJ | 5 |
| Yeh, RW | 3 |
| Driscoll-Shempp, P | 1 |
| Cutlip, DE | 2 |
| Normand, SL | 1 |
| Cohen, DJ | 4 |
| Holmes, DR | 4 |
| Krucoff, MW | 1 |
| Hermiller, J | 1 |
| Dauerman, HL | 1 |
| Simon, DI | 2 |
| Kandzari, DE | 2 |
| Garratt, KN | 2 |
| Lee, DP | 1 |
| Pow, TK | 1 |
| Ver Lee, P | 1 |
| Rinaldi, MJ | 2 |
| Massaro, JM | 1 |
| Yakovlev, DS | 1 |
| Spasov, AA | 1 |
| Bukatina, TM | 1 |
| Smirnov, AV | 1 |
| Suzdalev, KF | 1 |
| Kristensen, SL | 1 |
| Galløe, AM | 1 |
| Thuesen, L | 2 |
| Kelbæk, H | 1 |
| Thayssen, P | 2 |
| Havndrup, O | 1 |
| Hansen, PR | 2 |
| Bligaard, N | 1 |
| Saunamäki, K | 2 |
| Junker, A | 1 |
| Aarøe, J | 1 |
| Abildgaard, U | 1 |
| Jeppesen, JL | 1 |
| Huynh, K | 1 |
| Sawada, T | 3 |
| Masaru, K | 1 |
| Geersing, GJ | 1 |
| Kappelle, LJ | 1 |
| Braun, OÖ | 1 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 1 |
| Koul, S | 1 |
| Tydén, P | 1 |
| Scherstén, F | 1 |
| Jovinge, S | 1 |
| Svensson, PJ | 1 |
| Gustav Smith, J | 1 |
| van der Pals, J | 1 |
| Capodanno, D | 3 |
| Gori, AM | 7 |
| Paniccia, R | 4 |
| Cantini, G | 1 |
| Marrani, M | 1 |
| Yang, J | 2 |
| Zhu, X | 1 |
| Wang, X | 3 |
| Peng, L | 1 |
| Li, X | 2 |
| Cheng, P | 1 |
| Yin, T | 1 |
| Jeong, KH | 1 |
| Cho, JH | 1 |
| Woo, JS | 1 |
| Kim, JB | 1 |
| Kim, WS | 1 |
| Lee, TW | 1 |
| Kim, KS | 2 |
| Ihm, CG | 1 |
| Garg, P | 1 |
| Galper, BZ | 1 |
| Martin-Yuste, V | 2 |
| Alvarez-Contreras, L | 1 |
| Sabaté, M | 6 |
| Kelbaek, H | 1 |
| Jørgensen, E | 1 |
| Kocka, V | 1 |
| Zaliunas, R | 1 |
| Zaliaduonyte-Peksiene, D | 1 |
| Grabauskyte, I | 1 |
| Dovidaitiene, D | 1 |
| Bumblauskas, K | 1 |
| Gonzalez-Torres, L | 1 |
| Garcia-Alcantara, Á | 1 |
| Reina-Toral, A | 1 |
| Arboleda Sánchez, JA | 1 |
| Rodríguez Yañez, JC | 1 |
| García Rubira, JC | 1 |
| Zhang, YJ | 1 |
| Zhao, YL | 1 |
| Xu, B | 2 |
| Han, YL | 1 |
| Li, B | 1 |
| Liu, Q | 1 |
| Su, X | 1 |
| Pang, S | 1 |
| Lu, SZ | 2 |
| Guo, XF | 1 |
| Yang, YJ | 1 |
| Rosencher, J | 1 |
| Gouffran, G | 1 |
| Bougouin, W | 1 |
| Varenne, O | 1 |
| Keaney, JF | 1 |
| Spencer, FA | 1 |
| Guyatt, G | 1 |
| Ntalas, IV | 1 |
| Kalantzi, KI | 2 |
| Tsoumani, ME | 1 |
| Vakalis, JN | 1 |
| Vasilakopoulos, V | 1 |
| Vardakis, K | 1 |
| Vemmos, KN | 1 |
| Voukelatou, M | 1 |
| Giannakoulas, G | 1 |
| Giatrakos, I | 1 |
| Giogiakas, V | 1 |
| Goumas, G | 1 |
| Dimoulis, N | 1 |
| Draganigos, A | 1 |
| Efthimiadis, I | 1 |
| Thoma, M | 1 |
| Kazakos, E | 1 |
| Kipouridis, N | 1 |
| Konstantinou, S | 1 |
| Bourdakis, A | 1 |
| Nikolopoulos, D | 1 |
| Peltekis, L | 1 |
| Prokopakis, N | 1 |
| Sinteles, I | 1 |
| Stroumbis, CS | 1 |
| Terzoudi, K | 1 |
| Tsilias, K | 1 |
| Xaraktsis, I | 1 |
| Charmpas, C | 1 |
| Hatziathanasiou, G | 1 |
| Christogiannis, Z | 1 |
| Panagiotakos, DB | 1 |
| Goudevenos, JA | 1 |
| Tselepis, AD | 2 |
| Li, S | 1 |
| Shi, Y | 2 |
| Wang, H | 2 |
| Zhang, W | 1 |
| Sipahi, I | 1 |
| Dohan, JL | 1 |
| Marrs, JC | 1 |
| Pfisterer, M | 1 |
| Kaiser, C | 1 |
| Jeger, R | 1 |
| Tomoda, H | 1 |
| Jia, M | 1 |
| Li, Z | 2 |
| Chu, H | 1 |
| Chen, K | 1 |
| Ma, ST | 1 |
| Dai, GL | 1 |
| Cheng, XG | 1 |
| Zhao, WZ | 1 |
| Sun, BT | 1 |
| Ju, WZ | 1 |
| Tan, HS | 1 |
| Kirtane, A | 1 |
| Freynhofer, MK | 2 |
| ten Berg, J | 1 |
| Janssen, P | 1 |
| Siller-Matula, JM | 3 |
| Patti, G | 3 |
| Mangiacapra, F | 2 |
| Valgimigli, M | 5 |
| Morel, O | 8 |
| Palmerini, T | 1 |
| Cuisset, T | 3 |
| Lerman, TT | 1 |
| Zahger, D | 5 |
| Arad, J | 1 |
| Gilutz, H | 1 |
| Reitblat, O | 1 |
| Shimony, A | 1 |
| Suzuki, Y | 1 |
| Suzuki, H | 1 |
| Umetsu, R | 1 |
| Uranishi, H | 1 |
| Abe, J | 1 |
| Nishibata, Y | 1 |
| Sekiya, Y | 1 |
| Miyamura, N | 1 |
| Hara, H | 2 |
| Tsuchiya, T | 1 |
| Kinosada, Y | 1 |
| Verdoia, M | 3 |
| Barbieri, L | 3 |
| Suryapranata, H | 4 |
| Calabrò, P | 1 |
| Saia, F | 1 |
| Plicner, D | 1 |
| Mazur, P | 2 |
| Hymczak, H | 1 |
| Stoliński, J | 1 |
| Litwinowicz, R | 1 |
| Drwiła, R | 1 |
| Undas, A | 3 |
| Agewall, S | 1 |
| Lip, GY | 6 |
| Johnson, SG | 1 |
| Gruntowicz, D | 1 |
| Chua, T | 1 |
| Morlock, RJ | 1 |
| Sueta, D | 2 |
| Hokimoto, S | 2 |
| Ogawa, H | 2 |
| Capranzano, P | 3 |
| Castiglioni, B | 1 |
| Pottegård, A | 1 |
| García Rodríguez, LA | 1 |
| Poulsen, FR | 1 |
| Hallas, J | 1 |
| Gaist, D | 1 |
| Polzin, A | 1 |
| Afzal, S | 1 |
| Balzer, J | 1 |
| Rassaf, T | 1 |
| Kelm, M | 2 |
| Zeus, T | 1 |
| Makkawi, M | 1 |
| Moheimani, F | 1 |
| Alserihi, R | 1 |
| Howells, D | 1 |
| Wright, M | 1 |
| Ashman, L | 1 |
| Jackson, DE | 1 |
| Lee, S | 3 |
| Hizoh, I | 1 |
| Kovacs, A | 1 |
| Horvath, Z | 1 |
| Kiss, N | 1 |
| Toth-Zsamboki, E | 1 |
| Rangé, G | 1 |
| Van Belle, E | 1 |
| Elhadad, S | 1 |
| Rousseau, H | 1 |
| Sabouret, P | 1 |
| O'Connor, SA | 2 |
| Abtan, J | 1 |
| Kerneis, M | 1 |
| Saint-Etienne, C | 1 |
| Barthélémy, O | 2 |
| Beygui, F | 3 |
| Silvain, J | 2 |
| Montalescot, G | 15 |
| Golukhova, EZ | 1 |
| Grigorian, MV | 1 |
| Ryabinina, MN | 1 |
| Bulaeva, NI | 1 |
| Fortmann, S | 1 |
| Izumi, D | 1 |
| Miyahara, M | 1 |
| Fujimoto, N | 1 |
| Fukuoka, S | 1 |
| Sakai, M | 1 |
| Dohi, K | 1 |
| Ito, M | 2 |
| Kuliczkowski, W | 3 |
| Sliwka, J | 1 |
| Kaczmarski, J | 1 |
| Zysko, D | 1 |
| Zembala, M | 3 |
| Steter, D | 1 |
| Gierlotka, M | 1 |
| Kim, MH | 2 |
| Serebruany, V | 4 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Schoechlin, S | 1 |
| Ruile, P | 1 |
| Neumann, FJ | 7 |
| Pache, G | 1 |
| Brodie, BR | 2 |
| Garg, A | 1 |
| Stuckey, TD | 1 |
| Kirtane, AJ | 2 |
| Witzenbichler, B | 1 |
| Maehara, A | 1 |
| Weisz, G | 1 |
| Metzger, DC | 1 |
| Parvataneni, R | 1 |
| Sabbag, A | 2 |
| Herscovici, R | 1 |
| Shlomo, N | 1 |
| Atar, S | 2 |
| Hammerman, H | 1 |
| Polak, A | 2 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Pergolini, P | 2 |
| Rolla, R | 2 |
| Nardin, M | 1 |
| Schaffer, A | 1 |
| Marino, P | 2 |
| Bellomo, G | 2 |
| Trindade, AJ | 1 |
| Hirten, R | 1 |
| Slattery, E | 1 |
| Inamdar, S | 1 |
| Sejpal, DV | 1 |
| Thomas, MR | 1 |
| Outteridge, SN | 1 |
| Ajjan, RA | 2 |
| Phoenix, F | 2 |
| Sangha, GK | 1 |
| Faulkner, RE | 1 |
| Ecob, R | 1 |
| Judge, HM | 2 |
| Khan, H | 1 |
| West, LE | 1 |
| Dockrell, DH | 1 |
| Sabroe, I | 1 |
| Geddings, JE | 1 |
| Hisada, Y | 1 |
| Boulaftali, Y | 1 |
| Getz, TM | 1 |
| Whelihan, M | 1 |
| Fuentes, R | 1 |
| Dee, R | 1 |
| Cooley, BC | 2 |
| Key, NS | 1 |
| Wolberg, AS | 1 |
| Bergmeier, W | 2 |
| Mackman, N | 1 |
| Grifoni, E | 1 |
| Caroff, E | 1 |
| Hubler, F | 1 |
| Meyer, E | 1 |
| Renneberg, D | 1 |
| Gnerre, C | 1 |
| Treiber, A | 1 |
| Rey, M | 1 |
| Hess, P | 1 |
| Steiner, B | 1 |
| Hilpert, K | 1 |
| Riederer, MA | 1 |
| Kim, JY | 1 |
| Choi, YS | 1 |
| Kwon, A | 1 |
| Chung, WB | 1 |
| Park, CS | 1 |
| Kim, HY | 2 |
| Lee, MY | 1 |
| Oliphant, CS | 1 |
| Trevarrow, BJ | 1 |
| Dobesh, PP | 1 |
| King, R | 1 |
| Ketterer, U | 1 |
| D'Ancona, G | 1 |
| Siegel, I | 1 |
| Ortak, J | 1 |
| Ince, H | 4 |
| Kische, S | 1 |
| Adams-Huet, B | 1 |
| Sarode, R | 1 |
| Toto, RD | 1 |
| Banerjee, S | 2 |
| Arima, Y | 1 |
| Kaikita, K | 1 |
| Ishii, M | 1 |
| Oimatsu, Y | 1 |
| Sakamoto, K | 1 |
| Tsujita, K | 1 |
| Kojima, S | 1 |
| Nakagawa, K | 1 |
| Morofuji, T | 1 |
| Inaba, S | 1 |
| Hitsumoto, T | 1 |
| Takahashi, K | 1 |
| Aisu, H | 1 |
| Higashi, H | 1 |
| Saito, M | 1 |
| Ohshima, K | 1 |
| Ikeda, S | 1 |
| Hamada, M | 1 |
| Sumimoto, T | 1 |
| Erdem, A | 1 |
| Avcilar, T | 1 |
| Yesilcimen, K | 1 |
| Guney, AI | 1 |
| Emre, A | 1 |
| Yazici, S | 1 |
| Terzi, S | 1 |
| Kaspar, EC | 1 |
| Cetin, SE | 1 |
| Isbir, T | 1 |
| Guo, LZ | 1 |
| Kim, TH | 1 |
| Park, JS | 2 |
| Jin, E | 1 |
| Shim, CH | 1 |
| Choi, SY | 1 |
| Tang, C | 1 |
| Lei, D | 1 |
| Huang, L | 1 |
| Wang, G | 1 |
| Chi, Q | 1 |
| Zheng, Y | 1 |
| Gachet, C | 8 |
| Mangin, PH | 1 |
| Zhu, L | 1 |
| Oguri, A | 1 |
| Ando, J | 1 |
| Watanabe, Y | 2 |
| Kozuma, K | 1 |
| Ishikawa, S | 2 |
| Hosogoe, N | 1 |
| Isshiki, T | 1 |
| Jayakumar, T | 1 |
| Yang, CH | 2 |
| Geraldine, P | 1 |
| Yen, TL | 1 |
| Sheu, JR | 1 |
| Pereira, NL | 1 |
| Geske, JB | 1 |
| Mayr, M | 1 |
| Shah, SH | 1 |
| Rihal, CS | 2 |
| Basaraba, JE | 1 |
| Barry, AR | 1 |
| Whalen, JD | 1 |
| Davies, G | 2 |
| Du, M | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Shimada, YJ | 1 |
| Bansilal, S | 1 |
| Himmelmann, A | 1 |
| Neely, B | 1 |
| Lopes, RD | 1 |
| Abu-Much, A | 1 |
| Goldenberg, I | 1 |
| Segev, A | 1 |
| Shlezinger, M | 1 |
| Yamazaki, M | 2 |
| Ohnishi, T | 2 |
| Hosokawa, K | 2 |
| Yamaguchi, K | 1 |
| Yoneyama, T | 1 |
| Kawashima, A | 1 |
| Okada, Y | 1 |
| Kitagawa, K | 1 |
| Uchiyama, S | 2 |
| Fett, N | 1 |
| Sinha, A | 2 |
| Morici, N | 1 |
| Perna, E | 1 |
| Cipriani, M | 1 |
| Femia, EA | 1 |
| Oliva, F | 1 |
| Frigerio, M | 1 |
| Cattaneo, M | 3 |
| Hong, KS | 1 |
| Lee, SH | 2 |
| Kim, EG | 1 |
| Cho, KH | 1 |
| Chang, DI | 1 |
| Rha, JH | 1 |
| Bae, HJ | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Park, JM | 1 |
| Cha, JK | 1 |
| Yu, KH | 1 |
| Lee, YS | 1 |
| Lee, SJ | 1 |
| Choi, JC | 1 |
| Cho, YJ | 1 |
| Kwon, SU | 1 |
| Kim, GM | 1 |
| Sohn, SI | 1 |
| Park, KY | 1 |
| Kang, DW | 1 |
| Sohn, CH | 1 |
| Lee, J | 1 |
| Yoon, BW | 1 |
| Di Vito, L | 1 |
| Versaci, F | 1 |
| Limbruno, U | 1 |
| Pawlowski, T | 1 |
| Gatto, L | 1 |
| Cattabiani, MA | 1 |
| Micari, A | 1 |
| Trivisonno, A | 1 |
| Marco, V | 1 |
| Prati, F | 1 |
| Dugo, D | 1 |
| Bordignon, S | 1 |
| Konstantinou, A | 1 |
| Perrotta, L | 1 |
| Fürnkranz, A | 1 |
| Chun, JK | 1 |
| Schmidt, B | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 2 |
| Kedhi, E | 1 |
| Lee, SW | 7 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 2 |
| Zhang, H | 3 |
| Lauver, DA | 1 |
| Sun, D | 1 |
| Hollenberg, PF | 1 |
| Chen, YE | 1 |
| Osawa, Y | 1 |
| Eitzman, DT | 1 |
| Li, RH | 1 |
| Stern, JA | 1 |
| Ho, V | 1 |
| Tablin, F | 1 |
| Harris, SP | 1 |
| Gunarathne, A | 1 |
| Hussain, S | 1 |
| Gershlick, AH | 4 |
| Myat, A | 1 |
| Kubica, J | 2 |
| Liang, JJ | 1 |
| Fenstad, ER | 1 |
| Janish, CD | 1 |
| Sinak, LJ | 1 |
| Karadağ, B | 1 |
| Brice, AE | 1 |
| Hernandez, GA | 1 |
| Sanchez, M | 1 |
| Haynick, M | 1 |
| Mendoza, CE | 1 |
| Cavallari, LH | 1 |
| Obeng, AO | 1 |
| Windecker, S | 3 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Vranckx, P | 2 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 2 |
| Kukula, K | 1 |
| Klopotowski, M | 1 |
| Kunicki, PK | 1 |
| Jamiolkowski, J | 1 |
| Debski, A | 1 |
| Bekta, P | 1 |
| Polanska-Skrzypczyk, M | 1 |
| Chmielak, Z | 1 |
| Witkowski, A | 3 |
| Reiner, MF | 1 |
| Akhmedov, A | 1 |
| Stivala, S | 1 |
| Keller, S | 1 |
| Gaul, DS | 1 |
| Bonetti, NR | 1 |
| Savarese, G | 1 |
| Glanzmann, M | 1 |
| Ruf, W | 1 |
| Matter, CM | 1 |
| Lüscher, TF | 2 |
| Camici, GG | 1 |
| Beer, JH | 1 |
| Piccolo, R | 1 |
| Magnani, G | 2 |
| Ariotti, S | 1 |
| Gargiulo, G | 1 |
| Marino, M | 1 |
| Santucci, A | 1 |
| Franzone, A | 1 |
| Tebaldi, M | 3 |
| Heg, D | 1 |
| Ghodsizad, A | 1 |
| Badiye, A | 1 |
| Zeriouh, M | 1 |
| Pae, W | 1 |
| Koerner, MM | 1 |
| Loebe, M | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Renou, P | 1 |
| Sibon, I | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Sakata, C | 1 |
| Suzuki, KI | 1 |
| Morita, Y | 1 |
| Kawasaki, T | 3 |
| Tong, X | 1 |
| Lo, WT | 1 |
| Mo, D | 1 |
| Gao, F | 1 |
| Ma, N | 1 |
| Wang, B | 1 |
| Miao, Z | 1 |
| Saydam, F | 1 |
| Değirmenci, İ | 1 |
| Birdane, A | 2 |
| Özdemir, M | 1 |
| Ulus, T | 1 |
| Özbayer, C | 1 |
| Çolak, E | 1 |
| Ata, N | 1 |
| Güneş, HV | 1 |
| Le, TT | 1 |
| Breet, NJ | 6 |
| Hackeng, CM | 7 |
| Hudec, V | 1 |
| Bena, M | 1 |
| Artemiou, P | 1 |
| Gasparovic, I | 1 |
| Hulman, M | 1 |
| Tam, CC | 1 |
| Kwok, J | 1 |
| Wong, A | 1 |
| Yung, A | 1 |
| Shea, C | 1 |
| Kong, SL | 1 |
| Tang, WH | 1 |
| Siu, D | 1 |
| Chan, R | 1 |
| Payanam Ramachandra, U | 1 |
| Shenoy, SJ | 1 |
| Arumugham, S | 1 |
| Jahn, K | 1 |
| Suchodolski, K | 1 |
| Schäfer, A | 2 |
| Sahlmann, B | 1 |
| Küster, U | 1 |
| Echtermeyer, F | 1 |
| Calmer, S | 1 |
| Theilmeier, G | 1 |
| Johanning, K | 1 |
| Duconge, J | 1 |
| Hernandez-Suarez, DF | 1 |
| Orme, R | 1 |
| Danielak, D | 1 |
| Komosa, A | 1 |
| Tomczak, A | 1 |
| Graczyk-Szuster, A | 1 |
| Lesiak, M | 1 |
| Główka, F | 1 |
| Karaźniewicz-Łada, M | 1 |
| Chase, M | 1 |
| Ozdemir, K | 1 |
| Aygül, N | 1 |
| Can, I | 1 |
| Aribaş, A | 1 |
| Shim, CY | 1 |
| Yoon, SJ | 1 |
| Park, S | 1 |
| Choi, JR | 1 |
| Ha, JW | 1 |
| Chung, N | 1 |
| Shim, WH | 1 |
| Cho, SY | 1 |
| Bauersachs, J | 1 |
| Eigenthaler, M | 1 |
| Maeng, M | 1 |
| Jensen, LO | 1 |
| Kaltoft, A | 1 |
| Hansen, HH | 1 |
| Bøttcher, M | 1 |
| Lassen, JF | 1 |
| Krusell, LR | 1 |
| Rasmussen, K | 1 |
| Pedersen, L | 1 |
| Sørensen, HT | 1 |
| Johnsen, SP | 1 |
| Mood, GR | 1 |
| Bavry, AA | 2 |
| Halperin, JL | 2 |
| Airaksinen, KE | 2 |
| Buerke, M | 3 |
| Eeckhout, E | 1 |
| Freedman, SB | 1 |
| Schlitt, A | 4 |
| Tse, HF | 1 |
| Arai, F | 1 |
| Kita, T | 1 |
| Sasaki, S | 2 |
| Pokov, I | 1 |
| Vahabi, J | 1 |
| Atar, D | 2 |
| Mehilli, J | 6 |
| Byrne, RA | 4 |
| Iijima, R | 1 |
| Büttner, HJ | 2 |
| Khattab, AA | 1 |
| Blankenship, JC | 1 |
| Pache, J | 1 |
| Minners, J | 1 |
| Seyfarth, M | 1 |
| Graf, I | 2 |
| Skelding, KA | 1 |
| Dirschinger, J | 1 |
| Berger, PB | 16 |
| Schömig, A | 13 |
| Madersbacher, S | 1 |
| Ponholzer, A | 1 |
| Cohen, M | 2 |
| Hoekstra, J | 1 |
| Giugliano, R | 1 |
| Hollander, JE | 1 |
| Manoukian, SV | 5 |
| Pollack, CV | 2 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 3 |
| Jackowski, L | 1 |
| Stocks, N | 1 |
| Rowett, D | 1 |
| Krötz, F | 1 |
| Sohn, HY | 1 |
| Klauss, V | 1 |
| Wusirika, R | 1 |
| Rao, P | 1 |
| Fourtounas, C | 1 |
| Vlachojannis, JG | 1 |
| Macia, JC | 1 |
| Roubille, F | 1 |
| Rabesendratana, H | 1 |
| Piot, C | 1 |
| Schved, JF | 1 |
| Müller-Ehmsen, J | 1 |
| Erdmann, E | 1 |
| Jozic, J | 1 |
| Roldán, V | 1 |
| Marín, F | 1 |
| Lansky, AJ | 3 |
| Tsuchiya, Y | 1 |
| Brener, M | 1 |
| Cristea, E | 1 |
| Pietras, C | 1 |
| Grines, CL | 1 |
| Cox, DA | 3 |
| Garcia, E | 1 |
| Tcheng, JE | 2 |
| Guagliumi, G | 2 |
| Stuckey, T | 1 |
| Turco, M | 1 |
| Carroll, JD | 1 |
| Rutherford, BD | 1 |
| Moses, J | 1 |
| Feher, A | 1 |
| Pusch, G | 1 |
| Lupkovics, G | 1 |
| Szapary, L | 1 |
| Papp, E | 1 |
| Demaret, C | 1 |
| Crousier, M | 1 |
| Hanss, M | 1 |
| Ffrench, P | 1 |
| Piriou, V | 2 |
| Mega, JL | 2 |
| Close, SL | 1 |
| Shen, L | 2 |
| Hockett, RD | 1 |
| Brandt, JT | 1 |
| Walker, JR | 1 |
| Macias, W | 1 |
| Hochholzer, W | 1 |
| Müller, B | 1 |
| Stratz, C | 1 |
| Valina, CM | 1 |
| Schmiebusch, P | 1 |
| Wong, PC | 2 |
| Crain, EJ | 2 |
| Watson, CA | 2 |
| Hua, J | 1 |
| Schumacher, WA | 1 |
| Rehfuss, R | 1 |
| Shantsila, E | 2 |
| Fedi, S | 1 |
| Antonucci, E | 2 |
| Buonamici, P | 3 |
| Roy, AM | 1 |
| Baboushkin, T | 1 |
| Rinfret, S | 1 |
| Polonski, L | 1 |
| Watala, C | 1 |
| Filipiak, K | 1 |
| Golanski, J | 1 |
| Sitkiewicz, D | 1 |
| Pregowski, J | 1 |
| Gorski, J | 1 |
| Opolski, G | 1 |
| Arnesen, H | 1 |
| Kristensen, SD | 2 |
| De Caterina, R | 1 |
| Singh, J | 1 |
| Zeller, W | 1 |
| Zhou, N | 1 |
| Hategen, G | 1 |
| Mishra, R | 1 |
| Polozov, A | 1 |
| Yu, P | 1 |
| Onua, E | 1 |
| Zhang, J | 1 |
| Zembower, D | 1 |
| Kiselyov, A | 1 |
| Ramírez, JL | 1 |
| Sigthorsson, G | 1 |
| Bjornsson, JM | 1 |
| Thorsteinsdottir, M | 1 |
| Andrésson, T | 1 |
| Bjarnadottir, M | 1 |
| Magnusson, O | 1 |
| Milani, RV | 1 |
| Mohler, ER | 1 |
| Mak, KH | 3 |
| Shao, M | 3 |
| Haffner, SM | 2 |
| Hankey, GJ | 5 |
| Johnston, SC | 2 |
| Steinhubl, SR | 12 |
| Fox, KA | 7 |
| Topol, EJ | 12 |
| Jensen, MK | 1 |
| Hüttel, M | 1 |
| Hussein, A | 1 |
| Kasmani, R | 1 |
| Irani, F | 1 |
| Mohan, G | 1 |
| Vogt, W | 2 |
| von Beckerath, N | 8 |
| Mahla, E | 3 |
| Antonino, MJ | 1 |
| Brennan, DM | 3 |
| Mukerji, G | 1 |
| Munasinghe, I | 1 |
| Raza, A | 1 |
| Dai, X | 1 |
| Makaryus, AN | 1 |
| Makaryus, JN | 1 |
| Jauhar, R | 1 |
| Prasad, A | 1 |
| Steinwender, C | 1 |
| Hartenthaler, B | 1 |
| Lambert, T | 1 |
| Kypta, A | 1 |
| Kammler, J | 1 |
| Hönig, S | 1 |
| Hofmann, R | 1 |
| Kerschner, K | 1 |
| Leisch, F | 1 |
| Apostolakis, S | 1 |
| Pecot, CV | 1 |
| Fuller, M | 1 |
| Muldowney, JA | 1 |
| Misra, S | 1 |
| Park, DW | 4 |
| Yun, SC | 4 |
| Lee, CW | 6 |
| Cheong, SS | 2 |
| Kim, JJ | 4 |
| Park, SW | 6 |
| Park, SJ | 7 |
| Gladding, P | 3 |
| Webster, M | 3 |
| Zeng, I | 2 |
| Farrell, H | 2 |
| Stewart, J | 2 |
| Ruygrok, P | 2 |
| Ormiston, J | 2 |
| El-Jack, S | 2 |
| Armstrong, G | 2 |
| Kay, P | 2 |
| Scott, D | 2 |
| Gunes, A | 2 |
| Dahl, ML | 2 |
| Lincoff, AM | 4 |
| Chew, D | 1 |
| Feit, F | 2 |
| Ware, JH | 1 |
| Bertrand, ME | 2 |
| Ohman, EM | 2 |
| Desmet, W | 1 |
| Margolis, JR | 1 |
| Han, Y | 1 |
| Jing, Q | 1 |
| Yang, L | 1 |
| Liu, H | 2 |
| Shang, X | 1 |
| Jiang, T | 1 |
| Li, H | 1 |
| Qiu, J | 1 |
| Liu, Y | 2 |
| Chen, X | 1 |
| Gao, R | 1 |
| van Werkum, JW | 11 |
| Bredenoord, AJ | 1 |
| Gawaz, M | 4 |
| Feldman, DN | 1 |
| Wong, SC | 1 |
| Bergman, G | 1 |
| Minutello, RM | 1 |
| Spinler, SA | 1 |
| Rees, C | 1 |
| Curtiss, FR | 1 |
| Fairman, KA | 1 |
| Roffi, M | 1 |
| Eberli, FR | 1 |
| Suryadevara, S | 1 |
| Polena, S | 1 |
| Gupta, MP | 1 |
| Shaikh, H | 1 |
| Zazzali, K | 1 |
| Coplan, N | 1 |
| Gintautas, J | 1 |
| Labana, SS | 1 |
| Soffer, D | 1 |
| Ferreiro, JL | 4 |
| Kogushi, M | 1 |
| Dastros-Pitei, D | 1 |
| Flather, M | 1 |
| Alban, S | 1 |
| Mani, H | 1 |
| Lindhoff-Last, E | 2 |
| Zündorf, I | 1 |
| Dingermann, T | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Leibundgut, G | 2 |
| Nietlispach, F | 1 |
| Pittl, U | 1 |
| Brunner-La Rocca, H | 1 |
| Kaiser, CA | 2 |
| Pfisterer, ME | 1 |
| Moussa, ID | 1 |
| Perez de Prado, A | 1 |
| Cuellas, C | 1 |
| Diego, A | 1 |
| de Miguel, A | 1 |
| Fernandez-Vazquez, F | 1 |
| van Giezen, JJ | 2 |
| Berntsson, P | 1 |
| Sakariassen, KS | 2 |
| Alberts, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 1 |
| Sorensen, AS | 1 |
| Ray, MJ | 1 |
| Juneja, M | 1 |
| Bett, N | 1 |
| Walters, DL | 1 |
| Henry, RG | 2 |
| Nikolsky, E | 2 |
| McLaurin, B | 1 |
| Moses, JW | 1 |
| Fahy, M | 1 |
| Ishikawa, T | 1 |
| Nakano, Y | 1 |
| Endoh, A | 1 |
| Kubota, T | 1 |
| Suzuki, T | 1 |
| Nakata, K | 1 |
| Miyamoto, T | 1 |
| Murakami, M | 1 |
| Sakamoto, H | 1 |
| Imai, K | 1 |
| Mochizuki, S | 1 |
| Yoshimura, M | 1 |
| Mutoh, M | 1 |
| Yasuda, H | 1 |
| Yamada, M | 1 |
| Sawada, S | 1 |
| Endo, Y | 1 |
| Inoue, K | 1 |
| Asano, F | 1 |
| Takeyama, Y | 1 |
| Yoshiba, M | 1 |
| Elsenberg, EH | 1 |
| van de Wal, RM | 1 |
| Zomer, AC | 1 |
| Bouman, HJ | 5 |
| Berg, JM | 1 |
| Armstrong, PC | 1 |
| Dhanji, AR | 1 |
| Truss, NJ | 1 |
| Zain, ZN | 1 |
| Tucker, AT | 1 |
| Mitchell, JA | 1 |
| Chatterjee, T | 1 |
| Rehders, TC | 1 |
| Chatterjee, A | 1 |
| Schüpfer, C | 1 |
| Nienaber, CA | 4 |
| Vila, PM | 1 |
| Zafar, MU | 2 |
| Malmström, RE | 1 |
| Ostergren, J | 1 |
| Jørgensen, L | 1 |
| Hjemdahl, P | 1 |
| Norgard, NB | 1 |
| Abu-Fadel, M | 1 |
| Osmancik, P | 1 |
| Jirmar, R | 1 |
| Hulikova, K | 1 |
| Peroutka, Z | 1 |
| Pompachova, A | 1 |
| Motovska, Z | 1 |
| Christ, G | 2 |
| Lang, IM | 2 |
| Delle-Karth, G | 2 |
| Jilma, B | 2 |
| Stegherr, J | 2 |
| Danenberg, HD | 1 |
| Marincheva, G | 1 |
| Varshitzki, B | 1 |
| Nassar, H | 1 |
| Lotan, C | 2 |
| Sharma, RK | 2 |
| Reddy, HK | 1 |
| Singh, VN | 1 |
| Sharma, R | 1 |
| Voelker, DJ | 1 |
| Bhatt, G | 1 |
| Kurisu, S | 1 |
| Inoue, I | 1 |
| Kawagoe, T | 1 |
| Tacke, J | 1 |
| Guerra, DR | 1 |
| Kawamura, Y | 1 |
| Takahari, Y | 1 |
| Tamura, N | 1 |
| Eguchi, Y | 1 |
| Urano, T | 1 |
| Ishida, H | 1 |
| Goto, S | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Sidorenko, BA | 2 |
| Batyraliev, TA | 3 |
| Vural, A | 1 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Fettser, DV | 2 |
| Ibáñez, B | 1 |
| Choi, BG | 1 |
| Vorchheimer, DA | 1 |
| Piñero, A | 1 |
| Jin, X | 1 |
| Willerson, JT | 1 |
| Cable, G | 1 |
| Yeh, ET | 1 |
| Izuhara, Y | 1 |
| Yamaoka, N | 1 |
| Kodama, H | 1 |
| Dan, T | 1 |
| Takizawa, S | 1 |
| Hirayama, N | 1 |
| Meguro, K | 1 |
| van Ypersele de Strihou, C | 1 |
| Miyata, T | 1 |
| Fukushima, K | 1 |
| Kobayashi, Y | 2 |
| Kitahara, H | 2 |
| Iwata, Y | 1 |
| Kuroda, N | 2 |
| Ooyama, M | 1 |
| Kuwabara, Y | 1 |
| Nomura, F | 1 |
| Komuro, I | 2 |
| Gkaliagkousi, E | 1 |
| Passacquale, G | 1 |
| Douma, S | 1 |
| Zamboulis, C | 1 |
| Ferro, A | 1 |
| Bidet, A | 1 |
| Jais, C | 1 |
| Puymirat, E | 1 |
| Coste, P | 1 |
| Nurden, A | 1 |
| Jakubowski, J | 1 |
| Nurden, P | 2 |
| Jambor, J | 1 |
| Spannagl, M | 2 |
| Zwissler, B | 1 |
| Kim, WJ | 2 |
| Lee, JY | 2 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Natarajan, MK | 1 |
| Croce, K | 1 |
| Wang, N | 1 |
| Ruven, HJ | 2 |
| Bal, ET | 1 |
| Deneer, VH | 2 |
| Harmsze, AM | 3 |
| van der Heyden, JA | 2 |
| Rensing, BJ | 1 |
| Suttorp, MJ | 1 |
| Faxon, DP | 2 |
| Létienne, R | 1 |
| Leparq-Panissié, A | 1 |
| Calmettes, Y | 1 |
| Nadal-Wollbold, F | 1 |
| Perez, M | 1 |
| Le Grand, B | 1 |
| Moerenhout, CM | 1 |
| Claeys, MJ | 2 |
| Haine, S | 1 |
| Miljoen, H | 1 |
| Bosmans, JM | 2 |
| Vertessen, F | 2 |
| Kluppels, K | 1 |
| Van der Planken, M | 1 |
| Vrints, CJ | 2 |
| Islam, AM | 1 |
| Patel, PM | 1 |
| Kang, SJ | 3 |
| Han, KH | 3 |
| Lee, SG | 1 |
| Rha, SW | 3 |
| Seong, IW | 1 |
| Jeong, MH | 2 |
| Hur, SH | 2 |
| Lee, NH | 1 |
| Yang, JY | 1 |
| Lee, BK | 2 |
| Choi, YJ | 1 |
| Chae, JK | 1 |
| Nah, DY | 1 |
| Jeon, DS | 1 |
| Jang, JS | 1 |
| Park, HS | 2 |
| Lee, K | 1 |
| Ruparelia, N | 1 |
| Spyrou, N | 1 |
| Dumont, LA | 1 |
| Rongières, M | 1 |
| Tchénio, P | 1 |
| Gangloff, D | 1 |
| Garrido-Stowhas, I | 1 |
| Pickett, AM | 1 |
| Taylor, DA | 1 |
| Cortese, B | 1 |
| Danzi, GB | 1 |
| Sofi, F | 1 |
| White, H | 1 |
| Kessler, L | 1 |
| Ohlmann, P | 7 |
| Bareiss, P | 6 |
| Can, MM | 1 |
| Tanboğa, IH | 1 |
| Ozveren, O | 1 |
| Karabay, CY | 1 |
| Akgün, T | 1 |
| Türkyilmaz, E | 1 |
| Tokgöz, HC | 1 |
| Kaymaz, C | 1 |
| Konishi, N | 1 |
| Hiroe, K | 1 |
| Kawamura, M | 2 |
| Lemesle, G | 4 |
| Delhaye, C | 2 |
| Sudre, A | 1 |
| Bauters, C | 1 |
| Lablanche, JM | 1 |
| Garavalia, L | 1 |
| Ho, PM | 1 |
| Garavalia, B | 1 |
| Foody, JM | 1 |
| Kruse, H | 1 |
| Spertus, JA | 2 |
| Decker, C | 2 |
| Fuster, V | 4 |
| Hacke, W | 4 |
| Möllmann, H | 2 |
| Nef, HM | 1 |
| Al-Dehneh, A | 1 |
| Virk, H | 1 |
| Alkhouri, Y | 1 |
| Hamdan, A | 1 |
| Bikkina, M | 1 |
| Kalyanasundaram, A | 1 |
| Weise, J | 1 |
| Reinhöfer, M | 1 |
| Witte, OW | 1 |
| Mayer, TE | 1 |
| Boden, WE | 2 |
| Flather, MD | 3 |
| Givol, N | 1 |
| Halkin, A | 1 |
| Tsimikas, S | 1 |
| El Ghannudi, S | 2 |
| Meyer, N | 1 |
| Wiesel, ML | 2 |
| Radulescu, B | 2 |
| Chauvin, M | 1 |
| Sternad, H | 1 |
| Quehenberger, F | 1 |
| Rainer, F | 1 |
| Neumeister, P | 1 |
| Pakhomov, IaM | 1 |
| Hindy-François, C | 1 |
| Bachelot-Loza, C | 1 |
| Le Bonniec, B | 1 |
| Grelac, F | 1 |
| Dizier, B | 1 |
| Godier, A | 1 |
| Emmerich, J | 1 |
| Gaussem, P | 1 |
| Samama, CM | 3 |
| Sarafoff, N | 1 |
| Sonntag, U | 1 |
| Ellert, J | 1 |
| Edmunds, I | 1 |
| Avakian, Z | 1 |
| Metzler, H | 2 |
| Ferreira-González, I | 1 |
| Marsal, JR | 1 |
| Ribera, A | 1 |
| Permanyer-Miralda, G | 1 |
| García-Del Blanco, B | 1 |
| Martí, G | 1 |
| Cascant, P | 1 |
| Brugaletta, S | 1 |
| Alfonso, F | 5 |
| Capote, ML | 1 |
| De La Torre, JM | 1 |
| Ruíz-Lera, M | 1 |
| Sanmiguel, D | 1 |
| Cárdenas, M | 1 |
| Pujol, B | 1 |
| Baz, JA | 1 |
| Iñiguez, A | 2 |
| Trillo, R | 1 |
| González-Béjar, O | 1 |
| Casanova, J | 1 |
| Sánchez-Gila, J | 1 |
| García-Dorado, D | 1 |
| Weber, R | 1 |
| Diener, HC | 2 |
| Dineen, PF | 1 |
| Curtin, RJ | 1 |
| Harty, JA | 1 |
| Collins, SD | 2 |
| Gaglia, MA | 3 |
| Syed, AI | 2 |
| Ben-Dor, I | 2 |
| Kaneshige, K | 1 |
| Xue, Z | 3 |
| Kent, KM | 4 |
| Suddath, WO | 2 |
| Löwenberg, EC | 1 |
| Crosby, JR | 1 |
| MacLeod, AR | 1 |
| Zhao, C | 1 |
| Gao, D | 1 |
| Black, C | 2 |
| Revenko, AS | 1 |
| Meijers, JC | 1 |
| Stroes, ES | 1 |
| Levi, M | 1 |
| Monia, BP | 1 |
| Jolly, SS | 1 |
| Joyner, CD | 1 |
| Rupprecht, HJ | 3 |
| Avezum, A | 1 |
| Bassand, JP | 1 |
| Macaya, C | 6 |
| Di Pasquale, G | 1 |
| Niemela, K | 1 |
| Ajani, AE | 5 |
| Chrolavicius, S | 1 |
| Gao, P | 1 |
| Yusuf, S | 1 |
| Gandhi, NK | 1 |
| Abdel-Karim, AR | 1 |
| Brilakis, ES | 1 |
| Lin, GM | 1 |
| Chu, KM | 1 |
| Han, CL | 1 |
| Rideg, O | 2 |
| Tokés-Füzesi, M | 1 |
| Magyarlaki, T | 2 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Heestermans, AA | 2 |
| Zwart, B | 1 |
| van't Hof, AW | 1 |
| Dambrink, JH | 1 |
| Koolen, JJ | 1 |
| Brueren, BR | 1 |
| Zijlstra, F | 1 |
| Park, Y | 3 |
| Kim, IS | 2 |
| Yun, SE | 2 |
| Kang, MK | 1 |
| Hwang, SJ | 3 |
| Kwak, CH | 2 |
| Hwang, JY | 2 |
| Laizure, SC | 1 |
| Parker, RB | 1 |
| Jin, B | 1 |
| Ni, HC | 1 |
| Shen, W | 1 |
| Li, J | 1 |
| Shi, HM | 1 |
| Braber, TL | 1 |
| Verheggen, PW | 1 |
| Van Der Have-Roeffel, SM | 1 |
| Małek, LA | 1 |
| Przyłuski, J | 1 |
| Spiewak, M | 1 |
| Kłopotowski, M | 1 |
| Kostrzewa, G | 1 |
| Kruk, M | 1 |
| Płoski, R | 1 |
| Rużyłło, W | 1 |
| Ilhan, E | 1 |
| Demirci, D | 1 |
| Güvenç, TS | 1 |
| Calık, AN | 1 |
| Hahn, JY | 2 |
| Song, YB | 2 |
| Choi, JH | 2 |
| Choi, SH | 2 |
| Lee, SY | 3 |
| Han, KR | 1 |
| Cho, BR | 1 |
| Gwon, HC | 3 |
| Tentzeris, I | 1 |
| Jarai, R | 1 |
| Farhan, S | 1 |
| Brozovic, I | 1 |
| Smetana, P | 1 |
| Geppert, A | 1 |
| Wojta, J | 1 |
| Siller-Matula, J | 1 |
| Mylotte, D | 1 |
| Peace, AJ | 1 |
| Tedesco, AT | 1 |
| Dicker, P | 1 |
| Kenny, D | 1 |
| Foley, DP | 1 |
| Stolla, M | 1 |
| Stefanini, L | 1 |
| Roden, RC | 1 |
| Chavez, M | 1 |
| Hirsch, J | 1 |
| Greene, T | 2 |
| Ouellette, TD | 1 |
| Maloney, SF | 1 |
| Diamond, SL | 1 |
| Poncz, M | 1 |
| Woulfe, DS | 1 |
| Simon, T | 2 |
| Anderson, JL | 1 |
| Bliden, K | 1 |
| Danchin, N | 1 |
| Gurbel, P | 3 |
| Horne, BD | 1 |
| Cui, S | 1 |
| Chen, YD | 1 |
| He, GX | 1 |
| Yan, HB | 1 |
| Meng, LJ | 1 |
| Song, XT | 1 |
| Jin, ZN | 1 |
| Ge, CJ | 1 |
| Du, XJ | 1 |
| Shan, L | 1 |
| Gao, XM | 1 |
| Kiriazis, H | 1 |
| Lobo, A | 1 |
| Head, GA | 1 |
| Dart, AM | 1 |
| Páramo, JA | 1 |
| Silvano, M | 1 |
| Zambon, CF | 1 |
| De Rosa, G | 1 |
| Plebani, M | 1 |
| Pengo, V | 1 |
| Napodano, M | 1 |
| Padrini, R | 1 |
| Carragee, EJ | 1 |
| Golish, SR | 1 |
| Scuderi, GJ | 1 |
| Honjo, T | 1 |
| Haraguchi, Y | 2 |
| Shinohara, M | 2 |
| Toh, R | 2 |
| Ishida, T | 2 |
| Kozuki, A | 2 |
| Sambu, N | 2 |
| Warner, T | 1 |
| Curzen, N | 2 |
| Lettino, M | 2 |
| Komarov, AL | 1 |
| Hussaini, BE | 1 |
| Thatte, HS | 1 |
| Rhodes, BA | 1 |
| Treanor, PR | 1 |
| Birjiniuk, V | 1 |
| Singh, PP | 1 |
| Singh, M | 1 |
| Bedi, U | 1 |
| Molnar, J | 1 |
| Arora, R | 1 |
| Khosla, S | 1 |
| Lazzaro, MA | 1 |
| Malhotra, K | 1 |
| Mohammad, YM | 1 |
| Lordkipanidzé, M | 1 |
| Harrison, P | 1 |
| Dick, RJ | 1 |
| Dear, AE | 1 |
| Byron, KA | 1 |
| Schork, NJ | 2 |
| Magallon, J | 1 |
| Rabbani, L | 1 |
| Dangas, G | 3 |
| Bussel, J | 1 |
| Diacovo, T | 1 |
| Ueno, M | 2 |
| Tomasello, SD | 1 |
| Kodali, M | 1 |
| Seecheran, N | 1 |
| Dharmashankar, K | 1 |
| Alissa, R | 1 |
| Charlton, RK | 1 |
| Václavík, J | 1 |
| Táborský, M | 1 |
| Dimitriou, AA | 1 |
| Milionis, HJ | 1 |
| Goudevenos, IA | 1 |
| Chu, MB | 1 |
| Turner, RB | 1 |
| Kriegel, DA | 1 |
| Bonatti, J | 1 |
| Zimrin, D | 1 |
| O'Gara, P | 1 |
| Mohammad, RA | 1 |
| Goldberg, T | 1 |
| Dorsch, MP | 1 |
| Cheng, JW | 1 |
| Teirstein, PS | 2 |
| Puri, S | 1 |
| Robbins, M | 1 |
| Bertrand, OF | 1 |
| Stillabower, ME | 1 |
| Stillablower, ME | 1 |
| Aragon, JR | 1 |
| Stinis, CT | 1 |
| Lee, MS | 1 |
| Klisch, J | 1 |
| Turk, A | 1 |
| Turner, R | 1 |
| Woo, HH | 1 |
| Fiorella, D | 1 |
| Arima, M | 1 |
| Matsuda, A | 1 |
| Nitta, M | 1 |
| Yoshida, K | 1 |
| Shimizu, M | 1 |
| Diehl, P | 1 |
| Halscheid, C | 1 |
| Olivier, C | 1 |
| Helbing, T | 1 |
| Bode, C | 1 |
| Moser, M | 1 |
| Yang, EH | 1 |
| Perez, E | 1 |
| Zhiroff, KA | 1 |
| Burstein, S | 1 |
| Briongos Figuero, S | 1 |
| Salido-Tahoces, L | 1 |
| de Juan-Bagudá, J | 1 |
| Martí-Sánchez, D | 1 |
| Park, KW | 2 |
| Kwon, DA | 1 |
| Kang, HJ | 1 |
| Koo, BK | 2 |
| Chae, IH | 1 |
| Ahn, T | 1 |
| Yoon, JH | 1 |
| Jang, YS | 1 |
| Tahk, SJ | 1 |
| Kim, HS | 2 |
| Park, KS | 1 |
| Park, JR | 1 |
| Koh, EH | 1 |
| Kim, S | 1 |
| de Labriolle, A | 1 |
| Ziegelstein, RC | 1 |
| Green, A | 1 |
| Sauder, M | 1 |
| Jesel, L | 3 |
| El Adraa, E | 1 |
| Crimizade, U | 1 |
| Nam, D | 1 |
| Lerakis, S | 1 |
| Taguchi, I | 1 |
| Abe, S | 1 |
| Behr, T | 1 |
| Kuch, B | 1 |
| Behr, W | 1 |
| von Scheidt, W | 1 |
| Ardissino, D | 4 |
| Mantovani, F | 2 |
| Demola, MA | 2 |
| Rajendran, S | 1 |
| Parikh, D | 1 |
| Shugman, I | 1 |
| French, JK | 1 |
| Juergens, CP | 1 |
| Gajos, G | 1 |
| Zalewski, J | 1 |
| Rostoff, P | 1 |
| Nessler, J | 1 |
| Piwowarska, W | 1 |
| Campo, G | 2 |
| Miccoli, M | 1 |
| Marchesini, J | 2 |
| Fileti, L | 1 |
| Monti, M | 2 |
| Ferrari, R | 2 |
| Amin, AP | 1 |
| Kennedy, KF | 1 |
| Pencina, M | 1 |
| Berger, P | 2 |
| Piana, RN | 1 |
| Lopez, J | 1 |
| Kleiman, N | 2 |
| Garg, N | 1 |
| Rajpurohit, N | 1 |
| Flaker, G | 1 |
| Calabrò, RS | 1 |
| Pezzini, A | 1 |
| Gervasi, G | 1 |
| Pollicino, P | 1 |
| Bramanti, P | 1 |
| Pasceri, V | 1 |
| Di Sciascio, G | 1 |
| Cohen, MJ | 1 |
| Flaherty, MP | 1 |
| Johnston, PV | 1 |
| Rade, JJ | 1 |
| Haberstock-Debic, H | 1 |
| Andre, P | 2 |
| Mills, S | 1 |
| Phillips, DR | 2 |
| Conley, PB | 2 |
| Yazıcı, HU | 1 |
| Nadiradze, A | 1 |
| Ünalır, A | 1 |
| Berger, JS | 2 |
| Grdinic, A | 1 |
| Vojvodic, D | 1 |
| Djukanovic, N | 2 |
| Colic, M | 1 |
| Grdinic, AG | 1 |
| Ignjatovic, V | 1 |
| Majstorovic, I | 1 |
| Ilic, V | 1 |
| Magic, Z | 1 |
| Obradovic, S | 2 |
| Ostojic, M | 2 |
| Dolijanovic, SP | 1 |
| Albaladejo, P | 1 |
| Marret, E | 1 |
| Abhay, K | 1 |
| Loutrel, O | 1 |
| Charbonneau, H | 1 |
| Jaber, S | 1 |
| Thoret, S | 1 |
| Bosson, JL | 1 |
| Kwan, J | 1 |
| Htun, WW | 1 |
| Huang, Y | 1 |
| Ko, W | 1 |
| Kwan, TW | 1 |
| Bakaeen, FG | 1 |
| Chu, D | 1 |
| Todorovic, Z | 1 |
| Zamaklar-Trifunovic, D | 1 |
| Njegomirovic, S | 1 |
| Milic, NM | 1 |
| Prostran, M | 1 |
| Kassimis, G | 1 |
| Xanthopoulou, I | 1 |
| Stavrou, EF | 1 |
| Athanassiadou, A | 1 |
| Souverein, PC | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Lillie, E | 1 |
| Qureshi, Z | 1 |
| Hobson, AR | 1 |
| Peppard, SR | 1 |
| Held-Godgluck, BM | 1 |
| Beddingfield, R | 1 |
| Morgan, KP | 1 |
| More, RS | 1 |
| Chauhan, A | 1 |
| Damman, P | 1 |
| Klomp, M | 1 |
| Beijk, M | 1 |
| Woudstra, P | 1 |
| Silber, S | 2 |
| Ribeiro, EE | 1 |
| Sim, KH | 1 |
| Tijssen, JG | 1 |
| de Winter, RJ | 1 |
| Notarangelo, MF | 1 |
| Marziliano, N | 1 |
| Giacalone, R | 1 |
| Conte, G | 1 |
| Labarthe, B | 1 |
| Babin, J | 1 |
| Bryckaert, M | 1 |
| Théroux, P | 1 |
| Bonnefoy, A | 1 |
| Rayoo, R | 1 |
| Sharma, N | 1 |
| van Gaal, WJ | 1 |
| Cardona, L | 1 |
| Ana, G | 1 |
| Luísa, B | 1 |
| Leal, A | 1 |
| António, F | 1 |
| Lídia, S | 1 |
| Cruz, FR | 1 |
| Vogt, A | 1 |
| Mannes, F | 1 |
| Wolf, HH | 1 |
| Werdan, K | 1 |
| Plehn, A | 1 |
| Ait-Mokhtar, O | 1 |
| Benamara, S | 1 |
| Paganelli, F | 1 |
| Pathak, A | 1 |
| Gruel, Y | 2 |
| Vignalou, JB | 1 |
| Huerre, Y | 1 |
| de la Briolle, A | 1 |
| Allanic, F | 1 |
| Wiwanitkit, V | 1 |
| Kuijpers, MJ | 1 |
| Megens, RT | 1 |
| Nikookhesal, E | 1 |
| Feijge, MA | 2 |
| De Mey, JG | 1 |
| oude Egbrink, MG | 1 |
| Heemskerk, JW | 2 |
| Sangiorgi, GM | 1 |
| Morice, MC | 4 |
| Ferlini, M | 1 |
| Grinfeld, L | 1 |
| Petronio, AS | 1 |
| Pierli, C | 1 |
| Iadanza, A | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Tang, HL | 1 |
| Hu, YF | 1 |
| Xie, HG | 1 |
| Roth, GA | 1 |
| Morden, NE | 1 |
| Zhou, W | 1 |
| Malenka, DJ | 1 |
| Skinner, J | 1 |
| Cantor, WJ | 1 |
| Hess, TM | 1 |
| Liu, ES | 1 |
| Hod, H | 1 |
| Buber, J | 1 |
| Vatury, O | 1 |
| Chatterjee, S | 2 |
| Maitra, S | 1 |
| Chakraborty, A | 1 |
| Sylvester, DC | 1 |
| Coatesworth, AP | 1 |
| Kim, JH | 2 |
| Park, HM | 1 |
| Delaney, JT | 1 |
| Ramirez, AH | 1 |
| Bowton, E | 1 |
| Pulley, JM | 1 |
| Basford, MA | 1 |
| Schildcrout, JS | 1 |
| Zink, R | 1 |
| Oetjens, M | 1 |
| Xu, H | 1 |
| Cleator, JH | 1 |
| Jahangir, E | 1 |
| Ritchie, MD | 1 |
| Masys, DR | 1 |
| Roden, DM | 1 |
| Crawford, DC | 1 |
| Denny, JC | 1 |
| Holmes, MV | 1 |
| Perel, P | 1 |
| Shah, T | 1 |
| Hingorani, AD | 1 |
| Casas, JP | 1 |
| Neunteufl, T | 1 |
| Kozinski, M | 1 |
| Maurer, G | 3 |
| Linkowska, K | 1 |
| Grzybowski, T | 1 |
| Namazi, S | 1 |
| Kojuri, J | 1 |
| Khalili, A | 1 |
| Azarpira, N | 1 |
| Zghal, FM | 1 |
| Amri, A | 1 |
| Mourali, MS | 1 |
| Farhati, A | 1 |
| Larbi, N | 1 |
| Mechmèche, R | 1 |
| Akkus, NI | 1 |
| Rajpal, S | 1 |
| Agnani, S | 1 |
| Steele, MJ | 1 |
| Fox, JS | 1 |
| Fletcher, JP | 1 |
| Grigg, LE | 1 |
| Bell, G | 1 |
| Jaitner, J | 1 |
| Gebhard, D | 1 |
| Koch, W | 2 |
| Jennings, LK | 1 |
| Michelson, AD | 5 |
| Jacoski, MV | 1 |
| Tyagi, A | 1 |
| Grgurevich, S | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 2 |
| Linnemann, B | 1 |
| Thalhammer, A | 1 |
| Wolf, Z | 1 |
| Tirneci, V | 1 |
| Vogl, TJ | 1 |
| Edelgard Lindhoff-Last, A | 1 |
| Krishna, V | 1 |
| Diamond, GA | 1 |
| Kaul, S | 1 |
| Lee, H | 1 |
| Sturgeon, SA | 2 |
| Mountford, JK | 1 |
| Hamilton, JR | 1 |
| Boulé, S | 1 |
| Marquié, C | 1 |
| Vanesson-Bricout, C | 1 |
| Kouakam, C | 1 |
| Brigadeau, F | 1 |
| Guédon-Moreau, L | 1 |
| Acheré, C | 1 |
| Goéminne-Boulé, C | 1 |
| Lacroix, D | 1 |
| Klug, D | 1 |
| Kacet, S | 1 |
| Percoco, G | 1 |
| Tumscitz, C | 1 |
| Castriota, F | 1 |
| Colombo, F | 1 |
| Fucà, G | 1 |
| Kubbajeh, M | 1 |
| Cangiano, E | 1 |
| Minarelli, M | 1 |
| Scalone, A | 1 |
| Cavazza, C | 1 |
| Frangione, A | 1 |
| Borghesi, M | 1 |
| Parrinello, G | 1 |
| Ben Morrison, T | 1 |
| Horst, BM | 1 |
| Brown, MJ | 1 |
| Bell, MR | 3 |
| Daniels, PR | 1 |
| Hondo, T | 1 |
| Matsumura, H | 1 |
| Matsuda, K | 1 |
| Iwamoto, A | 1 |
| Eno, S | 1 |
| Kimura, M | 1 |
| Paré, G | 1 |
| Simonsen, KL | 1 |
| Emison, ES | 1 |
| Bhakta, N | 1 |
| Cacoub, P | 2 |
| Creager, MA | 2 |
| Murugesan, G | 1 |
| Kottke-Marchant, K | 1 |
| Rossi, M | 1 |
| Serraino, GF | 1 |
| Spadafora, A | 1 |
| Renzulli, A | 1 |
| Kreutz, RP | 1 |
| Breall, JA | 1 |
| Kreutz, Y | 1 |
| Owens, J | 1 |
| Lu, D | 1 |
| Bolad, I | 1 |
| von der Lohe, E | 1 |
| Flockhart, DA | 1 |
| Kiviniemi, T | 1 |
| Karjalainen, P | 1 |
| Pietilä, M | 1 |
| Ylitalo, A | 1 |
| Niemelä, M | 1 |
| Vikman, S | 1 |
| Puurunen, M | 1 |
| Biancari, F | 1 |
| Jaberi, A | 1 |
| Lum, C | 1 |
| Stefanski, P | 1 |
| Thornhill, RE | 1 |
| Dowlatshahi, D | 1 |
| Tang, FK | 1 |
| Lin, LJ | 1 |
| Hua, N | 1 |
| Lu, H | 1 |
| Qi, Z | 1 |
| Tang, XZ | 1 |
| Frołow, M | 1 |
| Niżankowski, R | 1 |
| Sadowski, J | 1 |
| Polasek, TM | 1 |
| Doğan, A | 1 |
| Icli, A | 1 |
| Varol, E | 1 |
| Erdogan, D | 1 |
| Sheikh-Taha, M | 1 |
| Ghosn, S | 1 |
| Lyseng-Williamson, KA | 2 |
| Vidali, M | 1 |
| Parrella, M | 1 |
| Cassani, C | 1 |
| Manzini, M | 1 |
| Portalupi, MR | 1 |
| Serino, R | 1 |
| Prando, MD | 1 |
| Vetter, TR | 1 |
| Boudreaux, AM | 1 |
| Papapietro, SE | 1 |
| Smith, PW | 1 |
| Taylor, BB | 1 |
| Porterfield, JR | 1 |
| Tsantes, A | 1 |
| Ikonomidis, I | 1 |
| Papadakis, I | 1 |
| Kottaridi, C | 1 |
| Tsante, A | 1 |
| Kalamara, E | 1 |
| Kardoulaki, A | 1 |
| Kopterides, P | 1 |
| Kapsimali, V | 1 |
| Karakitsos, P | 1 |
| Lekakis, J | 1 |
| Travlou, A | 1 |
| Rao, SV | 1 |
| Zeymer, U | 1 |
| Thompson, VP | 1 |
| Kochman, J | 1 |
| McClure, MW | 1 |
| Gretler, DD | 1 |
| Berdan, LG | 1 |
| Paynter, G | 1 |
| Madan, M | 1 |
| French, WJ | 1 |
| Riegger, J | 1 |
| Joner, M | 1 |
| Tada, T | 1 |
| Okrojek, R | 1 |
| Hausleiter, J | 1 |
| Massberg, S | 3 |
| Liu, A | 1 |
| Saman, H | 1 |
| Pusalkar, P | 1 |
| Höchtl, T | 1 |
| Prüller, F | 1 |
| Barn, K | 1 |
| Nagoshi, R | 1 |
| Charlot, M | 1 |
| Nielsen, LH | 1 |
| Lindhardsen, J | 1 |
| Ahlehoff, O | 1 |
| Olsen, AM | 1 |
| Hansen, ML | 1 |
| Madsen, JK | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Isordia-Salas, I | 1 |
| Olalde-Román, MJ | 1 |
| Santiago-Germán, D | 1 |
| de la Peña, NC | 1 |
| Valencia-Sánchez, JS | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Vatankulu, MA | 1 |
| Tasal, A | 1 |
| Erdoğan, E | 1 |
| Göktekin, Ö | 1 |
| Popov, AF | 1 |
| Hosseini, MT | 1 |
| Hards, R | 1 |
| Amrani, M | 1 |
| Bahrami, T | 1 |
| Simon, AR | 1 |
| Savage, JR | 1 |
| Parmar, A | 1 |
| Robinson, PJ | 1 |
| Fassa, AA | 1 |
| Urban, P | 2 |
| Meade, T | 1 |
| Chan, MY | 1 |
| Reinhart, WH | 1 |
| Cornel, JH | 1 |
| Goodman, SG | 1 |
| Santoso, A | 1 |
| Steg, G | 1 |
| Vintila, M | 1 |
| Sun, JL | 1 |
| Horrow, J | 2 |
| Harrington, R | 1 |
| James, S | 1 |
| Iversen, AZ | 1 |
| Iancu, A | 1 |
| Ober, C | 1 |
| Bondor, CI | 1 |
| Cadiş, H | 1 |
| Schechter, CB | 1 |
| Becker, EM | 1 |
| Perzborn, E | 1 |
| Klipp, A | 1 |
| Lücker, C | 1 |
| Bütehorn, U | 1 |
| Kast, R | 1 |
| Laux, V | 1 |
| Moore, TJ | 1 |
| Bennett, CL | 1 |
| Meyer, S | 1 |
| Lala, A | 1 |
| Sharma, G | 1 |
| Hochman, JS | 1 |
| Scott Braithwaite, R | 1 |
| Ladapo, JA | 1 |
| Oberhänsli, M | 1 |
| Lehner, C | 1 |
| Puricel, S | 1 |
| Lehmann, S | 1 |
| Togni, M | 2 |
| Stauffer, JC | 1 |
| Baeriswyl, G | 1 |
| Goy, JJ | 1 |
| Cook, S | 1 |
| Sameshima, H | 1 |
| Miura, N | 1 |
| Ito, T | 1 |
| Koide, T | 1 |
| Maruyama, I | 1 |
| Ghose, A | 1 |
| Sharma, A | 1 |
| Guha, G | 1 |
| Mukherjee, D | 1 |
| Frankel, R | 1 |
| Jones, GM | 1 |
| Twilla, JD | 1 |
| Hoit, DA | 1 |
| Arthur, AS | 1 |
| Lee, GY | 1 |
| Kim, HJ | 1 |
| Ahn, JM | 1 |
| Song, HG | 1 |
| Harper, AR | 1 |
| Kohli, P | 1 |
| Reyes, E | 1 |
| Morais, J | 1 |
| Nicolau, JC | 1 |
| Oto, A | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Renoux, C | 1 |
| Suissa, S | 1 |
| Gremmel, T | 1 |
| Steiner, S | 2 |
| Seidinger, D | 1 |
| Koppensteiner, R | 1 |
| Panzer, S | 1 |
| Kopp, CW | 2 |
| Gao, W | 1 |
| Zhang, Q | 1 |
| Ge, H | 1 |
| Guo, Y | 1 |
| Zhou, Z | 1 |
| Fathi, R | 1 |
| Shamma, HN | 1 |
| Fathi, A | 1 |
| Avegliano, G | 1 |
| Evangelista, A | 1 |
| Elorz, C | 1 |
| González-Alujas, T | 1 |
| García del Castillo, H | 1 |
| Soler-Soler, J | 1 |
| Turpie, AG | 1 |
| Bartorelli, AL | 1 |
| Trabattoni, D | 1 |
| Hauroeder, B | 1 |
| Peetz, D | 1 |
| Victor, A | 1 |
| Hundt, F | 1 |
| Bickel, C | 1 |
| Meyer, J | 1 |
| Mann, JT | 1 |
| Fry, ET | 1 |
| DeLago, A | 1 |
| Wilmer, C | 1 |
| Kam, PC | 1 |
| Nethery, CM | 1 |
| Dupin, JP | 1 |
| Gryglewski, RJ | 3 |
| Gravier, D | 1 |
| Hou, G | 1 |
| Casadebaig, F | 1 |
| Swies, J | 3 |
| Chlopicki, S | 1 |
| Bick, RL | 1 |
| Alfar, H | 1 |
| Goedecke, C | 1 |
| Wunderlich, H | 1 |
| Beer, J | 1 |
| Allgaier, C | 1 |
| Abe, Y | 1 |
| Asakura, T | 1 |
| Sakamoto, N | 1 |
| Muroi, S | 1 |
| Saitoh, F | 1 |
| Satoh, M | 1 |
| Suzuki, S | 1 |
| Ono, M | 1 |
| Sakabe, A | 1 |
| Iwai, M | 1 |
| Sando, M | 1 |
| Gotou, J | 1 |
| Nagata, K | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Baumgart, D | 2 |
| Hehrlein, C | 1 |
| Meinertz, T | 1 |
| Mügge, A | 1 |
| Rutsch, W | 1 |
| vom Dahl, J | 1 |
| Toutouzas, K | 1 |
| Di Mario, C | 1 |
| Falotico, R | 2 |
| Takagi, T | 1 |
| Stankovic, G | 1 |
| Albiero, R | 2 |
| Corvaja, N | 1 |
| Gerschutz, GP | 1 |
| Easton, JD | 2 |
| Lecompte, T | 2 |
| Müller, I | 1 |
| Besta, F | 1 |
| Schulz, C | 2 |
| Schönig, A | 1 |
| Ziegler, BK | 1 |
| Rasmussen, LH | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Husted, SE | 1 |
| Steinhubl, S | 1 |
| Lenain, N | 1 |
| Freund, M | 3 |
| Léon, C | 2 |
| Cazenave, JP | 5 |
| Collart, F | 1 |
| Derouck, D | 1 |
| Kerbaul, F | 1 |
| Feier, H | 1 |
| Mesana, TG | 1 |
| Friess, D | 1 |
| Lämmle, B | 1 |
| Alberio, L | 1 |
| Hodgson, PK | 1 |
| Larsen, RL | 1 |
| Kaufman, JS | 3 |
| O'Connor, TZ | 2 |
| Zhang, JH | 1 |
| Cronin, RE | 1 |
| Fiore, LD | 1 |
| Ganz, MB | 1 |
| Goldfarb, DS | 1 |
| Peduzzi, PN | 1 |
| Priglinger, U | 1 |
| Probst, P | 1 |
| Minar, E | 1 |
| Hohnloser, SH | 1 |
| Connolly, SJ | 1 |
| Alex, M | 1 |
| Klocke, A | 1 |
| Morgenstern, E | 1 |
| Moosbauer, C | 1 |
| Eckly, A | 1 |
| Engelmann, B | 1 |
| Davutoglu, V | 1 |
| Soydinc, S | 1 |
| Sezen, Y | 1 |
| Tan, KT | 1 |
| Baralis, G | 1 |
| Steffenino, G | 1 |
| Dellavalle, A | 1 |
| La Scala, E | 1 |
| Uslenghi, E | 1 |
| Bal dit Sollier, C | 1 |
| Mahé, I | 1 |
| Berge, N | 1 |
| Simoneau, G | 1 |
| Bergmann, JF | 1 |
| Drouet, L | 2 |
| Lorrain, J | 1 |
| Lechaire, I | 1 |
| Gauffeny, C | 1 |
| Masson, R | 1 |
| Roome, N | 1 |
| Herault, JP | 2 |
| O'Connor, SE | 1 |
| Schaeffer, P | 1 |
| Herbert, JM | 12 |
| Bogousslavsky, J | 2 |
| Brass, LM | 1 |
| Cimminiello, C | 1 |
| Csiba, L | 1 |
| Kaste, M | 1 |
| Leys, D | 2 |
| Matias-Guiu, J | 1 |
| Rao, U | 1 |
| Weston, C | 1 |
| Samara, WM | 2 |
| Fernandez-Ortiz, A | 5 |
| Bernardo, E | 5 |
| Ramírez, C | 4 |
| Hernández-Antolín, R | 3 |
| Moreno, R | 4 |
| Escaned, J | 4 |
| Bañuelos, C | 3 |
| Ringleb, PA | 1 |
| Schellinger, PD | 1 |
| Schwark, C | 1 |
| Schrör, K | 3 |
| Trabetti, E | 1 |
| Pignatti, PF | 1 |
| Weber, AA | 2 |
| Taubert, D | 3 |
| Harlfinger, S | 1 |
| Gorchakova, O | 1 |
| Lazar, A | 1 |
| Schömig, E | 2 |
| Casselman, FP | 1 |
| Meco, M | 1 |
| Dom, H | 1 |
| Foubert, L | 1 |
| Van Praet, F | 1 |
| Vanermen, H | 1 |
| Janicki, K | 2 |
| Pietura, R | 2 |
| Bojarska-Szmygin, A | 2 |
| Gieryng, J | 1 |
| Orłowska, A | 1 |
| Janicka, L | 2 |
| Stiefelhagen, P | 1 |
| Klima, U | 1 |
| MacVaugh, H | 1 |
| Bagaev, E | 1 |
| Maringka, M | 1 |
| Kirschner, S | 1 |
| Beilner, J | 1 |
| Haverich, A | 1 |
| Vilahur, G | 3 |
| Segalés, E | 1 |
| Salas, E | 1 |
| Badimon, L | 3 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Woodward, M | 1 |
| Lowe, GD | 1 |
| Francis, LM | 1 |
| Rumley, A | 1 |
| Cobbe, SM | 1 |
| Barrera-Ramirez, C | 1 |
| Hernández, R | 2 |
| Costa, MA | 2 |
| Van der Planken, MG | 1 |
| Michiels, JJ | 1 |
| Van Der Goten, P | 1 |
| Wuyts, FL | 1 |
| Kumana, CR | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Cheung, BM | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kwon, JA | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Rho, YM | 1 |
| Kapetanakis, EI | 1 |
| Medlam, DA | 1 |
| Boyce, SW | 1 |
| Haile, E | 1 |
| Hill, PC | 1 |
| Dullum, MK | 1 |
| Bafi, AS | 1 |
| Petro, KR | 1 |
| Corso, PJ | 1 |
| Gould, WR | 1 |
| Baxi, SM | 1 |
| Schroeder, R | 1 |
| Peng, YW | 1 |
| Leadley, RJ | 2 |
| Peterson, JT | 1 |
| Perrin, LA | 1 |
| Lechin, F | 1 |
| van der Dijs, B | 1 |
| Orozco, B | 1 |
| Rodríguez, S | 1 |
| Baez, S | 1 |
| Kadakia, RA | 1 |
| Ferguson, JJ | 3 |
| Moussouttas, M | 1 |
| Boeynaems, JM | 1 |
| van Giezen, H | 1 |
| Savi, P | 5 |
| Pogatsa-Murray, G | 2 |
| Wieczorek, A | 2 |
| Packham, MA | 2 |
| Mustard, JF | 2 |
| Hechler, B | 2 |
| Niitsu, Y | 2 |
| Jakubowski, JA | 2 |
| Sugidachi, A | 3 |
| Asai, F | 3 |
| Kawata, M | 1 |
| Kuramoto, E | 1 |
| Kataoka, T | 1 |
| Saito, A | 2 |
| Adachi, K | 1 |
| Sakamoto, S | 1 |
| Elsässer, A | 1 |
| Wenaweser, P | 2 |
| Dörffler-Melly, J | 1 |
| Imboden, K | 1 |
| Meier, B | 1 |
| Haeberli, A | 1 |
| Hess, OM | 1 |
| Ajzenberg, N | 1 |
| Aubry, P | 2 |
| Huisse, MG | 1 |
| Cachier, A | 1 |
| El Amara, W | 1 |
| Feldman, LJ | 1 |
| Himbert, D | 1 |
| Baruch, D | 1 |
| Guillin, MC | 1 |
| Charnigo, R | 1 |
| Moliterno, DJ | 2 |
| van der Meijden, PE | 1 |
| Giesen, PL | 1 |
| Huijberts, M | 1 |
| van Raak, LP | 1 |
| Benito, B | 1 |
| Masotti, M | 1 |
| Betriu, A | 1 |
| Cadroy, Y | 3 |
| Thalamas, C | 3 |
| Sakariassen, K | 3 |
| Boneu, B | 4 |
| Sinha, U | 1 |
| Rocca, B | 1 |
| Patrono, C | 1 |
| Morel, N | 1 |
| Ridard, C | 1 |
| Faure, A | 2 |
| Grunebaum, L | 3 |
| Toti, F | 2 |
| Taniguchi, M | 1 |
| Moritani, Y | 1 |
| Uemura, T | 1 |
| Shigenaga, T | 1 |
| Takamatsu, H | 1 |
| Hayashi, K | 1 |
| Takasaki, J | 1 |
| Saito, T | 1 |
| Nagai, K | 1 |
| Nayak, VK | 1 |
| Deschler, DG | 2 |
| Wolak, A | 1 |
| Massel, D | 1 |
| Yip, HK | 1 |
| Wu, CJ | 1 |
| Hang, CL | 1 |
| Chang, HW | 1 |
| Hung, WC | 1 |
| Yeh, KH | 1 |
| Hess, O | 1 |
| Ringborg, A | 1 |
| Lindgren, P | 1 |
| Jönsson, B | 1 |
| Meyer Samama, M | 1 |
| Trimarchi, H | 1 |
| Young, P | 1 |
| Forrester, M | 1 |
| Schropp, J | 1 |
| Pereyra, H | 1 |
| Freixas, E | 1 |
| Samara, W | 1 |
| Yoho, JA | 1 |
| Hayes, K | 1 |
| Fissha, MZ | 1 |
| Song, JM | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Finkelstein, Y | 1 |
| Nurmohamed, L | 1 |
| Avner, M | 1 |
| Benson, LN | 1 |
| Koren, G | 1 |
| Wanke, I | 1 |
| Doerfler, A | 1 |
| Goericke, S | 1 |
| Gizewski, ER | 1 |
| Sandalcioglu, E | 1 |
| Moemken, S | 1 |
| Stolke, D | 1 |
| Forsting, M | 1 |
| Fisher, M | 1 |
| Daykin, HJ | 1 |
| Jones, C | 1 |
| Wright, CE | 1 |
| Dropinski, J | 1 |
| Musial, J | 1 |
| Jakiela, B | 1 |
| Wegrzyn, W | 1 |
| Sanak, M | 1 |
| Szczeklik, A | 1 |
| Yokoyama, K | 1 |
| Murata, M | 1 |
| Sauer, H | 1 |
| Leschke, M | 1 |
| Mitsudo, K | 1 |
| Kuchulakanti, PK | 1 |
| Chu, WW | 1 |
| Clavijo, LC | 1 |
| Kim, SW | 1 |
| Bui, A | 1 |
| Gevorkian, N | 1 |
| Smith, K | 1 |
| Fournadjieva, J | 1 |
| Jimenez-Quevedo, P | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Wåhlander, K | 1 |
| Eriksson-Lepkowska, M | 1 |
| Nyström, P | 1 |
| Eriksson, UG | 1 |
| Sarich, TC | 1 |
| Kalies, I | 1 |
| Elg, M | 1 |
| Bylock, A | 1 |
| Black, HR | 1 |
| Cohen, EA | 1 |
| Mas, JL | 1 |
| Pearson, TA | 1 |
| Weber, MA | 1 |
| Fabry-Ribaudo, L | 1 |
| Booth, J | 1 |
| Guyon, P | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Wijns, W | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Malinin, A | 1 |
| Pokov, A | 1 |
| Spergling, M | 1 |
| Defranco, A | 1 |
| Schwartz, K | 1 |
| Schwartz, D | 1 |
| Mahmud, E | 1 |
| Klutmann, M | 1 |
| Tillmanns, C | 1 |
| Gulba, DC | 1 |
| Calvo-Romero, JM | 1 |
| Lima-Rodríguez, EM | 1 |
| Hoffmann, R | 2 |
| Zernecke, A | 1 |
| Kaiser, A | 1 |
| Weber, C | 2 |
| Batisse, A | 1 |
| Batisse, JP | 1 |
| Choussat, R | 1 |
| Jaarsma, W | 1 |
| Hautvast, RW | 1 |
| Buller, CE | 1 |
| Pate, GE | 1 |
| Armstrong, PW | 1 |
| O'Neill, BJ | 1 |
| Gallo, R | 1 |
| Schneider, H | 3 |
| Weber, F | 2 |
| Holzhausen, C | 1 |
| Körber, T | 1 |
| Rehders, T | 1 |
| Barsky, AA | 1 |
| Arora, RR | 1 |
| Buhk, JH | 1 |
| Wellmer, A | 1 |
| Knauth, M | 1 |
| Eikelboom, J | 1 |
| Lutsep, HL | 1 |
| Gaciong, Z | 1 |
| Suh, JW | 1 |
| Zhang, SY | 1 |
| Cho, JY | 1 |
| Jang, IJ | 1 |
| Lee, DS | 1 |
| Sohn, DW | 1 |
| Lee, MM | 1 |
| Turgeon, J | 1 |
| Pharand, C | 1 |
| Michaud, V | 1 |
| Niccoli, G | 1 |
| Siviglia, M | 1 |
| De Vita, M | 1 |
| Altamura, L | 1 |
| Fusco, B | 1 |
| Leone, AM | 1 |
| Ferrante, G | 1 |
| Rebuzzi, AG | 1 |
| Kettelkamp, R | 1 |
| Vance, C | 1 |
| Jones, PG | 1 |
| Rumsfeld, JS | 1 |
| Messenger, JC | 1 |
| Khanal, S | 1 |
| Bach, RG | 1 |
| Krumholz, HM | 1 |
| Frelinger, AL | 1 |
| Furman, MI | 3 |
| Linden, MD | 1 |
| Fox, ML | 1 |
| Barnard, MR | 1 |
| Ozben, B | 1 |
| Ekmekci, A | 1 |
| Bugra, Z | 1 |
| Umman, S | 1 |
| Meric, M | 1 |
| Studer, MA | 1 |
| Kennedy, CE | 1 |
| Dreyer, WJ | 1 |
| Price, JF | 1 |
| Moffett, BS | 1 |
| Teitel, ER | 1 |
| Carberry, KE | 1 |
| Morales, DL | 1 |
| McKenzie, ED | 1 |
| Chang, AC | 1 |
| Norris, JW | 1 |
| Barnett, HJ | 1 |
| Gilard, M | 2 |
| Arnaud, B | 1 |
| Le Gal, G | 1 |
| Abgrall, JF | 1 |
| Boschat, J | 1 |
| Mannini, L | 1 |
| Giglioli, C | 1 |
| Valente, S | 1 |
| Prisco, D | 1 |
| Borgdorff, P | 1 |
| Tangelder, GJ | 1 |
| Paulus, WJ | 1 |
| Sekiya, H | 1 |
| Noguchi, K | 1 |
| Ohashi, Y | 1 |
| Kariya, Y | 1 |
| Hoshino, Y | 1 |
| Konishi, H | 1 |
| Bünger, CM | 1 |
| Grabow, N | 1 |
| Sternberg, K | 1 |
| Ketner, L | 1 |
| Kröger, C | 1 |
| Lorenzen, B | 1 |
| Hauenstein, K | 1 |
| Schmitz, KP | 1 |
| Kreutzer, HJ | 1 |
| Lootz, D | 1 |
| Klar, E | 1 |
| Schareck, W | 1 |
| Collins, P | 1 |
| Ford, I | 1 |
| Greaves, M | 1 |
| Macaulay, E | 1 |
| Brittenden, J | 1 |
| von Beckerath, O | 1 |
| Reich, A | 1 |
| Bialynicki-Birula, R | 1 |
| Szepietowski, JC | 1 |
| Swallow, RA | 1 |
| Agarwala, RA | 1 |
| Dawkins, KD | 1 |
| Curzen, NP | 1 |
| Riesmeyer, J | 2 |
| Weerakkody, G | 2 |
| Winters, KJ | 1 |
| Warmke, JW | 1 |
| McCabe, CH | 3 |
| Harder, S | 1 |
| Chrissoheris, MP | 1 |
| Mruthyunjayanna, V | 1 |
| Donohue, TJ | 1 |
| Richardson, G | 1 |
| Alviar, CL | 1 |
| Arikan, ME | 1 |
| Dave, BP | 1 |
| Granada, JF | 1 |
| DeLao, T | 1 |
| Tellez, A | 1 |
| Maresh, K | 2 |
| Topakian, R | 1 |
| Nussbaumer, K | 1 |
| Trenkler, J | 1 |
| Aichner, FT | 1 |
| McLachlan, CS | 1 |
| Tay, SK | 1 |
| Almsherqi, Z | 1 |
| Chia, SH | 1 |
| Guirguis, M | 1 |
| Wexler, RR | 1 |
| Lam, PY | 1 |
| Quan, ML | 1 |
| Knabb, RM | 1 |
| Plosker, GL | 1 |
| Pena, E | 1 |
| Padró, T | 1 |
| Kozek-Langenecker, S | 1 |
| Vicenzi, MN | 1 |
| Münch, A | 1 |
| Aleil, B | 1 |
| Rochoux, G | 1 |
| Monassier, JP | 2 |
| Moore, MG | 1 |
| Maree, AO | 1 |
| Fitzgerald, DJ | 1 |
| Bali, L | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Saidi, LN | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Wang, YX | 1 |
| Vincelette, J | 1 |
| da Cunha, V | 1 |
| Martin-McNulty, B | 1 |
| Mallari, C | 1 |
| Fitch, RM | 1 |
| Alexander, S | 1 |
| Islam, I | 1 |
| Buckman, BO | 1 |
| Yuan, S | 1 |
| Post, JM | 1 |
| Subramanyam, B | 1 |
| Vergona, R | 1 |
| Sullivan, ME | 1 |
| Dole, WP | 1 |
| Morser, J | 1 |
| Bryant, J | 1 |
| Meadows, TA | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Santini, A | 1 |
| Moschi, G | 1 |
| Campbell, CL | 1 |
| Gulmez, O | 1 |
| Yildirir, A | 1 |
| Kaynar, G | 1 |
| Konas, D | 1 |
| Aydinalp, A | 1 |
| Ertan, C | 1 |
| Ozin, B | 1 |
| Muderrisoglu, H | 1 |
| Payne, DA | 1 |
| Jones, CI | 1 |
| Hayes, PD | 1 |
| Naylor, AR | 1 |
| Goodall, AH | 1 |
| Spiess, BD | 1 |
| Eder, C | 1 |
| Funke, U | 1 |
| Schulze, M | 1 |
| Lutze, G | 1 |
| Zimmermann, M | 1 |
| Prasse, T | 1 |
| Töpfer, G | 1 |
| Chelliah, R | 1 |
| Unverdorben, M | 1 |
| Degenhardt, R | 1 |
| Wiemer, M | 1 |
| Horstkotte, D | 1 |
| Nienaber, C | 1 |
| Bocksch, W | 1 |
| Gross, M | 1 |
| Boxberger, M | 1 |
| Vallbracht, C | 1 |
| Jakabcin, J | 1 |
| Bystron, M | 1 |
| Spacek, R | 1 |
| Veselka, J | 1 |
| Kvasnak, M | 1 |
| Kala, P | 1 |
| Malý, J | 1 |
| Cervinka, P | 1 |
| Casaní, L | 1 |
| Riddell, JW | 1 |
| Chiche, L | 1 |
| Plaud, B | 1 |
| Hamon, M | 2 |
| Desprez, D | 2 |
| de Korte, FI | 1 |
| Vijverberg, PL | 1 |
| Ruzyllo, W | 1 |
| Gottlieb, S | 1 |
| De Servi, S | 2 |
| Murphy, SA | 2 |
| Ogawa, T | 2 |
| Hashimoto, M | 1 |
| Isobe, T | 1 |
| Otsuguro, K | 1 |
| Blindt, R | 1 |
| Stellbrink, K | 1 |
| de Taeye, A | 1 |
| Müller, R | 1 |
| Kiefer, P | 1 |
| Yagmur, E | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Fujimoto, Y | 1 |
| Nakamura, Y | 1 |
| Nakayama, T | 1 |
| Himi, T | 1 |
| Miyazaki, A | 1 |
| Simmons, BB | 1 |
| Salzman, BE | 1 |
| Rott, D | 1 |
| Leibowitz, D | 1 |
| Amit, G | 1 |
| Weiss, AT | 1 |
| Palazuelos, J | 1 |
| Weisberg, I | 1 |
| Zenni, MZ | 1 |
| Konrad, I | 1 |
| Sauer, S | 1 |
| Orschiedt, L | 1 |
| Koellnberger, M | 1 |
| Lorenz, R | 1 |
| Walter, U | 1 |
| Pershukov, IV | 1 |
| Bernhard, N | 1 |
| Freyssinet, JM | 1 |
| Landolfi, R | 1 |
| Di Gennaro, L | 1 |
| Kornowski, R | 2 |
| Vaknin-Assa, H | 1 |
| Brosh, D | 1 |
| Fuchs, S | 1 |
| Battler, A | 1 |
| Assali, A | 1 |
| May, AE | 2 |
| Topcu, Y | 1 |
| Postma, S | 1 |
| Ellahham, S | 1 |
| Sevdalis, N | 1 |
| Jacklin, R | 1 |
| Horvath, I | 1 |
| Keltai, M | 1 |
| Herrman, JP | 1 |
| Van de Werf, F | 1 |
| Downey, WE | 1 |
| Scirica, BM | 1 |
| Karnicki, K | 1 |
| Baxi, S | 1 |
| Peterson, T | 1 |
| Wysokinski, W | 1 |
| McBane, RD | 1 |
| Kapoor, JR | 1 |
| Billett, HH | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Lee, R | 1 |
| Ezekowitz, M | 1 |
| Valencia, J | 1 |
| Mainar, V | 1 |
| Bordes, P | 1 |
| Pineda, J | 1 |
| Gómez, S | 1 |
| Sogorb, F | 1 |
| Lefkovits, J | 1 |
| Dember, LM | 1 |
| Beck, GJ | 1 |
| Allon, M | 1 |
| Delmez, JA | 1 |
| Dixon, BS | 1 |
| Greenberg, A | 2 |
| Himmelfarb, J | 1 |
| Vazquez, MA | 1 |
| Gassman, JJ | 1 |
| Radeva, MK | 1 |
| Braden, GL | 1 |
| Ikizler, TA | 1 |
| Rocco, MV | 1 |
| Davidson, IJ | 1 |
| Meyers, CM | 1 |
| Kusek, JW | 1 |
| Feldman, HI | 1 |
| Angiolillo, D | 2 |
| Bates, E | 2 |
| Bhatt, D | 2 |
| Peterson, E | 2 |
| Wiviott, S | 2 |
| Cassetti, E | 1 |
| Alvarez, W | 1 |
| Glusa, E | 1 |
| Verstraete, M | 3 |
| Weichert, W | 1 |
| Pauliks, V | 1 |
| Breddin, HK | 1 |
| Kester, RC | 1 |
| Kher, A | 1 |
| Gaillard, JL | 1 |
| Samama, M | 2 |
| Gordon, JL | 2 |
| Panak, E | 3 |
| Blanchard, J | 4 |
| Roe, RL | 1 |
| Takayama, T | 3 |
| Pinon, JF | 1 |
| Kumashiro, R | 2 |
| Pavlides, CA | 1 |
| Kholoussy, AM | 2 |
| Matsumoto, T | 2 |
| Maffrand, JP | 6 |
| Picard-Fraire, C | 1 |
| Vallée, E | 1 |
| Roncucci, R | 1 |
| Bertelé, V | 2 |
| Castaigne, A | 1 |
| Benghozi, R | 1 |
| Bienvenu, MP | 1 |
| Pumphrey, CW | 1 |
| Dewanjee, MK | 1 |
| Murphy, KP | 1 |
| Vlietstra, RE | 1 |
| Kaye, MP | 1 |
| Kobayashi, K | 2 |
| Maeda, K | 2 |
| Koshikawa, S | 1 |
| Kawaguchi, Y | 1 |
| Shimizu, N | 1 |
| Naito, C | 1 |
| Usuda, M | 1 |
| Kawaguchi, S | 1 |
| Shinzato, T | 1 |
| Ohta, K | 1 |
| Ohbayashi, S | 1 |
| Narita, M | 1 |
| Renner, C | 1 |
| Guilmet, D | 1 |
| Curtet, JM | 1 |
| Bernat, A | 9 |
| Yokota, K | 1 |
| Yamashita, A | 1 |
| Oda, M | 1 |
| Toyohira, H | 1 |
| Nakamura, K | 1 |
| Kariyazono, H | 1 |
| Yamada, K | 1 |
| Moriyama, Y | 1 |
| Shimokawa, S | 1 |
| Saigenji, H | 1 |
| Taira, A | 1 |
| Zemour, G | 2 |
| Benveniste, E | 2 |
| Biron, Y | 2 |
| Bourdonnec, C | 1 |
| Faivre, R | 1 |
| Fajadet, J | 1 |
| Gaspard, P | 1 |
| Glatt, B | 2 |
| Joly, P | 2 |
| Pongratz, G | 1 |
| Pohle, K | 1 |
| Stingl, D | 1 |
| Bachmann, K | 1 |
| Zoldhelyi, P | 1 |
| Hirata, Y | 1 |
| Umemura, K | 1 |
| Uematsu, T | 1 |
| Nakashima, M | 1 |
| Basile, AP | 1 |
| Fiala, TG | 1 |
| Yaremchuk, MJ | 1 |
| May, JW | 1 |
| Terashita, Z | 1 |
| Imura, Y | 1 |
| Kato, K | 1 |
| Nishikawa, K | 1 |
| Shirakura, S | 1 |
| Higo, K | 1 |
| Takeda, M | 1 |
| Karasawa, A | 1 |
| Mazoyer, E | 2 |
| Ripoll, L | 1 |
| Boisseau, MR | 1 |
| Roald, HE | 1 |
| Barstad, RM | 1 |
| Kierulf, P | 1 |
| Skjørten, F | 1 |
| Dickinson, JP | 1 |
| Kieffer, G | 1 |
| Carreras, LO | 1 |
| Kindermans, M | 1 |
| Dumas, A | 1 |
| Aït-Chek, L | 1 |
| Kirichenko, AA | 2 |
| Prekina, VI | 1 |
| Sainte-Marie, M | 1 |
| Dol, F | 3 |
| Rinaldi, M | 1 |
| Narita, H | 1 |
| Kaburaki, M | 1 |
| Doi, H | 1 |
| Yasoshima, A | 1 |
| Murata, S | 1 |
| Hall, P | 2 |
| Nakamura, S | 2 |
| Maiello, L | 1 |
| Itoh, A | 2 |
| Blengino, S | 2 |
| Martini, G | 2 |
| Ferraro, M | 2 |
| Bihour, C | 1 |
| Smith, M | 1 |
| Raymond, JM | 1 |
| Nurden, AT | 2 |
| Nishimura, H | 1 |
| Naritomi, H | 1 |
| Iwamoto, Y | 1 |
| Tachibana, H | 1 |
| Sugita, M | 1 |
| Tohgi, H | 1 |
| Watanabe, K | 1 |
| Kuki, H | 1 |
| Shirasawa, Y | 1 |
| Lienhart, Y | 1 |
| Valeix, B | 1 |
| Louvard, Y | 1 |
| Lefevre, T | 2 |
| Guérin, Y | 1 |
| Schafer, AI | 2 |
| Kosugi, T | 1 |
| Masuda, Y | 1 |
| Kinjoh, K | 1 |
| Yamashita, S | 1 |
| Sunagawa, M | 1 |
| Goods, CM | 1 |
| al-Shaibi, KF | 1 |
| Liu, MW | 1 |
| Yadav, JS | 1 |
| Mathur, A | 1 |
| Jain, SP | 1 |
| Dean, LS | 1 |
| Iyer, SS | 1 |
| Parks, JM | 1 |
| Roubin, GS | 1 |
| Markert, T | 1 |
| Bertsch, G | 1 |
| Langenfeld, H | 1 |
| Schanzenbächer, P | 1 |
| Lowe, H | 1 |
| Roy, P | 1 |
| Baron, D | 1 |
| Baim, DS | 2 |
| Carrozza, JP | 1 |
| Keil, Tu | 1 |
| Matsuyama, N | 1 |
| Asada, K | 1 |
| Kondou, K | 1 |
| Kodama, T | 1 |
| Minohara, S | 1 |
| Hasegawa, Y | 1 |
| Sawada, Y | 1 |
| Okamoto, J | 1 |
| Okamoto, K | 1 |
| Runyon, JP | 1 |
| Broderick, TM | 1 |
| Higby, NA | 1 |
| Martin, LH | 1 |
| Hantsbarger, G | 1 |
| McDonald, S | 1 |
| Anders, RJ | 1 |
| Hoffmann, P | 1 |
| Elias, J | 1 |
| Maillard, L | 1 |
| Spaulding, C | 1 |
| Raynaud, P | 1 |
| Cribier, A | 1 |
| Barragan, P | 3 |
| Juliard, JM | 1 |
| Faugier, JP | 1 |
| Masquet, C | 1 |
| Rioux, P | 1 |
| Bedossa, M | 1 |
| Petiteau, PY | 1 |
| Royer, T | 1 |
| Roriz, R | 1 |
| Meyer, P | 1 |
| Blanchard, D | 1 |
| Khalifé, K | 1 |
| Wheeldon, N | 1 |
| Cumberland, D | 1 |
| Sainsous, J | 1 |
| Silvestri, M | 1 |
| Simeoni, JB | 1 |
| Bayet, G | 1 |
| Roquebert, PO | 2 |
| Bouvier, JL | 2 |
| Comet, B | 2 |
| Quatre, JM | 1 |
| Linnemeier, TJ | 1 |
| Iturbe, T | 1 |
| Sánchez, C | 1 |
| Moreno, JA | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Ott, I | 1 |
| Walter, H | 1 |
| Anzuini, A | 1 |
| Rosanio, S | 1 |
| Legrand, V | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Bonnier, H | 1 |
| Sheiban, I | 1 |
| Kulbertus, HE | 1 |
| Chierchia, SL | 1 |
| Feldman, TE | 1 |
| Schneider, D | 1 |
| Kim, YS | 1 |
| Pyo, MK | 1 |
| Park, KM | 1 |
| Park, PH | 1 |
| Hahn, BS | 1 |
| Wu, SJ | 1 |
| Yun-Choi, HS | 1 |
| Bossavy, JP | 2 |
| Sagnard, L | 2 |
| Barret, A | 1 |
| Lalé, A | 1 |
| Zidar, JP | 1 |
| Saucedo, J | 1 |
| Harker, LA | 3 |
| Marzec, UM | 1 |
| Kelly, AB | 1 |
| Chronos, NR | 1 |
| Sundell, IB | 1 |
| Hanson, SR | 1 |
| Popma, JJ | 1 |
| Gordon, PC | 1 |
| Ho, KK | 1 |
| Giambartolomei, A | 1 |
| Diver, DJ | 1 |
| Lasorda, DM | 1 |
| Williams, DO | 1 |
| Pocock, SJ | 1 |
| Kuntz, RE | 1 |
| Ennamany, R | 1 |
| Bingen, A | 1 |
| Creppy, EE | 1 |
| Kretz, O | 1 |
| Gut, JP | 1 |
| Dubuisson, L | 1 |
| Balabaud, C | 1 |
| Bioulac Sage, P | 1 |
| Kirn, A | 1 |
| Dormandy, JA | 1 |
| Hasdai, D | 1 |
| Grill, DE | 1 |
| Melby, S | 1 |
| Calverley, DC | 1 |
| Roth, GJ | 1 |
| Korbut, R | 1 |
| Uracz, W | 2 |
| Wilson, SH | 1 |
| Velianou, JL | 1 |
| Ferrer, F | 1 |
| Moraleda, JM | 1 |
| Vicente, V | 1 |
| Gaich, C | 1 |
| O'Connor, CM | 1 |
| Cummings, CC | 1 |
| Fabris, F | 1 |
| Luzzatto, G | 1 |
| Sartori, MT | 1 |
| Zanella, I | 1 |
| Girolami, A | 1 |
| Léger, P | 1 |
| Magues, JP | 1 |
| Wilson, JM | 1 |
| Kohda, N | 1 |
| Tani, T | 1 |
| Nakayama, S | 1 |
| Adachi, T | 1 |
| Marukawa, K | 1 |
| Ito, R | 1 |
| Ishida, K | 1 |
| Matsumoto, Y | 1 |
| Kimura, Y | 1 |
| Jafary, FH | 1 |
| Kimmelstiel, CD | 1 |
| Henry, P | 1 |
| Beverelli, F | 1 |
| Fredrickson, BJ | 1 |
| Turner, NA | 1 |
| Graziadei, N | 1 |
| Mascelli, MA | 1 |
| Effron, MB | 1 |
| McIntire, LV | 1 |
| Koike, H | 1 |
| Guilmot, JL | 1 |
| Diot, E | 1 |
| Kobza, II | 1 |
| Kolansky, DM | 1 |
| Klugherz, BD | 1 |
| Curran, SC | 1 |
| Herrmann, HC | 1 |
| Magness, K | 1 |
| Wilensky, RL | 1 |
| Hirshfeld, JW | 1 |
| Block, PC | 1 |
| Jarvis, B | 1 |
| Simpson, K | 1 |
| Moore, SA | 1 |
| Fiore, L | 1 |
| Hasbargen, JA | 1 |
| Perdriset, G | 1 |
| Curry, BH | 1 |
| Paliou, M | 1 |
| Naber, CK | 1 |
| Rahman, YA | 1 |
| Haude, M | 1 |
| Erbel, R | 1 |
| Hutten, BA | 1 |
| Plokker, HW | 1 |
| White, RL | 1 |
| Pinnow, E | 1 |
| Dieble, R | 1 |
| Bui, AB | 1 |
| Taaffe, M | 1 |
| Gruberg, L | 1 |
| Mintz, GS | 1 |
| Kent, KK | 1 |
| Lindsay, J | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Lowry, DR | 1 |
| te Poele, JA | 1 |
| van Kleef, EM | 1 |
| van der Wal, AF | 1 |
| Dewit, LG | 1 |
| Stewart, FA | 1 |
| Voskoboĭ, IV | 1 |
| Rebrov, AP | 1 |
| Kirichuk, VF | 1 |
| Pozin, PIa | 1 |
| Kihara, H | 1 |
| Koganei, H | 1 |
| Hirose, K | 1 |
| Yoshimoto, R | 1 |
| Paterson, KR | 1 |
| Seyfarth, HJ | 1 |
| Koksch, M | 1 |
| Roethig, G | 1 |
| Rother, T | 1 |
| Neugebauer, A | 1 |
| Klein, N | 1 |
| Pfeiffer, D | 1 |
| Teuma, X | 1 |
| Botosezzy, I | 1 |
| Commeau, P | 1 |
| Macaluso, G | 1 |
| Mouthon, MA | 1 |
| Gaugler, MH | 1 |
| Vandamme, M | 1 |
| Gourmelon, P | 1 |
| Wagemaker, G | 1 |
| Van der Meeren, A | 1 |
| Little, JW | 1 |
| Miller, CS | 1 |
| McIntosh, BA | 1 |
| Griffanti-Bartoli, F | 1 |
| Altomonte, F | 1 |
| Pitton, L | 1 |
| Armani, U | 1 |
| Piana, A | 1 |
| Hirsh, J | 1 |
| Dalen, JE | 1 |
| Harker, LB | 1 |
| Salzman, EW | 1 |
| Yamamoto, J | 1 |
| Ishii, I | 1 |
| Sasaki, Y | 1 |
| Nagamatsu, Y | 1 |
| Matsuda, T | 1 |
| Ando, E | 1 |
| Bokarev, IN | 1 |
| Velikov, VK | 1 |
| Zelenchuk, NM | 1 |
| Bonnin, P | 1 |
| Bonneau, M | 1 |
| Pignaud, G | 1 |
| Bailliart, O | 1 |
| Viars, P | 1 |
| Caen, JP | 1 |
| Drouet, LO | 1 |
| Gutiérrez Díaz, JA | 1 |
| Tolón, RM | 1 |
| Sunkel, C | 1 |
| Maruyama, S | 1 |
| Mantz, F | 1 |
| Shimada, H | 1 |
| Kitajima, A | 1 |
| Tamao, Y | 1 |
| Morishita, K | 1 |
| Wada, M | 1 |
| Kumada, T | 1 |
| Tanaka, T | 1 |
| Tomikawa, M | 1 |
| Iwamoto, M | 1 |
| Finelli, C | 1 |
| Palareti, G | 1 |
| Poggi, M | 1 |
| Torricelli, P | 1 |
| Vianelli, N | 1 |
| Fiacchini, M | 1 |
| Zuffa, E | 1 |
| Ricci, P | 1 |
| Gugliotta, L | 1 |
| Coccheri, S | 1 |
| Bellotti, P | 1 |
| Claudiani, F | 1 |
| Chiarella, F | 1 |
| Domenicucci, S | 1 |
| Scopinaro, G | 1 |
| Mazzotta, G | 1 |
| Lupi, G | 1 |
| Strada, P | 1 |
| Vecchio, C | 1 |
| Itoh, T | 1 |
| Shiba, E | 1 |
| Kambayashi, J | 1 |
| Watase, M | 1 |
| Sakon, M | 1 |
| Mori, T | 1 |
| Defreyn, G | 2 |
| Delebassee, D | 2 |
| Saitoh, H | 2 |
| Matsumoto, H | 1 |
| Ide, H | 1 |
| Miyawaki, F | 1 |
| Furuse, A | 1 |
| Strano, A | 2 |
| Davì, G | 2 |
| Cannizzaro, S | 1 |
| Giubilato, A | 1 |
| Hayashida, N | 1 |
| Binaghi, F | 1 |
| Fronteddu, PF | 1 |
| Cannas, F | 1 |
| Martelli, V | 1 |
| Arcan, JC | 1 |
| Boissel, JP | 1 |
| Destors, JM | 1 |
| Botindari, G | 1 |
| Catalano, I | 1 |
| Escolar, G | 2 |
| Bastida, E | 2 |
| Castillo, R | 1 |
| Ordinas, A | 2 |
| Almirall, L | 1 |
| Di Perri, T | 1 |
| Fiskerstrand, CE | 1 |
| Thompson, IW | 1 |
| Burnet, ME | 1 |
| Williams, P | 1 |
| Anderton, JL | 1 |
| Gröntoft, KC | 1 |
| Mulec, H | 1 |
| Gutierrez, A | 1 |
| Olander, R | 1 |
| Piotrowski, JJ | 1 |
| Hashimoto, N | 1 |
| Winocour, PD | 1 |
| Somers, DA | 1 |
| Groves, HM | 1 |
| Kinlough-Rathbone, RL | 1 |
| Glukhov, AI | 1 |
| Goriunov, VS | 1 |
| Smirnova, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)[NCT03255928] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-06-29 | Recruiting | |||
| MANCO: Measuring the ACT During Non-cardiac Arterial Procedures.[NCT03426293] | 500 participants (Anticipated) | Observational [Patient Registry] | 2016-12-21 | Recruiting | |||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Practice Patterns of Antithrombotic Therapy in REAL-world Patients Undergoing PCI in Spain: Parenteral Antiplatelet Agents[NCT05193019] | 1,000 participants (Anticipated) | Observational | 2022-03-14 | Recruiting | |||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt[NCT00396877] | Phase 3 | 906 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Impact of LDL-cholesterol Lowering on Platelet Activation[NCT03331666] | Phase 4 | 4 participants (Actual) | Interventional | 2018-11-16 | Terminated (stopped due to Terminated Prematurely due to COVID-19) | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Targeting Platelets in Chronic HIV Infection[NCT02578706] | Phase 2 | 27 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| "Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (Biofreedom): the CHANCE a Multicenter Study"[NCT03622203] | 1,000 participants (Actual) | Observational [Patient Registry] | 2016-01-01 | Completed | |||
| Clinical Trial Program of a Medical Instrument Product[NCT01157455] | Phase 4 | 1,900 participants (Anticipated) | Interventional | 2010-05-31 | Recruiting | ||
| CAOCT Study is a Prospective, Multi-centre, Single Cohort, Diagnostic Accuracy Study, Planned to Include 131 Patients in About 3 European Countries After Successful Return of Spontaneous Circulation After Out of Hospital Cardiac Arrest[NCT04431661] | 28 participants (Actual) | Observational | 2021-01-29 | Terminated (stopped due to Low patient recruitment rate and change of hopsital procedures for handling cardiac arrest patients during emergency) | |||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers[NCT01846559] | Phase 4 | 30 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Characterisation of a Novel Regimen of Very Low-dose Aspirin Combined With Rivaroxaban in Patients With Chronic Coronary Syndromes: WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?[NCT04990791] | Phase 4 | 48 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin[NCT01768637] | Phase 1 | 48 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268] | Phase 4 | 358 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome[NCT01994941] | Phase 4 | 133 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054] | Phase 4 | 4,570 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Periprocedural Cangrelor in Patients With ST-Elevation Myocardial Infarction to Reduce Development of Myocardial Necrosis[NCT03043274] | Phase 4 | 23 participants (Actual) | Interventional | 2017-01-31 | Terminated | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544] | Phase 4 | 187 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture[NCT02475187] | 33 participants (Anticipated) | Observational | 2015-09-30 | Terminated | |||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion[NCT00794014] | 258 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients[NCT02707445] | 5,000 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Evaluating Pharmacogenomic Variants for Cardiology Therapeutics: the Lighthouse Pilot (Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects)[NCT04702113] | 300 participants (Actual) | Interventional | 2020-12-03 | Completed | |||
| Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545] | 130 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918] | 2,800 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185] | Phase 4 | 154 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.[NCT01045850] | 1,312 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066] | Phase 4 | 65 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| 150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention[NCT00638326] | Phase 3 | 500 participants (Anticipated) | Interventional | 2008-03-31 | Terminated (stopped due to Greater differences between randomized patients than previously anticipated) | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment[NCT05277116] | 25,000 participants (Anticipated) | Interventional | 2022-02-16 | Recruiting | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI[NCT00751231] | Phase 2 | 652 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Effect of Glucocorticoid Therapy on Left Ventricular Remodelling in Acute ST-segment Elevation Myocardial Infarction (RECONSIDER)[NCT03371784] | Phase 2/Phase 3 | 77 participants (Actual) | Interventional | 2018-03-08 | Active, not recruiting | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms[NCT05945563] | 208 participants (Anticipated) | Observational [Patient Registry] | 2023-01-17 | Recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669] | Phase 4 | 200 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)[NCT03973931] | 9,501 participants (Actual) | Interventional | 2019-07-01 | Active, not recruiting | |||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119] | Phase 3 | 649 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| Clinical Evaluation of a Vascular Venous Anastomotic Connector for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis [InterGraft VIG-only Study][NCT02532621] | 158 participants (Actual) | Interventional | 2018-02-21 | Completed | |||
| Randomized Controlled Trial Comparing endoAVF Versus surgAVF[NCT05654103] | 90 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis[NCT03289520] | Phase 3 | 877 participants (Actual) | Interventional | 2003-01-07 | Completed | ||
| Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease[NCT05457881] | 226 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | |||
| Effects of Heparin on Early Patency of Arteriovenous Fistula in Angioaccess Surgery of Patients With End-Stage Renal Disease[NCT02493504] | Phase 4 | 150 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access[NCT02475837] | Phase 2 | 17 participants (Actual) | Interventional | 2015-08-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Treatment Arm | 257 |
| Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
| Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
| Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
| Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
| Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times. (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Spontaneous | Post-traumatic | Puncture (vascular access site) | Surgical | |
| Clopidogrel 0.2 mg/kg/Day | 56 | 11 | 9 | 17 |
| Placebo | 60 | 6 | 19 | 10 |
"The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.~Only the first event was counted." (NCT00396877)
Timeframe: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Death / Shunt Thrombosis / Cardiac Procedure | - Death | - Shunt thrombosis | - Cardiac procedure <120 days of thrombotic nature | |
| Clopidogrel 0.2 mg/kg/Day | 89 | 51 | 26 | 12 |
| Placebo | 90 | 60 | 21 | 9 |
"Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted." (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 87 | 30 | 1 | 9 |
| Placebo | 88 | 32 | 1 | 9 |
ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow Aspirin assay (Accriva Diagnostics) will be performed. Unit: Aspirin Reaction Unit (ARU) (NCT03331666)
Timeframe: Day 7, Day 14, Day 21, Day 28, Day 84
| Intervention | ARU (Number) | ||||
|---|---|---|---|---|---|
| Aspirin Test, Day 7 | Aspirin Test Day 14 | Aspirin Test, Day 21 | Aspirin Test, Day 28 | Aspirin Test, Day 84 | |
| Evolocumab | 521 | 608 | 533 | 530 | 406 |
| Placebo | 432 | 401 | 490 | 512 | 386 |
ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 (VerifyNow PRUTest) will be performed. Unit: PRU (NCT03331666)
Timeframe: Day 7, Day 14, Day 21, Day 28, Day 84
| Intervention | PRU (Number) | ||||
|---|---|---|---|---|---|
| P2Y12 Test, Day 7 | P2Y12 Test, Day 14 | P2Y12 test, Day 21 | P2Y12 Test, Day 28 | P2Y12 Test, Day 84 | |
| Evolocumab | 266 | 268 | 268 | 276 | 256 |
| Placebo | 216 | 226 | 233 | 225 | 267 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Alpha angle is measured using thromboelastography, measured by a tangent to the clotting curve through the 2mm point (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | degree (Mean) |
|---|---|
| Aspirin and Placebo | 0.00 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.50 |
The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16- monocyte) (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | -0.09 |
| Clopidogrel and Placebo | -0.12 |
| Placebo Only | -0.04 |
Clot formation time is measured using thromboelastography. time from 2 to 20 mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | -1.00 |
| Clopidogrel and Placebo | 2.00 |
| Placebo Only | 1.63 |
Clot formation kinetics, or coagulation time, is measured using thromboelastography. time to 2mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | 3.00 |
| Clopidogrel and Placebo | 1.00 |
| Placebo Only | -13.13 |
D-Dimer level looks at coagulation of blood. D-dimers are not normally present in blood except when coagulation has occurred. (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | mcg/L (Mean) |
|---|---|
| Aspirin and Placebo | -295.99 |
| Clopidogrel and Placebo | 151.96 |
| Placebo Only | 1109.38 |
Interleukin 6 gene encodes a cytokine that functions in inflammation and implicated in a variety of inflammatory-associated disease states. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -0.36 |
| Clopidogrel and Placebo | 0.02 |
| Placebo Only | 0.85 |
The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes). (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.02 |
| Clopidogrel and Placebo | 0.06 |
| Placebo Only | 0.04 |
Maximum Clot Firmness (MCF) is measured using thromboelastography. maximum ampliture in mm (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | mm (Mean) |
|---|---|
| Aspirin and Placebo | 1.38 |
| Clopidogrel and Placebo | 1.20 |
| Placebo Only | 0.38 |
Soluble CD163 is a specific macrophage activation marker, associated with morphological disease grade. A high sCD163 indicates more disease. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 26.88 |
| Clopidogrel and Placebo | 15.8 |
| Placebo Only | -63.38 |
Change in % platelet monocyte aggregates from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet monocyte aggregates (Mean) |
|---|---|
| Aspirin and Placebo | 10.55 |
| Clopidogrel and Placebo | 3.88 |
| Placebo Only | 8.96 |
The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[ (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.002 |
| Clopidogrel and Placebo | 0.03 |
| Placebo Only | -0.03 |
Change in % platelet aggregation in response to stimulation by Adenosine Diphosphate (ADP) from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -7.25 |
| Clopidogrel and Placebo | -32.40 |
| Placebo Only | -6.50 |
Change in % platelet aggregation in response to stimulation by arachidonic acid 1500µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -53.33 |
| Clopidogrel and Placebo | -31.00 |
| Placebo Only | -13.25 |
Change in % platelet aggregation in response to stimulation by Collagen 2µg/mL from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -40.37 |
| Clopidogrel and Placebo | -9.60 |
| Placebo Only | 8.62 |
Change in % platelet aggregation in response to stimulation by light transmission aggregometry as measured by epinephrine 5µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -35.25 |
| Clopidogrel and Placebo | -21.40 |
| Placebo Only | -10.63 |
Soluble CD14 (sCD14) levels in blood. sCD14 is a nonspecific maker of monocyte activation. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | 35.75 |
| Clopidogrel and Placebo | -251.40 |
| Placebo Only | -101.75 |
Soluble CD40-ligand levels (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -28.05 |
| Clopidogrel and Placebo | -25.68 |
| Placebo Only | 13.65 |
Change in spontaneous % platelet from baseline to week 24. Spontaneous platelet aggregation? (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet (Mean) |
|---|---|
| Aspirin and Placebo | -0.75 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.88 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 137.77 |
| Clopidogrel and Placebo | 59.46 |
| Placebo Only | 19.78 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 283.13 |
| Clopidogrel and Placebo | 347.00 |
| Placebo Only | 4.25 |
substudy - Change in thrombus formation by Badimon chamber (high shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. The high shear chambers (inner lumen diameter 0.1 mm, Reynolds number 60, shear rate 1690 s- 1) mimic the rheologic conditions of a moderately stenosed coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -3052.20 |
| Clopidogrel and Placebo | -2798.80 |
| Placebo Only | -753.00 |
substudy - Change in thrombus formation by Badimon chamber (low shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. μ(2)/mm is the area of thrombus. The low shear chamber (inner lumen diameter 0.2 mm, Reynolds number 30, shear rate 500 s- 1) simulates flow conditions of a normal coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -1036 |
| Clopidogrel and Placebo | -899.20 |
| Placebo Only | -203.75 |
Safety as measured by a Summary of the number of subjects with at least one grade 3 or higher sign/symptom or laboratory abnormality. A grade 3 sign/symptom was defined as medically significant but not immediately life threatening. (NCT02578706)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and Placebo | 0 |
| Clopidogrel and Placebo | 1 |
| Placebo Only | 0 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (arachidonic acid at 5 mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks
| Intervention | ohms (Median) | |
|---|---|---|
| Baseline | visit 2 | |
| Chronic Kidney Disease | 21.0 | 0 |
| Normal Controls | 18.0 | 0 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (collagen at 2mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks
| Intervention | ohms (Median) | |
|---|---|---|
| Baseline | visit 2 | |
| Chronic Kidney Disease | 28.5 | 19.5 |
| Normal Controls | 25.0 | 19.0 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (adenosine diphosphate at 20mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) and on aspirin (visit 2) was compared between groups with post treatment values (visit 3) after 2 weeks of aspirin and clopidogrel treatment (NCT01768637)
Timeframe: 4 weeks
| Intervention | ohms (Mean) | ||
|---|---|---|---|
| Baseline | visit 2 | visit 3 | |
| Chronic Kidney Disease | 13.5 | 11.0 | 8.0 |
| Normal Controls | 9.0 | 10.0 | 3.0 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
ELISA assay. (NCT03043274)
Timeframe: 6 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Cangrelor | 41.4 |
| No Cangrelor | 103.3 |
ELISA assay will be performed on plasma to quantify the amount of the inflammatory cytokine interleukin-6 in pg/mL. (NCT03043274)
Timeframe: 6 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Cangrelor | 33.2 |
| No Cangrelor | 57.8 |
ELISA assay macrophage-derived chemokine (NCT03043274)
Timeframe: 6 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Cangrelor | 593.3 |
| No Cangrelor | 873.8 |
Cardiac MRI is obtained at 48 hours and 3 months to compare differences in infarct size. The outcome is assessed as the difference in infarct size between 48 hours and 3 months in each group. (NCT03043274)
Timeframe: 48 hours and 3 months
| Intervention | percent of left ventricular mass (Mean) | |
|---|---|---|
| 48 hours | 3 months | |
| Cangrelor | 8.6 | 6.7 |
| No Cangrelor | 11.1 | 6.98 |
Flow cytometry on peripheral blood will be performed to quantify peripheral counts of inflammatory cells, stem cells, and monocyte subtypes. (NCT03043274)
Timeframe: 6 hours
| Intervention | cells per microliter (Mean) | |
|---|---|---|
| granulocyte platelet aggregates | Monocyte-platelet aggregate | |
| Cangrelor | 1166.7 | 139.8 |
| No Cangrelor | 2550.4 | 333.9 |
Platelet reactivity testing will be performed 10 minutes after infusion has started. (NCT03043274)
Timeframe: 10 minutes
| Intervention | seconds (Mean) | |
|---|---|---|
| ADP-induced aggregation | TRAP-induced aggregation | |
| Cangrelor | 102.2 | 285.8 |
| No Cangrelor | 333.4 | 624.8 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up
| Intervention | US dollars (Mean) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 5483 |
| Drug Eluting Stents | 7658.2 |
Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months
| Intervention | vessels (Number) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 14 |
| Drug Eluting Stents | 15 |
Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| MACCE | Death | Acute Myocardial Infarction | Stroke | |
| Drug Eluting Stents | 15 | 7 | 9 | 1 |
| Oral Sirolimus + Bare Metal Stent | 9 | 3 | 6 | 0 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Bleeding events according to GUSTO (criteria for bleeding: Severe, Moderate or Mild) and BARC (bleeding criteria Type 0-5, with 0 being no bleeding and 5 referring to probable or definite fatal bleeding) Criteria (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 0 |
| Placebo Intervention | 1 |
Participants able to use their AV fistula for dialysis within 180 days of surgery were considered to have met the outcome. (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 2 |
| Placebo Intervention | 4 |
Criteria for outcome: AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement. (NCT02475837)
Timeframe: 150-238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 1 |
| Placebo Intervention | 5 |
Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks). (NCT02475837)
Timeframe: up to 238 days
| Intervention | Days to functional maturation (Median) |
|---|---|
| Vorapaxar Intervention | 169 |
| Placebo Intervention | 145 |
225 reviews available for ticlopidine and Blood Clot
| Article | Year |
|---|---|
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hem | 2016 |
Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.
Topics: Blood Platelets; Humans; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitor | 2017 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2017 |
Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhibitors; P | 2013 |
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Interv | 2013 |
Pharmacogenomics of anti-platelet and anti-coagulation therapy.
Topics: Anticoagulants; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Treat | 2013 |
Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
Topics: Aspirin; Cardiotonic Agents; Clopidogrel; Drug-Eluting Stents; Everolimus; Humans; Percutaneous Coro | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perc | 2014 |
What's new about clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Plat | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
Topics: Alleles; Asian People; Clopidogrel; Coronary Occlusion; Cytochrome P-450 CYP2C19; Databases, Factual | 2014 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Topics: Alleles; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coro | 2015 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Hum | 2015 |
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronar | 2015 |
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinati | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2 | 2016 |
Clopidogrel Response Variability: Review of the Literature and Practical Considerations.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosi | 2016 |
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Drug Therapy, | 2016 |
What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Percuta | 2016 |
Management of Antiplatelet Allergy After Cardiac Stenting.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Eruptions; Drug-Elut | 2016 |
Cangrelor for the management and prevention of arterial thrombosis.
Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Humans; Percutaneous Coronary Int | 2016 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; P | 2016 |
Genetic Determinants of P2Y
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutane | 2017 |
Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
Topics: Carotid Artery Diseases; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resi | 2017 |
Monitoring Antiplatelet Therapy.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation Inhibitors; Pla | 2017 |
[Clopidogrel--clinical use and potential therapeutic problems].
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Dose-Response Relationship, Dr | 2008 |
Clopidogrel and coronary stents: risks and benefits.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Vessels; Humans; Platelet Aggregation Inhibito | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardio | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
Reducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Thrombosis | 2008 |
Antiplatelet drugs in cardiological practice: established strategies and new developments.
Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platele | 2008 |
Drug-eluting stents and antiplatelet resistance.
Topics: Aspirin; Clopidogrel; Drug Resistance; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2008 |
The genetics of antiplatelet drug resistance.
Topics: Aspirin; Blood Platelets; Clopidogrel; Humans; Platelet Activation; Platelet Aggregation; Platelet A | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Aspirin; Clopidogrel; Coro | 2009 |
Review of prasugrel for the secondary prevention of atherothrombosis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piper | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O | 2009 |
Clopidogrel response variability: current status and future directions.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2009 |
[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
Topics: Animals; Biotransformation; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasu | 2009 |
[Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Interactions; Drug Resistance; Humans; Phosphorylation; | 2009 |
[A current problem for regulators. Clopidogrel and pharmacokinetics].
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Industry; Drug Interactio | 2009 |
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, C | 2009 |
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl | 2009 |
Antiplatelet resistance--fact or myth?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2009 |
Dental management of patients taking antiplatelet medications.
Topics: Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Dental Care for Chronically Ill; Humans; Oral Hemor | 2009 |
[Perioperative antiplatelet therapy of patients with coronary stents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort S | 2009 |
Platelet reactivity and nonresponse to dual antiplatelet therapy: a review.
Topics: Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Platelet Aggregatio | 2009 |
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazine | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma | 2009 |
[Medicinal therapy for interventional surgery of the peripheral vascular system].
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap | 2010 |
Prasugrel: Clinical development and therapeutic application.
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggrega | 2009 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon; Aspirin; Clinical Trials | 2009 |
Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions.
Topics: Atherosclerosis; Clopidogrel; Forecasting; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Re | 2010 |
Combination antithrombotic therapies.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Pyrid | 2010 |
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Stents; | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem | 2010 |
Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.
Topics: Angioplasty; Anticoagulants; Aspirin; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Arte | 2010 |
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Corona | 2011 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedu | 2010 |
Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; D | 2010 |
Prasugrel.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activa | 2010 |
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans | 2010 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
A review of the use of common antiplatelet agents in orthopaedic practice.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2010 |
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Human | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopi | 2010 |
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Human | 2011 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
[New era in antiplatelet therapy based on results from recent clinical trials].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Recept | 2011 |
Clopidogrel withdrawal: is there a "rebound" phenomenon?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration S | 2011 |
Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Platel | 2010 |
[Efficacy and safety of various doses of acetylsalicylic Acid in prevention of complications of atherothrombosis].
Topics: Aspirin; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2010 |
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fib | 2011 |
The role of antithrombotics in secondary stroke prevention.
Topics: Anticoagulants; Clopidogrel; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Humans; Phosphodiestera | 2010 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2011 |
Patients with drug-eluting stents and management of their anticoagulant therapy in cutaneous surgery.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dermatologic Surgical Procedures; Drug-Eluting Stents; Humans; | 2011 |
Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Huma | 2010 |
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.
Topics: Aspirin; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors | 2011 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Human | 2011 |
High platelet reactivity and clinical outcome - fact and fiction.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platel | 2011 |
Genetic determinants of on-clopidogrel high platelet reactivity.
Topics: Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Su | 2011 |
Clopidogrel hydrogen sulphate for atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel | 2011 |
Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Huma | 2011 |
Does CYP2C19 inhibition lead to clopidogrel thrombogenicity?
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Combinations; Drug Intera | 2011 |
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; | 2011 |
Clopidogrel "resistance": where are we now?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Substitution; Hemorrhage; Human | 2013 |
High on treatment platelet reactivity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Cyclooxygenase Inhi | 2012 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Predisposition to Dise | 2012 |
[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2011 |
Antiplatelet therapy in ENT surgery: a review.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Decision Making; Drug-Eluting Stents; Humans; Otorhinola | 2012 |
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; | 2011 |
Clopidogrel dilemma for orthopaedic surgeons.
Topics: Attitude of Health Personnel; Blood Loss, Surgical; Clopidogrel; Decision Making; Dose-Response Rela | 2011 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking | 2012 |
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Association S | 2012 |
[Platelet function: new drugs, new assays : possible impacts on operative medicine?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; P | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; H | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Stents and antiplatelet therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug-Eluting Stents; | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Thalidomide; Thrombosis; T | 2012 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; | 2013 |
Platelet function monitoring and clopidogrel.
Topics: Blood Platelets; Clopidogrel; Drug Monitoring; Humans; Myocardial Ischemia; Platelet Aggregation Inh | 2013 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug | 2013 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Contemporary antithrombotic strategies in patients undergoing coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic A | 2002 |
The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments.
Topics: Anesthesia; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized Contro | 2003 |
[Clopidogrel. Actions, pharmacokinetics, clinical studies].
Topics: Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Recepto | 2002 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography | 2002 |
Evidence with antiplatelet therapy and ADP-receptor antagonists.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic | 2003 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyrid | 2002 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Coronary Diseas | 2003 |
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate | 2003 |
[Should we use clopidogrel instead of ticlopidine in elective coronary angioplasty?].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Postoperative | 2003 |
Antiplatelet agents in atherothrombotic diseases.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit | 2004 |
Clopidogrel in the management of cerebrovascular events.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet Aggr | 2004 |
Antithrombotic drugs in vascular medicine: a historical perspective.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Endothelium, Vascular; | 2003 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Platelet function testing in cardiovascular diseases.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Case Management; Clopidogrel; Drug Resistance; H | 2004 |
Optimal antithrombotic treatment for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clinical Trials as Topic | 2005 |
P2Y receptor antagonists in thrombosis.
Topics: Adenosine Monophosphate; Animals; Clopidogrel; Humans; Mice; Platelet Aggregation; Platelet Aggregat | 2005 |
P2Y receptor antagonists in thrombosis.
Topics: Adenosine Monophosphate; Animals; Clopidogrel; Humans; Mice; Platelet Aggregation; Platelet Aggregat | 2005 |
P2Y receptor antagonists in thrombosis.
Topics: Adenosine Monophosphate; Animals; Clopidogrel; Humans; Mice; Platelet Aggregation; Platelet Aggregat | 2005 |
P2Y receptor antagonists in thrombosis.
Topics: Adenosine Monophosphate; Animals; Clopidogrel; Humans; Mice; Platelet Aggregation; Platelet Aggregat | 2005 |
Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adenylyl Cyclases; Animals; Calcium; Calcium Signalin | 2005 |
The P2 receptors in platelet function.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adenylyl Cyclases; Blood Vessels; Cell Shape; Clopido | 2005 |
The platelet P2 receptors in thrombosis.
Topics: Adenosine Diphosphate; Animals; Blood Vessels; Clinical Trials as Topic; Clopidogrel; Fibrinolytic A | 2005 |
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 2005 |
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic | 2005 |
[Oral antithrombotic therapy in primary and secondary prevention].
Topics: Animals; Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Primary Prevention; Secondary Prevention | 2005 |
[Mechanism and drug treatment of atherothrombosis].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; C-Reactive Protein; CD40 Antigens; Clopidogrel; Drug Ther | 2005 |
[Advances in adjunctive pharmacological therapy for percutaneous coronary interventions].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Clopi | 2005 |
Therapeutic approaches in arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl | 2005 |
Determinants of the interindividual variability in response to antiplatelet drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Drug Interactions; D | 2005 |
[Variable extent of platelet responsiveness to clopidogrel inhibition: "clopidogrel resistance"?].
Topics: Angioplasty, Balloon; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Humans; Platel | 2005 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami | 2005 |
Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
Topics: Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Platelet A | 2006 |
[Evidence-based medicine in antithrombotic therapy].
Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Thrombolytic Therapy; Thromb | 2005 |
[PCI: state of the art].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Humans; Japan; P | 2006 |
Thienopyridines in percutaneous coronary interventions: standard procedures and high risk subsets.
Topics: Angioplasty, Balloon, Coronary; Biocompatible Materials; Brachytherapy; Clopidogrel; Coronary Artery | 2006 |
[Dual antithrombotic therapy after implantation of coronary stents].
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Synergism; Humans; P | 2006 |
Clopidogrel resistance: myth or reality?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Hu | 2006 |
Aspirin resistance: does it exist and is it an important clinical problem?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidog | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.
Topics: Angina, Unstable; Angioplasty; Clopidogrel; Coronary Thrombosis; Female; Humans; Hypertension; Middl | 2006 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Cl | 2006 |
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi | 2006 |
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Dr | 2006 |
Clopidogrel: a review of its use in the prevention of thrombosis.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Treatment Outcome | 2007 |
[Coronary stents, dual antiplatelet therapy and peri-operative problems].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Perioperative Care; Platelet Aggregati | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers | 2007 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Con: continuation of aspirin/clopidogrel for cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Drug Therapy, Combination; Heart Diseases; Humans | 2007 |
Pro: continuation of aspirin/clopidogrel for cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Heart Diseases; Humans; Platelet Aggregation Inhi | 2007 |
Clopidogrel: an updated and comprehensive review.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Drug Approval; Drug Interactions; Hum | 2007 |
Coronary stents and noncardiac surgery.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Plate | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Co | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
[Platelet response to aspirin and clopidogrel. Biochemical evaluation, clinical impact, and pharmacological modulation].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Flow Cytometry; Humans; Platelet Agg | 2007 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci | 2007 |
Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; | 2008 |
Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; D | 2008 |
Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
Topics: Aspirin; Bias; Causality; Clinical Trials as Topic; Clopidogrel; Confounding Factors, Epidemiologic; | 2008 |
Antiplatelet agents and arterial thrombosis.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggreg | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug The | 2008 |
Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggregation Inhib | 2009 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; H | 1984 |
[Pharmacology of anti-platelet agents].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Dipyridamo | 1983 |
Overview: pharmacology of ticlopidine.
Topics: Animals; Anticoagulants; Bleeding Time; Blood Vessels; Humans; Kinetics; Platelet Aggregation; Thiop | 1984 |
[Platelet activation and platelet aggregation in the arteriosclerotic endothelium: pathophysiological aspects and new therapeutic concepts].
Topics: Anticoagulants; Arteriosclerosis; Cyclooxygenase Inhibitors; Endothelium, Vascular; Humans; Platelet | 1995 |
Novel antithrombotic drugs in development.
Topics: Amino Acid Sequence; Animals; Clinical Trials as Topic; Clopidogrel; Fibrinolytic Agents; Glycoprote | 1995 |
How does ticlopidine treatment lower plasma fibrinogen?
Topics: Blood Viscosity; Clinical Trials as Topic; Fibrinogen; Humans; Prospective Studies; Randomized Contr | 1994 |
[Ticlid : clinical use and current concepts about the mechanism of action].
Topics: Alprostadil; Hemostasis; Humans; Platelet Aggregation; Platelet Membrane Glycoproteins; Thrombosis; | 1993 |
Antiplatelet therapy.
Topics: Aspirin; Dipyridamole; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Tic | 1996 |
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Evaluation, Preclinical; Endothelium, Vascular; | 1996 |
Stent thrombosis. Closing in on the best preventive treatment.
Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents; | 1997 |
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Topics: Aspirin; Dipyridamole; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Pla | 1997 |
[A case of mobile left atrial thrombus without mitral valve disease].
Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Fibrinolytic Agents; Heart Atria; He | 1997 |
Pharmacologic prevention of acute ischemic complications of coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Constriction, Pathologic | 1997 |
Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Activation; | 1998 |
Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents.
Topics: Aspirin; Clopidogrel; Humans; Integrins; Platelet Aggregation; Platelet Aggregation Inhibitors; Thro | 1998 |
Low molecular weight heparins in the cardiac catheterization laboratory.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Clopidogrel: the future choice for preventing platelet activation during coronary stenting?
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Stents; | 1999 |
Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Topics: Animals; Arteriosclerosis; Aspirin; Disease Progression; Endothelium, Vascular; Humans; Platelet Act | 1999 |
Antiplatelet therapy in interventional cardiology: I. Newer oral antiplatelet agents.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2000 |
Clopidogrel: a review of its use in the prevention of atherothrombosis.
Topics: Arteriosclerosis; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Humans; Platelet Activat | 2000 |
Clopidogrel and coronary stenting: what is the next question?
Topics: Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized Controlle | 2000 |
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Purinergic P2 Receptor An | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?
Topics: Aspirin; Bone Marrow; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibi | 2001 |
Atherothrombosis--the neurologist's point of view.
Topics: Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Predictive Value | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2001 |
The WRIST series--what have we learnt?
Topics: Aged; Angioplasty, Balloon, Coronary; Brachytherapy; Clopidogrel; Cohort Studies; Coronary Restenosi | 2002 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol | 2002 |
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Dose-Response Relationship, Drug; | 1992 |
[Ticlid--a new development in the treatment and prevention of arterial thromboses].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Platelet Aggregation; Thrombosis; Ticlo | 1992 |
Pharmacology of platelet inhibitors.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Blood Platelets; Dex | 1986 |
Pharmacology of ticlopidine: a review.
Topics: Animals; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 1989 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
[Thrombosis in various diseases: myocardial infarct].
Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Th | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
[Antiplatelet drugs and prevention of aortocoronary bypass occlusion].
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Sulfinpyrazo | 1988 |
160 trials available for ticlopidine and Blood Clot
| Article | Year |
|---|---|
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.
Topics: Adenosine; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Plate | 2023 |
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized
Topics: Acute Coronary Syndrome; Adult; Area Under Curve; Asian People; Aspirin; Clopidogrel; Cross-Over Stu | 2020 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedu | 2017 |
Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.
Topics: Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome | 2018 |
Tiny Cerebral Aneurysms Can Be Treated Safely and Effectively with Low-Profile Visualized Intraluminal Support Stent-Assisted Coiling or Coiling Alone.
Topics: Adult; Aged; Aneurysm, Ruptured; Aspirin; Clopidogrel; Embolization, Therapeutic; Endovascular Proce | 2018 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Deci | 2013 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggrega | 2013 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2013 |
Clopidogrel in infants with systemic-to-pulmonary-artery shunts.
Topics: Anastomosis, Surgical; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heart Defects, C | 2013 |
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status.
Topics: Aged; Atorvastatin; Clopidogrel; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylgl | 2014 |
Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelet Disorders; Child; Clopidogrel; F | 2015 |
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; M | 2013 |
Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Interv
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Intraoperative Comp | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage | 2014 |
Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Platelet Activation | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cohort Studies; Drug Administration Schedule; | 2015 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Human | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug Combinations; Female; Human | 2015 |
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneo | 2015 |
Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel | 2016 |
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap | 2016 |
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
Topics: Abciximab; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopido | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2017 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytoc | 2017 |
The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation.
Topics: Aged; Cardiovascular Surgical Procedures; Clopidogrel; Drug Resistance; Drug Therapy, Combination; D | 2009 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow- | 2008 |
Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arachidonic Acid; As | 2008 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha | 2009 |
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Clopidogrel; D | 2008 |
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Sub | 2008 |
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2008 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate | 2009 |
Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interactions | 2008 |
Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents.
Topics: Angina Pectoris; Clopidogrel; Drug-Eluting Stents; Endpoint Determination; Humans; Myocardial Infarc | 2009 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; | 2009 |
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidog | 2009 |
Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Coagulation Tests; Clopidogrel; D | 2010 |
A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.
Topics: Administration, Oral; Adult; Bleeding Time; Clopidogrel; Cross-Over Studies; Dose-Response Relations | 2010 |
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Biomarkers; C-Re | 2009 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema | 2010 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F | 2010 |
Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Resistance; Drug-El | 2010 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; | 2011 |
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Coagulation; | 2011 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind M | 2011 |
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Comorbidity; Coronary Artery Disease; Cytokines; Female; Genetic Predisposition to Dise | 2012 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
Topics: Aged; Angina, Stable; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relations | 2012 |
Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Death; Fema | 2011 |
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2011 |
The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Topics: Aryl Hydrocarbon Hydroxylases; Blood Platelets; Catheter Ablation; Clopidogrel; Cross-Sectional Stud | 2012 |
Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.
Topics: Adenosine Diphosphate; Adult; Arteries; Blood Platelets; Child, Preschool; Clopidogrel; Double-Blind | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot | 2012 |
Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged | 2012 |
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Do | 2012 |
Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Coronary Angiogra | 2012 |
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP3A; Drug Resistance; | 2012 |
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet A | 2012 |
Microvascular effect of intracoronary eptifibatide in acute myocardial infarction.
Topics: Adolescent; Adult; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Eptifib | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Fem | 2012 |
Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy.
Topics: Adult; Aged; Blood Platelets; Cilostazol; Clopidogrel; Cross-Over Studies; Drug Administration Sched | 2013 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic A | 2013 |
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H | 2013 |
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
Topics: Aged; Aspirin; Catheters, Indwelling; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; F | 2003 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Coronary Restenosis; Female; Humans; Ma | 2004 |
Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Topics: Adenosine Diphosphate; Clopidogrel; Coronary Vessels; Female; Fibrinogen; Flow Cytometry; Humans; Ma | 2004 |
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
Preventive administration of Clopidogrel after restoring patency of acute dialysis fistula with surgical thrombectomy.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Drug Administration Schedule; Female; Follo | 2003 |
Preventive effects of Ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Drug Administration Schedule; Female; Follow-Up Studies; | 2003 |
Magnetic Vascular Port in minimally invasive direct coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Coronary Angiography; Drug Therapy, Combination; Equipment | 2004 |
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Blood Viscosity; C-Reactive Protein; Clopidogr | 2004 |
The difference between clopidogrel responsiveness and posttreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; P | 2005 |
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In | 2005 |
Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers.
Topics: Adolescent; Adult; Arteries; Aspirin; Clopidogrel; Collagen; Cross-Over Studies; Delayed-Action Prep | 2005 |
Clopidogrel diminishes hemodialysis access graft thrombosis.
Topics: Aged; Catheters, Indwelling; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation In | 2006 |
Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Genotype; Humans; Integrin beta3; Ma | 2005 |
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Topics: Administration, Oral; Adult; Anticoagulants; Arteries; Aspirin; Azetidines; Benzylamines; Bleeding T | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Clopidogrel; Coronary Disease; Fem | 2007 |
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Contrast Media; Coronary Angio | 2006 |
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzy | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth | 2006 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; | 2006 |
Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?
Topics: Adult; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2006 |
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Re | 2006 |
A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inh | 2007 |
Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cre | 2008 |
Therapeutic benefit of low-dose clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Body Weight; Clopidogrel; Endarterectomy, Carotid; | 2007 |
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female; | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cell Adhesion Molecules; Clopi | 2007 |
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; D | 2008 |
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets | 2008 |
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Fe | 2008 |
[The TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet | 2008 |
Approaching an age of reason with antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibito | 2008 |
Pharmacokinetics of clopidogrel in patients with stent thrombosis.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Pharmacokinetics; | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; H | 1984 |
Evaluation of the antithrombotic efficacy of ticlopidine in man.
Topics: Anticoagulants; Clinical Trials as Topic; Extracorporeal Circulation; Female; Fibrinolytic Agents; H | 1984 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
[Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)].
Topics: Adolescent; Adult; Aged; Blood Coagulation; Cardiac Surgical Procedures; Extracorporeal Circulation; | 1980 |
[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement].
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation; Depression, Chemical; Drug Therapy, Combina | 1995 |
Intracoronary stenting without coumadin: one month results of a French multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Ther | 1995 |
Clopidogrel--a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions.
Topics: Adult; Anticoagulants; Blood Flow Velocity; Clopidogrel; Fibrin; Fibrinopeptide A; Hematologic Tests | 1994 |
Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.
Topics: Adult; Aged; Argentina; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent Claudic | 1994 |
A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation.
Topics: Aged; Angiography; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet A | 1996 |
Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effects of aggregant concentration and antiplatelet medication.
Topics: Aged; Aspirin; Flow Cytometry; Humans; In Vitro Techniques; Lasers; Male; Middle Aged; Platelet Aggr | 1996 |
[Coronary artery stenting without antivitamin K. Results after a month].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Di | 1996 |
[Elective coronary implantation of a newly developed stent without conventional anticoagulation].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; H | 1996 |
Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy.
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Eq | 1997 |
[Recent antithrombotic gold standard?].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopi | 1997 |
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Benzamidines; Coronary Disea | 1997 |
Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Feasibility Studies; Female | 1997 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans.
Topics: Adult; Arteries; Aspirin; Blood; Blood Platelets; Collagen; Double-Blind Method; Drug Synergism; Dru | 1998 |
Low molecular weight heparin in coronary stenting.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pilot Proj | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra | 1999 |
Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; | 2000 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.
Topics: Adult; Arteries; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug T | 2000 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS).
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Gamma Rays; Hu | 2001 |
[Lectin-induced platelet aggregation inpatients with unstable angina pectoris treated with anti-aggregation agents].
Topics: Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Female; Humans; Lectins; Male; Middle Ag | 2001 |
Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study.
Topics: Aged; Aged, 80 and over; Blood Viscosity; Double-Blind Method; Fibrinogen; Humans; Male; Middle Aged | 1991 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; France; Humans; Intermittent Claudication; Ma | 1988 |
Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Graft | 1985 |
Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
Topics: Adult; Aged; Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind M | 1985 |
555 other studies available for ticlopidine and Blood Clot
| Article | Year |
|---|---|
Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines.
Topics: Animals; Cats; Collagen; Dihydropyridines; Humans; Kinetics; Male; Mice; Nitrendipine; Platelet Aggr | 1988 |
COX-1, COX-2 and CYP2C19 variations may be related to cardiovascular events due to acetylsalicylic acid resistance.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase 2; Cytochrome P-450 | 2022 |
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Perc | 2022 |
Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention.
Topics: Aryldialkylphosphatase; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Interve | 2023 |
Subacute stent thrombosis in a patient with type 2 diabetes and clopidogrel resistance: A case report
.
Topics: Clopidogrel; Diabetes Mellitus, Type 2; Humans; Male; Middle Aged; Percutaneous Coronary Interventio | 2020 |
Stent thrombosis: prevention is the only effective treatment.
Topics: Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2020 |
The effect of ticagrelor on microarterial thrombosis in an experimental model.
Topics: Adenosine; Animals; Clopidogrel; Models, Theoretical; Platelet Aggregation Inhibitors; Rats; Thrombo | 2021 |
Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
Topics: Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutane | 2017 |
Clopidogrel Load Reduces Emboli in Carotid Artery Stenosis With Free-Floating Thrombus.
Topics: Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Embolism; Humans; Magnetic Resonance Imagin | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; | 2017 |
Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Decompression, Surgical; Female; Hemorrhage; Humans; In | 2017 |
Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Male; Mi | 2018 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation | 2018 |
What is the significance, if any, of the increased incidence of stent thrombosis with dual therapy of dabigatran 110mg twice daily and clopidogrel in the RE-DUAL PCI trial?
Topics: Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Incidence; Percutaneous Coronary Interve | 2018 |
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Heart Failure; Heart-Assist | 2018 |
WATCHMAN device-related thrombus successfully treated with apixaban: A case report.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibit | 2017 |
Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report.
Topics: Adult; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Intracranial Aneurysm; Male; Pharmaco | 2017 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
Compression force sensing regulates integrin α
Topics: Adult; Animals; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 1; Female; Humans; Ma | 2018 |
Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; My | 2018 |
Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diag | 2018 |
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy.
Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiog | 2018 |
Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting St | 2019 |
Periprocedural prophylactic antithrombotic strategies in interventional radiology: current practice in the Netherlands and comparison with the United kingdom.
Topics: Clopidogrel; Fibrinolytic Agents; Heparin; Humans; Netherlands; Perioperative Care; Practice Pattern | 2013 |
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; | 2013 |
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra | 2013 |
The duel between dual antiplatelet therapies.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Myocardi | 2013 |
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2013 |
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co | 2013 |
Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study.
Topics: Aged; Analysis of Variance; Aspirin; Blood Transfusion; Clopidogrel; Cohort Studies; Coronary Artery | 2013 |
Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports.
Topics: Adenosine; Clopidogrel; Drug-Eluting Stents; Humans; Randomized Controlled Trials as Topic; Thrombos | 2013 |
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity.
Topics: Aged; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Female; Humans; Kidney Diseases; Male; | 2013 |
Perioperative management of a neurosurgical patient with a meningioma and recent coronary artery stent.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Coronary Artery Disease; Drug T | 2013 |
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dru | 2013 |
ACP Journal Club. Cangrelor reduced ischemic PCI complications more than clopidogrel without increasing severe bleeding.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Female; Humans; Male; Myocardial Ischemia; | 2013 |
Comparison of clinical efficacy and safety of clopidogrel resinate with clopidogrel bisulfate in patients undergoing percutaneous coronary intervention.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Female; Humans; Male; Middle | 2013 |
Arterial thrombosis after vehicular trauma and humeral fracture in a dog.
Topics: Accidents, Traffic; Animals; Anticoagulants; Clopidogrel; Dalteparin; Dog Diseases; Dogs; Female; Fo | 2013 |
Platelet inhibition with cangrelor during PCI.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Female; Humans; Male; Myocardial Ischemia; | 2013 |
Platelet inhibition with cangrelor during PCI.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Female; Humans; Male; Myocardial Ischemia; | 2013 |
DES thrombosis related to antiplatelet therapy noncompliance: a consequence of the Greek financial crisis.
Topics: Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Economic Recession; Greece; Humans; Male; Medic | 2013 |
Antiplatelet and anticoagulation therapy in microlaryngeal surgery.
Topics: Adult; Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence | 2014 |
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching.
Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; | 2014 |
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies | 2013 |
Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel.
Topics: Acute Disease; Aged; Aged, 80 and over; Clopidogrel; Cluster Analysis; Drug Substitution; Female; Hu | 2014 |
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
Topics: Adenosine Monophosphate; Blood Platelets; Clopidogrel; Data Interpretation, Statistical; Humans; Myo | 2014 |
Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence.
Topics: Acrylamides; Animals; Blood Platelets; Clopidogrel; Dinoprostone; Disease Models, Animal; Mice; Plaq | 2014 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Topics: Adult; Aged; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Cotinine; Female; F | 2014 |
The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P- | 2014 |
Role of paraoxonase-1 in CYP2C19 loss-of-function carriers.
Topics: Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Female; Humans; Male; Platelet Aggre | 2014 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resis | 2014 |
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
HeartWare left ventricular assist device thrombosis in aspirin non-responder.
Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Drug Resistance; Drug Substitution; Fibrinolyti | 2014 |
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Hu | 2014 |
Are we there yet? deciding when it is safe (and wise) to stop clopidogrel after stent implantation.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; T | 2014 |
A cautionary tale on the use of antiplatelet treatment following TURP.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca | 2014 |
Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation.
Topics: Cerebrovascular Circulation; Clopidogrel; Endovascular Procedures; Female; Humans; Intracranial Aneu | 2015 |
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal | 2014 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma | 2015 |
Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo.
Topics: Animals; Blood Coagulation; Blotting, Western; Cell-Derived Microparticles; Clopidogrel; Disease Mod | 2015 |
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura.
Topics: Aged; Aorta, Abdominal; Aortic Diseases; Clopidogrel; Female; Humans; Platelet Aggregation Inhibitor | 2014 |
[Perioperative management and postoperative complication rates of patients on dual antiplatelet therapies after coronary drug eluting stent implantation].
Topics: Aged; Aged, 80 and over; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneo | 2014 |
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; | 2014 |
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemo | 2014 |
First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea.
Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Dyspnea; Humans; Male; Purinergic P2Y Receptor Anta | 2014 |
Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Odds Ratio; Pe | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H | 2015 |
Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
Topics: Aged; Aspirin; Cardiac Catheterization; Chi-Square Distribution; Clopidogrel; Cohort Studies; Corona | 2014 |
Dual antiplatelet therapy after drug-eluting stents--how long to treat?
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation I | 2014 |
Antithrombotic activity of a new P2Y1 receptor antagonist, substance Sbt-119, on experimental models of thromboses in rats.
Topics: Administration, Oral; Animals; Animals, Outbred Strains; Drug Evaluation, Preclinical; Fibrinolytic | 2014 |
Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.
Topics: Aged; Angina, Stable; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Follow-Up Studies; H | 2014 |
Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet A | 2015 |
Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation.
Topics: Aged; Clopidogrel; Coronary Angiography; Cytochrome P-450 Enzyme System; Drug-Eluting Stents; Everol | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem | 2015 |
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebral Hemorrhage; Clopidogrel; Embolic Protection Dev | 2015 |
Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme | 2015 |
Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female | 2015 |
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Female; Humans; Male | 2015 |
Optimal antiplatelet therapy in out-hospital cardiac arrest patients treated by primary percutaneous coronary intervention.
Topics: Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Myocardial Infarction; Percutaneous Corona | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inh | 2015 |
ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel.
Topics: Aged; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Humans; Male; | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
[Synergistic action of Compound Danshen Dripping Pill (CDDP) on Clopidogrel Bisulfate (CPG) counteracting platelet aggregation].
Topics: Animals; Bleeding Time; Blood Coagulation; Blood Coagulation Tests; Clopidogrel; Drugs, Chinese Herb | 2014 |
In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience.
Topics: Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Interve | 2016 |
Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb | 2015 |
Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He | 2015 |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination | 2015 |
Could perioperative bleeding complications be predicted using a platelet aggregation test?
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Function Tests; Postoperative Hemorr | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Fibrin | 2015 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit | 2016 |
A complementary role for tetraspanin superfamily member CD151 and ADP purinergic P2Y12 receptor in platelets.
Topics: Animals; Blood Platelets; Cells, Cultured; Clopidogrel; Clot Retraction; Humans; Mice; Mice, Inbred | 2015 |
Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Area Under Curve; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronar | 2016 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp | 2015 |
Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Drug Therapy, Com | 2016 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolim | 2016 |
Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.
Topics: Adenosine Diphosphate; Aged; Aortic Valve; Arachidonic Acid; Area Under Curve; Aspirin; Blood Platel | 2016 |
Early hypoattenuated leaflet thickening and restricted leaflet motion of a Lotus transcatheter heart valve detected by 4D computed tomography angiography.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Clopidogrel; Coronary Angiography; Female; | 2015 |
Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Comorbidity; Coronary Artery By | 2016 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cl | 2016 |
Endoscopic ultrasound-guided fine-needle aspiration of solid lesions on clopidogrel may not be a high-risk procedure for bleeding: A case series.
Topics: Aged; Clopidogrel; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endoscopy, Gastrointestinal; | 2016 |
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice.
Topics: Adenocarcinoma; Animals; Blood Platelets; Cell Line, Tumor; Cell-Derived Microparticles; Clopidogrel | 2016 |
4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in
Topics: Animals; Carboxylic Acids; Clopidogrel; Dogs; Drug Discovery; Esterification; Humans; Male; Piperazi | 2015 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Evero | 2015 |
Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders.
Topics: Aged; Aged, 80 and over; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Female; Heart Diseases; | 2016 |
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectio | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
Topics: Blood Platelets; Case-Control Studies; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Femal | 2016 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Standardization of a well-controlled in vivo mouse model of thrombus formation induced by mechanical injury.
Topics: Animals; Aorta; Clopidogrel; Disease Models, Animal; Endothelium, Vascular; Eptifibatide; Hirudin Th | 2016 |
Is Dual Antiplatelet Therapy Necessary in Transcatheter Aortic Valve Implantation?
Topics: Aortic Valve Stenosis; Female; Humans; Male; Platelet Activation; Thrombosis; Ticlopidine; Transcath | 2016 |
Hyper-Response to Clopidogrel in Japanese Patients Undergoing Transcatheter Aortic Valve Implantation.
Topics: Aged, 80 and over; Aortic Valve Stenosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up S | 2016 |
Pharmacogenetics of Clopidogrel: An Unresolved Issue.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiography; Genotype; Humans; Male; Middle Aged; Myo | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Isr | 2016 |
Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy.
Topics: Adult; Aged; Arteries; Aspirin; Blood Coagulation Tests; Blood Platelets; Carotid Arteries; Cell Adh | 2016 |
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution.
Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug | 2016 |
Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Clopidogrel; Combined Modal | 2016 |
Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis.
Topics: Animals; Arteries; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Mice; Mice, Inbred C57B | 2016 |
Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3.
Topics: Adenosine Diphosphate; Animals; Carrier Proteins; Cat Diseases; Cats; Clopidogrel; Gene Expression R | 2016 |
Left ventricular non-compaction cardiomyopathy: Incidental diagnosis after ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiomyopathy, Hypertrophic, Familial; Clopidogrel; | 2016 |
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance.
Topics: Animals; Biomedical Research; Clopidogrel; Drug Resistance; Humans; Leptin; Mice; Obesity; Thrombosi | 2016 |
In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
Topics: Adenosine; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Dru | 2017 |
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl | 2016 |
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Topics: Adenosine; Animals; Blood Coagulation; Blood Platelets; Carotid Artery Injuries; Cells, Cultured; Cl | 2017 |
Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Heart Failure; Heart-Assist Devices; Humans; Male; Plat | 2016 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Additive antithrombotic effect of ASP6537, a selective cyclooxygenase (COX)-1 inhibitor, in combination with clopidogrel in guinea pigs.
Topics: Administration, Oral; Animals; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Synerg | 2017 |
Risk Factors of Subacute Thrombosis After Intracranial Stenting for Symptomatic Intracranial Arterial Stenosis.
Topics: Adult; Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Female; Humans; Ischemic Attack, Transi | 2017 |
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequenc | 2017 |
The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions.
Topics: Aged; Area Under Curve; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Hematocrit; Humans; | 2017 |
Reversible thrombotic mitral valve stenosis after transcatheter mitral valve replacement (TMVR): Is life-long anticoagulation therapy necessary?
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Cardiac Catheterization; Clopidogrel; Female; Heart Va | 2017 |
Improved Pig Model to Evaluate Heart Valve Thrombosis.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Disease Models, Animal; Heart Val | 2016 |
Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate.
Topics: Anticoagulants; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; | 2017 |
Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays.
Topics: Aged; Aged, 80 and over; Angioplasty; ATP Binding Cassette Transporter, Subfamily B; Biological Assa | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Antiaggregant and anticoagulant therapy of free-floating thrombus in left atrium.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Dyspnea; Echocardiography, Tra | 2008 |
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Ma | 2008 |
[Perioperative management of patients with drug-eluting coronary stents presenting for non-cardiac surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cilostazol; Drug Administration Schedule; Drug-Elu | 2008 |
Antiplatelet therapy for patients with stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Rando | 2008 |
Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Dyspnea; Fema | 2008 |
Re: Fleur I. de Korte, Jochem W. van Werkum, Peter L.M. Vijverberg, Jurriën M. ten Berg. Late coronary stent thrombosis complicating urologic surgery. Eur Urol 2008;54:221-5.
Topics: Coronary Stenosis; Drug-Eluting Stents; Humans; Lymph Node Excision; Male; Platelet Aggregation Inhi | 2009 |
Effect of clopidogrel on arteriovenous fistulas for dialysis.
Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation | 2008 |
Effect of clopidogrel on arteriovenous fistulas for dialysis.
Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation | 2008 |
Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Blood Platelets; Cell Adhesion Molecules; C | 2008 |
[Thrombocyte aggregation inhibitor after surgery for an abdominal aortic aneurysm].
Topics: Aortic Aneurysm, Abdominal; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Cardiov | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
[Management of a high risk of thrombosis patient with drug-eluting stents undergoing a complete gastrectomy].
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Gastrectomy; Humans; Male; Monitoring, Physiologic; Platelet | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogr | 2009 |
Predicting thrombotic events: creating a complex approach for a complex condition.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Colla | 2008 |
Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis.
Topics: Aged; Clopidogrel; Cost-Benefit Analysis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Pa | 2009 |
Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.
Topics: Acrylamides; Animals; Clopidogrel; Dinoprostone; Female; Hemorrhage; Humans; Male; Platelet Aggregat | 2009 |
[Bleeding or stent thrombosis in combination with drug-eluting stents].
Topics: Aneurysm, False; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug-Eluting St | 2009 |
Athero-embolic isolated splenic infarction following left cardiac catheterization.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Atherosclerosis | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Point-of-care platelet function analysis ready for prime time?
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; | 2009 |
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
A survey of the peri-operative management of urological patients on clopidogrel.
Topics: Anesthesia; Clopidogrel; Elective Surgical Procedures; Humans; Intraoperative Care; Medical Staff, H | 2009 |
Update on dual antiplatelet therapy for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Resistance; Drug The | 2009 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clop | 2009 |
Evidence guided antiplatelet treatment: time to move from bench to bedside.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiology; Cardiovascular Diseases; Clopidogrel; | 2009 |
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio | 2009 |
Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Adm | 2008 |
Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Sub | 2008 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2009 |
Proton pump inhibitors and clopidogrel: a difficult dilemma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage | 2009 |
Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combina | 2009 |
Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel.
Topics: Clopidogrel; Commerce; Drug Costs; Humans; Insurance, Pharmaceutical Services; Piperazines; Platelet | 2009 |
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Synergism; Fe | 2009 |
Drug-eluting coronary stents: many meta-analyses, little benefit.
Topics: Angina, Unstable; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Co | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Platelet reactivity and stent thrombosis: still some issues to solve.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Sten | 2009 |
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; He | 2009 |
Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies.
Topics: Acute Coronary Syndrome; Angina, Unstable; Clinical Trials as Topic; Drug-Eluting Stents; Europe; Hu | 2009 |
Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Co | 2009 |
The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cells, | 2009 |
Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.
Topics: Aspirin; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Combinations; Feasibility Studies; Huma | 2009 |
Poor performance with a platelet counting technique to monitor clopidogrel inhibitory effects in the point-of-care setting.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Platelet Count; Point-of-Care Systems; Reprodu | 2010 |
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Case-Control S | 2010 |
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; | 2010 |
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; C | 2010 |
Stent thrombosis: a poor man's disease?
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Cohort St | 2009 |
Right atrial thrombosis after upgrading to a biventricular pacing/defibrillation system.
Topics: Cardiac Pacing, Artificial; Defibrillators, Implantable; Echocardiography, Transesophageal; Heart At | 2009 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Chlorides; Clopidogrel; Dose-Response Relationship, Dru | 2009 |
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.
Topics: 4-Aminobenzoic Acid; Animals; Disease Models, Animal; Drug Design; Female; Fibrinolytic Agents; Hemo | 2010 |
Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art | 2010 |
Platelet activation in essential hypertension: implications for antiplatelet treatment.
Topics: Antihypertensive Agents; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Humans; Hypertensio | 2010 |
VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
Topics: Adult; Aged; Aged, 80 and over; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfil | 2010 |
[Perioperative management of patients with coronary stents in non-cardiac surgery].
Topics: Aspirin; Clopidogrel; Coronary Vessels; Drug-Eluting Stents; Elective Surgical Procedures; Guideline | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up | 2010 |
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chemotherapy, Adjuvant; Cilostazol; C | 2010 |
Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel.
Topics: Animals; Bleeding Time; Carthamus tinctorius; Clopidogrel; Drug Interactions; Drugs, Chinese Herbal; | 2010 |
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; C | 2010 |
Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat.
Topics: Animals; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Clopido | 2010 |
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels; | 2010 |
Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug-Eluting Stents; Humans; Platelet | 2010 |
Platelet inhibition with cangrelor.
Topics: Adenosine Monophosphate; Administration, Oral; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; | 2010 |
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].
Topics: Aspirin; Clopidogrel; Drug Monitoring; Evidence-Based Practice; Fibrinolytic Agents; France; Hemorrh | 2010 |
Optimal dual antiplatelet treatment after drug-eluting stent implantation: it's not the time for weaning.
Topics: Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Prosthesis Implantation; | 2010 |
Prasugrel, Māori, and personalised medicine in New Zealand.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genet | 2010 |
Late common iliac artery stent thrombosis in a patient with terminal malignancy.
Topics: Aged; Angiography; Aspirin; Atherosclerosis; Carcinoma, Renal Cell; Clopidogrel; Humans; Iliac Arter | 2010 |
Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats.
Topics: Animals; Aspirin; Blood Coagulation; Blood Coagulation Tests; Clopidogrel; Drug Synergism; Factor Xa | 2010 |
Clinician-patient discord: exploring differences in perspectives for discontinuing clopidogrel.
Topics: Aged; Attitude of Health Personnel; Attitude to Health; Clopidogrel; Communication; Comorbidity; Dru | 2011 |
Clinical pharmacology: antiplatelet therapy during surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhibit | 2010 |
Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Atherectomy; Blood Platelets; Clopidogrel; Diagnostic Tests, Routine; Human | 2010 |
Early stent thrombosis with progressive brainstem infarction in a clopidogrel non-responder.
Topics: Aged; Brain Infarction; Brain Ischemia; Clopidogrel; Disease Progression; Humans; Magnetic Resonance | 2010 |
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2010 |
[Dental management of patients using anti agregant drugs: background, risks and clinical guidelines].
Topics: Atherosclerosis; Clopidogrel; Dentistry; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practi | 2009 |
Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Cardiovascular Diseases; Cell Adhesion | 2010 |
Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Cardiovascular Diseases; Cell Adh | 2010 |
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Austria; Case-Control Studies; Clopid | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhag | 2010 |
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Co | 2010 |
Hand surgery on anticoagulated patients: a prospective study of 121 operations.
Topics: Anticoagulants; Aspirin; Clopidogrel; Hand; Hemostasis, Surgical; Humans; International Normalized R | 2010 |
Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Humans; Ische | 2010 |
Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?
Topics: Aged; Black People; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; | 2010 |
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi | 2010 |
Frequency and risk of noncardiac surgery after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Drug-Eluting Stents; Fem | 2011 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2010 |
Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Myo | 2010 |
Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel.
Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Fever; Humans; Male; Piperazines; P | 2011 |
Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopi | 2010 |
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Chi | 2010 |
Clopidogrel discontinuation and platelet reactivity following coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; | 2011 |
The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.
Topics: Animals; Blood Platelets; Clopidogrel; Female; Flow Cytometry; Green Fluorescent Proteins; Guanine N | 2011 |
[Efficacy of stents coated with antibody against CD105 on preventing restenosis and thrombosis in minipigs].
Topics: Animals; Antibodies; Antigens, CD; Aspirin; Clopidogrel; Coronary Restenosis; Endothelial Cells; Neo | 2010 |
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation; | 2011 |
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug | 2011 |
A case of late epidural hematoma in a patient on clopidogrel therapy postoperatively: when is it safe to resume antiplatelet agents?
Topics: Clopidogrel; Decompression, Surgical; Hematoma, Epidural, Spinal; Humans; Lumbar Vertebrae; Male; Mi | 2011 |
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Cardiovascular Ag | 2011 |
Thromboresistant surfaces with low-dose anticoagulation alleviate clopidogrel-related complications in patients undergoing coronary artery bypass grafting.
Topics: Aged; Anticoagulants; Biocompatible Materials; Blood Loss, Surgical; Blood Transfusion; Boston; Ches | 2011 |
Beware of being caught on the rebound.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co | 2011 |
Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Stenosis; Cytochrome P-450 CYP2C19; Drug Resist | 2011 |
Catapulting clopidogrel pharmacogenomics forward.
Topics: Amino Acid Substitution; Aryldialkylphosphatase; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2011 |
Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents.
Topics: Animals; Biomarkers; Cell Adhesion; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Humans | 2011 |
Functional profile of the platelet P2Y₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabetes Melli | 2011 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic | 2011 |
Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Inflammation; Male; Mid | 2011 |
Invited commentary.
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drainage; Humans; Intubation | 2011 |
Conversation with an expert. Plavix: what you need to know.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Costs; Drug | 2011 |
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Dr | 2011 |
Very late thrombosis of flow-diverting constructs after the treatment of large fusiform posterior circulation aneurysms.
Topics: Adult; Cerebral Angiography; Cerebral Revascularization; Cerebrovascular Circulation; Clopidogrel; F | 2011 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxyl | 2012 |
Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation.
Topics: Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Plate | 2011 |
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Clopidogrel; Corona | 2011 |
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; | 2011 |
High plasma interleukin-6 is associated with drug-eluting stent thrombosis: possible role of inflammatory cytokines in the development of stent thrombosis from the Korea Stent Thrombosis Registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Case-Control Studies; Chemokine CCL2; Chi-Square D | 2011 |
Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; District of Columbia; Drug Administration Schedul | 2011 |
Dual antiplatelet therapy and the risk of bleeding.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag | 2011 |
Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; | 2011 |
The use of contrast echo to clear the left atrial appendage.
Topics: Aspirin; Atrial Appendage; Clopidogrel; Contrast Media; Drug Therapy, Combination; Echocardiography; | 2011 |
Stent thrombosis after drug eluting stent implantation.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Chemokine CCL2; Clopidogrel; Drug-Eluting Stents; Humans | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascula | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
High on treatment platelet reactivity and stent thrombosis.
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middl | 2011 |
The impact of noncardiac surgery on selection of a revascularization strategy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Myocardial Infarction; Pat | 2011 |
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; H | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid St | 2011 |
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; M | 2011 |
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; | 2011 |
A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Topics: Animals; Clopidogrel; Cyclic AMP; Fibrinolytic Agents; Humans; Mice; Mice, Inbred C57BL; Mice, Knock | 2011 |
Late bare-metal stent thrombosis in a patient with Crohn's disease.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Crohn Disease; Humans; Male; Myocardial | 2011 |
PCI and clopidogrel: antiplatelet responsiveness and patient characteristics.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; | 2011 |
Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Hum | 2012 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; As | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting.
Topics: Aspirin; Cerebrovascular Circulation; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Drug Th | 2011 |
Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Substance Wit | 2011 |
Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; | 2011 |
Use of prasugrel in a patient with clopidogrel hypersensitivity.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myoca | 2011 |
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines.
Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Mal | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Applying platelet function testing in clinical practice: what are the unmet needs?
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Death; Humans; Myocardial Infarction; Platelet | 2011 |
[Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?].
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Elutin | 2011 |
Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Diseas | 2012 |
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.
Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides | 2012 |
Thrombus formation on a left atrial appendage closure device.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design; | 2011 |
[Diagnostic laparoscopy under dual antiplatelet therapy with clopidogrel and aspirin].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Diagnosis, Differential; Drug Substituti | 2011 |
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2011 |
CYP2C19 gene variants cut-off levels for on-clopidogrel platelet aggregation.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Dr | 2012 |
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Cytoprotection; Platelet Ac | 2011 |
High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype.
Topics: Aspirin; Atherosclerosis; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitor | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Ar | 2012 |
Managing antiplatelet therapy during ophthalmic procedures: communication is the key.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiology; Clopidogrel; Humans; I | 2011 |
Clopidogrel therapy in ophthalmic procedures: a survey of subspecialty ophthalmologists and review of current guidelines.
Topics: Clopidogrel; Guideline Adherence; Health Knowledge, Attitudes, Practice; Health Surveys; Humans; Med | 2011 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Atherosclerosis; Female; Hemorrhage; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibit | 2012 |
Unilateral femoral arterial thrombosis in a dog with malignant mammary gland tumor: clinical and thermographic findings, and successful treatment with local intra-arterial administration of streptokinase.
Topics: Animals; Anticoagulants; Clopidogrel; Dog Diseases; Dogs; Female; Femoral Artery; Fibrinolytic Agent | 2012 |
Predicting clopidogrel response using DNA samples linked to an electronic health record.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfa | 2012 |
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardi | 2012 |
CYP2C19 and clopidogrel response: more than validation in the real world.
Topics: Clopidogrel; Databases, Nucleic Acid; Electronic Health Records; Female; Humans; Male; Myocardial In | 2012 |
Bare metal stent thrombosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Ris | 2012 |
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic | 2012 |
No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cas | 2012 |
Late peripheral stent thrombosis due to stent fracture, vigorous exercise and hyporesponsiveness to clopidogrel.
Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Bicycling; Clopidogrel; Constriction, Pathologic; Dr | 2012 |
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2012 |
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2012 |
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Hemostasis; Mice; Mice, | 2012 |
Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures.
Topics: Cardiac Resynchronization Therapy; Case-Control Studies; Clopidogrel; Comorbidity; Drug-Related Side | 2012 |
Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Clopidogrel; Drug Administ | 2012 |
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies | 2012 |
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; | 2012 |
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla | 2012 |
Computed tomography angiography evaluation of internal carotid artery free-floating thrombus--single-center diagnosis, false-positives, and follow-up.
Topics: Aged; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Clopidogrel; Diagn | 2012 |
Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2012 |
Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.
Topics: Aged; Angioplasty; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Male; Mid | 2013 |
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angi | 2012 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi | 2012 |
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel | 2012 |
Role of the laboratory in monitoring patients receiving dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Clinical Laboratory Techniques; Clopidogrel; D | 2012 |
The perioperative management of patients with coronary artery stents: surveying the clinical stakeholders and arriving at a consensus regarding optimal care.
Topics: Adult; Advisory Committees; Alabama; Anesthesiology; Aspirin; Blood Loss, Surgical; Cardiac Catheter | 2012 |
Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell Adhesion Molecul | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazi | 2012 |
Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum.
Topics: Adult; Aspirin; Clopidogrel; Eisenmenger Complex; Epistaxis; Female; Humans; Platelet Aggregation In | 2011 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf | 2012 |
Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Greece; Human | 2012 |
[Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Avena; Chest Pain; Clopidogrel; Co | 2012 |
Left ventricular assist device thrombosis due to clopidogrel resistance.
Topics: Clopidogrel; Drug Resistance; Heart-Assist Devices; Humans; Male; Middle Aged; Platelet Aggregation | 2012 |
Antiplatelet drugs in elective ENT surgery.
Topics: Aspirin; Blood Loss, Surgical; Clinical Protocols; Clopidogrel; Data Collection; Elective Surgical P | 2012 |
High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Heterozygot | 2013 |
Failure of high-dose clopidogrel in recurrent stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocard | 2012 |
Platelets in vascular disease.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Hemostasis; Humans; Plaque, Atherosclerotic; | 2013 |
Intracoronary GP IIb/IIIa inhibitors: could eptifibatide be the new kid on the block?
Topics: Clopidogrel; Eptifibatide; Female; Humans; Male; Myocardial Infarction; Myocardial Reperfusion; Pept | 2012 |
Collagen-induced thrombosis in murine arteries and veins.
Topics: Animals; Arterial Occlusive Diseases; Blood Coagulation; Blood Platelets; Carotid Arteries; Clopidog | 2013 |
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Comp | 2013 |
Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Topics: Adult; Aged; Area Under Curve; Arteries; Aspirin; Automation, Laboratory; Blood Platelets; Capillari | 2013 |
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Topics: Carotid Artery, Internal, Dissection; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; | 2013 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemo | 2013 |
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combinat | 2013 |
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Blood Platelets; Case-Control Studies; Cell Adhesion Molec | 2013 |
Clopidogrel-associated vasculopathic cutaneous reaction.
Topics: Aged; Biopsy; Clopidogrel; Fibrin; Fingers; Gangrene; Humans; Male; Platelet Aggregation Inhibitors; | 2013 |
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv | 2002 |
Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.
Topics: Animals; Aspirin; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Heart Valve | 2002 |
Synthesis and thrombolytic activity of new thienopyrimidinone derivatives.
Topics: Animals; Arteries; Clopidogrel; Extracorporeal Circulation; Fibrinolytic Agents; Pyridones; Rats; Ra | 2002 |
Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Da | 2002 |
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp | 2003 |
The IST registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Brachytherapy; Clopidogrel; Coronary Resten | 2002 |
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Drug Resistance; Female; Humans; Male; Mi | 2003 |
Antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2003 |
Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Disease Models, Animal; Drug Interactions; Mesenteric A | 2003 |
Regression of intracardiac heparin-induced thrombosis after aortic root surgery.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug | 2003 |
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation | 2003 |
Cardiology patient page. Antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Heart Diseases; Humans; Platelet Aggregati | 2003 |
Platelet ADP receptors contribute to the initiation of intravascular coagulation.
Topics: Adult; Animals; Blood Coagulation; Blood Platelets; Clopidogrel; Collagen; Disease Models, Animal; D | 2004 |
Complete lysis of left ventricular giant thrombus with fibrinolytic therapy in clopidogrel resistant patient.
Topics: Clopidogrel; Drug Resistance; Electrocardiography; Female; Humans; Middle Aged; Thrombolytic Therapy | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Red vs white thrombi: treating the right clot is crucial.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2003 |
Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens.
Topics: Adult; Arterial Occlusive Diseases; Clopidogrel; Confidence Intervals; Drug Administration Schedule; | 2003 |
Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel.
Topics: Animals; Carotid Artery Injuries; Carotid Artery Thrombosis; Clopidogrel; Drug Synergism; Electric I | 2004 |
Paclitaxel-eluting coronary stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Humans; Paclita | 2004 |
807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Collagen; Coronary Disease; Female; Humans; Integrin alpha | 2004 |
Clopidogrel "resistance".
Topics: Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Pro | 2004 |
Pharmacokinetics of clopidogrel after administration of a high loading dose.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Platelets; Carbon; Chromatography, Liquid; Clop | 2004 |
Multivessel distal sutureless off-pump coronary artery bypass grafting procedure using magnetic connectors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Corona | 2004 |
[Cardiovascular pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl | 2004 |
Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Aspirin; Benzoates; Blood Pressure; Clopidogrel; Collag | 2004 |
Clopidogrel loading dose pre-PCI: how high?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Humans; Platelet Activation; Platelet Aggregation; Pl | 2004 |
Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
Topics: Aged; Clopidogrel; Coronary Vessels; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Activat | 2005 |
An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research.
Topics: Animals; Arterial Occlusive Diseases; Carotid Artery Diseases; Chlorides; Clopidogrel; Disease Model | 2005 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2004 |
Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Disease | 2005 |
Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses.
Topics: Adenosine Diphosphate; Animals; Axl Receptor Tyrosine Kinase; Blood Platelets; c-Mer Tyrosine Kinase | 2005 |
Elective stenting, platelet serotonin and thrombotic events.
Topics: Elective Surgical Procedures; Humans; Platelet Aggregation; Serotonin; Stents; Thrombosis; Ticlopidi | 2004 |
Emerging therapies: clopidogrel and aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopid | 2005 |
A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite.
Topics: Aged; Aspirin; Biotransformation; Clopidogrel; Drug Monitoring; Drug Resistance; Humans; Male; Plate | 2005 |
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fema | 2005 |
Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; | 2005 |
Resistance to antiplatelet resistance is it justified?
Topics: Aspirin; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors | 2005 |
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk.
Topics: Adenosine Diphosphate; Adult; Aged; Blood Platelets; Calcium Signaling; Case-Control Studies; Clopid | 2005 |
Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice.
Topics: Administration, Oral; Animals; Blood Pressure; Carotid Arteries; Cell Proliferation; Chlorides; Chro | 2005 |
Clopidogrel use for reducing the rate of thrombosis in a rat model of microarterial anastomosis.
Topics: Anastomosis, Surgical; Animals; Clopidogrel; Double-Blind Method; Femoral Artery; Male; Microsurgery | 2005 |
Management and prevention of thrombotic stent occlusion.
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Emergency Treatment; Graft Occ | 2005 |
P >0.05 not equal equivalent or noninferior.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Re | 2005 |
Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation.
Topics: Aged; Angina, Unstable; Clopidogrel; Drug Evaluation; Elective Surgical Procedures; Female; Humans; | 2005 |
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Humans; Risk Factors; Stents; Thrombosis; Ticlopidine | 2005 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2005 |
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.
Topics: Aged; Clopidogrel; Coronary Stenosis; Female; Humans; Male; Middle Aged; Platelet Activation; Stents | 2005 |
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; | 2005 |
Clopidogrel use in children.
Topics: Adolescent; Cardiac Catheterization; Child; Child, Preschool; Clopidogrel; Drug Administration Sched | 2005 |
Treatment of wide-necked intracranial aneurysms with a self-expanding stent: mid-term results.
Topics: Aneurysm, Ruptured; Clopidogrel; Follow-Up Studies; Humans; Intracranial Aneurysm; Neurosurgical Pro | 2005 |
Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
Topics: Animals; Anticoagulants; Aspirin; Bleeding Time; Carotid Arteries; Clopidogrel; Dose-Response Relati | 2006 |
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; He | 2006 |
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
Topics: Aged; Angiography; Case-Control Studies; Clopidogrel; Drug Delivery Systems; Female; Follow-Up Studi | 2006 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
[Postoperative antithrombotic treatment in diabetic patients].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mell | 2006 |
Basilar artery dolichoectasia with partial thrombosis.
Topics: Aged; Anticholesteremic Agents; Clopidogrel; Humans; Magnetic Resonance Imaging; Male; Platelet Aggr | 2006 |
[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].
Topics: Adult; Aged; Angina Pectoris; Aspirin; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Pla | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2006 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2006 |
[Drug-releasing stents. Little use in cardiology despite excellent data--what next?].
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Humans; Platelet Aggregation Inhibitors; Risk Fac | 2006 |
[Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study].
Topics: Aged; Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middl | 2006 |
Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.
Topics: Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Embolism, Ch | 2006 |
A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy?
Topics: Aged; Aspirin; Clopidogrel; Fatal Outcome; Humans; Male; Platelet Aggregation Inhibitors; Stents; Th | 2007 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2006 |
Plavix isn't for everyone. Adding Plavix to aspirin doesn't help people without heart disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc | 2006 |
An alternative treatment strategy for pump thrombus in the DeBakey VAD Child: use of clopidogrel as a thrombolytic agent.
Topics: Adolescent; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Equipment Failure; Fibrinolytic Agents; H | 2006 |
CHARISMA: the antiplatelet saga continues.
Topics: Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Platelet Aggregation Inhib | 2006 |
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.
Topics: Aged; Angioplasty; Aryl Hydrocarbon Hydroxylases; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cor | 2006 |
Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.
Topics: Animals; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Stenosis; Cyclooxygenase Inhibitors; | 2006 |
Saddle embolism after corrective femoral osteotomy: a case report.
Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em | 2006 |
Iliac anastomotic stenting with a biodegradable poly-L-lactide stent: a preliminary study after 1 and 6 weeks.
Topics: Absorbable Implants; Anastomosis, Surgical; Animals; Arteritis; Aspirin; Clopidogrel; Feasibility St | 2006 |
Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state.
Topics: Aged; Aged, 80 and over; Antithrombin III; Arterial Occlusive Diseases; Aspirin; Blood Coagulation; | 2006 |
Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine.
Topics: Acute Disease; Aged; Female; Fibrinolytic Agents; Humans; Lupus Erythematosus, Cutaneous; Thrombosis | 2006 |
Tackling the diabetic platelet: is high clopidogrel dosing the answer?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Pl | 2006 |
Biosignatures in thrombotic disorders.
Topics: Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Gene Expression Profiling; Humans; Pati | 2006 |
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial | 2006 |
Drug eluting stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Implants; Humans; Platelet Ag | 2006 |
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Flow Cytometry; | 2007 |
Does clopidogrel each day keep stent thrombosis away?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; Humans; | 2007 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2007 |
Atherothrombotic events and clopidogrel therapy.
Topics: Aged; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dr | 2007 |
Atherothrombotic events and clopidogrel therapy.
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzy | 2007 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2007 |
Late blood clots tarnish drug-coated stents. Uncommon complication raises questions about who really needs a drug-coated stent and how long to continue drug therapy after getting one.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Drug Implants; Forecasting; Foreign Bodies; Humans; Plate | 2007 |
Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.
Topics: Administration, Oral; Animals; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, | 2007 |
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases.
Topics: Aged; Angina, Unstable; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Flow Cytometr | 2007 |
Clopidogrel (Plavix) reduces the rate of thrombosis in the rat tuck model for microvenous anastomosis.
Topics: Anastomosis, Surgical; Animals; Clopidogrel; Male; Microsurgery; Platelet Aggregation Inhibitors; Ra | 2007 |
[Acute stent thrombosis due to resistance to clopidogrel ? A case report].
Topics: Aged; Clopidogrel; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibi | 2007 |
A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models.
Topics: Animals; Arteriovenous Shunt, Surgical; Carotid Artery Injuries; Clopidogrel; Disease Models, Animal | 2007 |
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Platelets; Clopidogrel; Comorbidity; Female; Humans; | 2007 |
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Platelets; Clopidogrel; Comorbidity; Female; Humans; | 2007 |
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Platelets; Clopidogrel; Comorbidity; Female; Humans; | 2007 |
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Platelets; Clopidogrel; Comorbidity; Female; Humans; | 2007 |
Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag.
Topics: Blood Platelets; Clopidogrel; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; | 2007 |
[Modified platelet aggregation test in patients on ASA and/or clopidogrel].
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Dose-Response Relatio | 2007 |
Drug-eluting stents: dual antiplatelet therapy for every survivor?
Topics: Algorithms; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Incidence; Paclitaxel; Platelet | 2007 |
The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Autopsy; Cardiovascular Agents; Clopidogrel; Coronary Angiography; D | 2008 |
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Diseas | 2007 |
Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis.
Topics: Aged; Algorithms; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Hum | 2007 |
Late coronary stent thrombosis complicating urologic surgery.
Topics: Aged; Clopidogrel; Coronary Stenosis; Drug-Eluting Stents; Fatal Outcome; Humans; Immunosuppressive | 2008 |
Post-stenting antithrombotic drug therapy in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Humans; Practice Guidelines as Topic | 2007 |
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Topics: Administration, Oral; Adult; Animals; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Drug Admi | 2008 |
Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation.
Topics: Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; In | 2008 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Coronary artery stenting in patients treated by clopidogrel without aspirin.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Agg | 2009 |
Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta; Apolipoproteins E; Aspirin; Atherosclerosis; Blood Platelets; Carotid Arteries; Chol | 2008 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary St | 2008 |
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; | 2008 |
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Topics: Administration, Oral; Animals; Aspirin; Bleeding Time; Blood Coagulation; Carotid Artery Injuries; C | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogr | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial | 2008 |
[Status and trends in the field of inhibitors of thrombocyte function].
Topics: Animals; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation; Thiop | 1984 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Hepari | 1983 |
The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs.
Topics: Arteries; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination | 1984 |
[Thrombus formation and its prevention during extracorporeal circulation--effect of preoperative administration with the antiplatelet drugs].
Topics: Adult; Dipyridamole; Extracorporeal Circulation; Humans; Microscopy, Electron, Scanning; Platelet Ad | 1984 |
In vivo study of platelet aggregation in rats.
Topics: Adenosine Diphosphate; Animals; Aspirin; Collagen; Diet; Dose-Response Relationship, Drug; Male; Met | 1984 |
Thrombotic etiology of stress ulcers. 1. The effect of anticoagulant and antiplatelet aggregators in the development of stress ulcers in rats.
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Gastric Acidity Determination; Gastric Mucosa; Hepar | 1983 |
Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications.
Topics: Animals; Anticoagulants; Blood Platelets; Hemodynamics; Humans; Kinetics; Thiophenes; Thrombosis; Ti | 1983 |
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
Topics: Anticoagulants; Bleeding Time; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1983 |
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Blood Platelets; Fibrinolytic Agents; Humans; Thiophe | 1984 |
[Platelet aggregation inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Dipyridamole; Humans; Platelet Aggregatio | 1981 |
A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Femoral A | 1982 |
Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.
Topics: Adult; Aged; Blood Urea Nitrogen; Chlorides; Creatinine; Double-Blind Method; Female; Fibrinolytic A | 1980 |
Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.
Topics: Adult; Arteriovenous Shunt, Surgical; Blood Coagulation; Female; Fibrinolytic Agents; Humans; Kidney | 1980 |
Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat.
Topics: Animals; Aprotinin; Arteriovenous Shunt, Surgical; Bleeding Time; Clopidogrel; Constriction; Hemorrh | 1993 |
Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis.
Topics: Animals; Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Extracorporeal Circulation; Guinea Pi | 1995 |
An experimental myocardial infarction model in the rat and its properties.
Topics: Animals; Biphenyl Compounds; Clopidogrel; Coronary Vessels; Disease Models, Animal; Electrocardiogra | 1995 |
The antithrombotic effects of ticlopidine and aspirin in a microvascular thrombogenic model.
Topics: Administration, Oral; Animals; Aspirin; Femoral Artery; Graft Occlusion, Vascular; Male; Microsurger | 1995 |
Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
Topics: Animals; Aspirin; Bleeding Time; Endothelium, Vascular; Fatty Acids, Monounsaturated; Femoral Vein; | 1995 |
Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Benzimidazoles; Benzoxepins; Blood Coagulation; Blood | 1994 |
Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells.
Topics: Adenosine Diphosphate; Animals; Aorta; Aspirin; Blood Platelets; Cattle; Clopidogrel; Endothelium, V | 1994 |
Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit.
Topics: Animals; Bleeding Time; Clopidogrel; Drug Synergism; Fibrinolytic Agents; Fluorobenzenes; Jugular Ve | 1993 |
Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats.
Topics: Administration, Oral; Animals; Antithrombins; Aspirin; Diltiazem; Dose-Response Relationship, Drug; | 1995 |
Platelet activation and thrombosis: studies in a patient with essential thrombocythemia.
Topics: Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Aspirin; Blood Platelets; Disease Susceptibili | 1996 |
In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cerebrov | 1996 |
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
Topics: Animals; Aspirin; Bleeding Time; Cell Division; Drug Synergism; Female; Fibrinolytic Agents; Platele | 1996 |
Effect of argatroban on the formation of artificial thrombus on dogs.
Topics: Animals; Arginine; Dogs; Male; Osmolar Concentration; Pipecolic Acids; Platelet Aggregation Inhibito | 1995 |
Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Plate | 1996 |
Combined ticlopidine and aspirin versus aspirin therapy alone after stent implantation.
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Postoperative Care; Ste | 1996 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
Topics: Animals; Aspirin; Benzylamines; Clopidogrel; Hemodynamics; Hemostasis; Male; Piperidines; Platelet A | 1997 |
Coronary artery stenting without anticoagulation, aspirin, ultrasound guidance, or high balloon pressure: prospective study of 1,051 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coronary Angiography; Coronary Vessels; Female; Foll | 1997 |
Stenting without ASA?
Topics: Humans; Incidence; Myocardial Ischemia; Platelet Aggregation Inhibitors; Postoperative Complications | 1997 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood | 1997 |
Revascularization after CABG: atherectomy and stenting.
Topics: Aftercare; Aged; Algorithms; Atherectomy, Coronary; Coronary Angiography; Coronary Artery Bypass; Co | 1998 |
[Thrombosis prophylaxis after stroke].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Heparin; Humans; Middle Aged; Plate | 1998 |
Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (EGb 761).
Topics: Animals; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Epinephrine | 1998 |
[Secondary cardiovascular prevention: convincing evidence concerning clopidogrel].
Topics: Arteriosclerosis; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 1998 |
The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Topics: Animals; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Synergism; Femoral Artery; Fibrinolyti | 1998 |
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow | 1998 |
Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Interactions; Endarterectomy; Hemostasis; Heparin | 1998 |
Coronary-artery stents--gauging, gorging, and gouging.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1998 |
Aspirin and heparin prevent hepatic blood stasis and thrombosis induced by the toxic glycoprotein Bolesatine in mice.
Topics: Agglutination; Animals; Aspirin; Blood Platelets; Chemical and Drug Induced Liver Injury; Dose-Respo | 1998 |
Rationale for antiplatelet therapy in patients with atherothrombotic disease.
Topics: Arteriosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Epopr | 1998 |
Effect of ticlopidine on streptokinase-induced thrombolysis in rats.
Topics: Animals; Blood Platelets; Dose-Response Relationship, Drug; Drug Synergism; Epoprostenol; Rats; Rats | 1999 |
Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Cor | 1999 |
Antithrombotic therapy after coronary-artery stenting.
Topics: Anemia, Aplastic; Aspirin; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination | 1999 |
Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat.
Topics: Animals; Blood Platelets; Clopidogrel; Flow Cytometry; Male; Platelet Activation; Platelet Aggregati | 1999 |
A paradoxical side-effect of antiaggregating treatment with ticlopidine: the Moschowitz syndrome.
Topics: Fibrinolytic Agents; Humans; Male; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Thrombosis; Ti | 1999 |
Comparison of the antithrombotic effects of heparin, hirudin and clopidogrel according to the nature of the thrombogenic surface in an arterioarterial shunt in rats.
Topics: Animals; Clopidogrel; Disease Models, Animal; Female; Fibrinolytic Agents; Heparin; Hirudins; Rats; | 1999 |
Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Carotid Arteries; Cilostazol; Cyclic Nucleotide Phosph | 1999 |
Safety and efficacy of ticlopidine after stent placement.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Coronary Vessels; Drug Administration Schedule; | 2000 |
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Compet | 2000 |
[Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrombosis].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factor | 2000 |
Combination therapy with clopidogrel and aspirin after coronary stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2000 |
Consider this: It's too little!
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopid | 2000 |
Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Complic | 2000 |
Unusual effects of aspirin on ticlopidine induced thrombolysis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Sy | 2000 |
A pharmacodynamic study of clopidogrel in chronic hemodialysis patients.
Topics: Adenosine Diphosphate; Arterial Occlusive Diseases; Chronic Disease; Clopidogrel; Dose-Response Rela | 2000 |
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Femal | 2001 |
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C | 2001 |
Radiation-induced glomerular thrombus formation and nephropathy are not prevented by the ADP receptor antagonist clopidogrel.
Topics: Animals; Apyrase; Clopidogrel; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; | 2001 |
Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time.
Topics: Animals; Bleeding Time; Fibrinolytic Agents; Isonipecotic Acids; Male; Rats; Rats, Wistar; Receptor, | 2001 |
Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Apyrase; Blood Platelets; Clopidogre | 2002 |
Ticlopidine inhibits the prothrombotic effects of thrombopoietin and ameliorates survival after supralethal total body irradiation.
Topics: Animals; Bone Marrow Transplantation; Drug Evaluation, Preclinical; Fibrinolysis; Fibrinolytic Agent | 2002 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
[Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
Topics: Adult; Aged; Blood Coagulation Disorders; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged | 1979 |
Antithrombotic effect of ticlopidine on He-Ne laser-induced thrombus formation in rat mesenteric microvessels.
Topics: Animals; Aspirin; Blood Cell Count; Blood Coagulation Tests; Helium; Humans; Lasers; Male; Mesentery | 1992 |
Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Disease Models, Animal; Female; Femoral Artery; Fibrin | 1992 |
Interaction of platelets with subendothelium in rats treated with PCA-4230, a new antithrombotic agent. Effect of PCA-4230 on experimental thrombosis.
Topics: Animals; Blood Platelets; Carotid Arteries; Dihydropyridines; Fibrinogen; Fibrinolytic Agents; Male; | 1992 |
[Antiplatelet effect of clopidogrel].
Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Bleeding Time; Clopidogrel; Disease Models, Anima | 1992 |
[Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats].
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Collagen; Disease Models, Animal; Fistula; Graft Oc | 1991 |
Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease.
Topics: Animals; Arterial Occlusive Diseases; Carrageenan; Fibrinolytic Agents; Infarction; Lauric Acids; Ma | 1991 |
Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats.
Topics: Animals; Arginine; Endothelium, Vascular; Fibrinolytic Agents; Freezing; Jugular Veins; Male; Micros | 1991 |
Left ventricular thrombi: changes in size and in platelet deposition during treatment with indobufen and ticlopidine.
Topics: Echocardiography; Heart Diseases; Humans; Indium Radioisotopes; Isoindoles; Phenylbutyrates; Platele | 1990 |
The pathogenesis of thrombosis in venous prostheses.
Topics: Animals; Blood Vessel Prosthesis; Graft Occlusion, Vascular; Male; Microscopy, Electron, Scanning; P | 1990 |
[Evaluation of antiplatelet drugs on platelet functions--comparison between ticlopidine and dipyridamole after prosthetic valve replacement].
Topics: Adult; Aged; Dipyridamole; Female; Heart Valve Prosthesis; Humans; Male; Middle Aged; Platelet Aggre | 1989 |
[Efficacy and mechanisms of action of ticlopidine: a drug useful in maintaining aortocoronary bypass patency].
Topics: beta-Thromboglobulin; Coronary Artery Bypass; Humans; Middle Aged; Postoperative Complications; Thro | 1987 |
ADP plays a key role in thrombogenesis in rats.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Cyclooxygenase Inhibitors; Disease Models, Animal; Fema | 1988 |
[Antithrombogenic therapy by use of antiplatelet agents with warfarin--its efficiency for the outpatients with prosthetic valve].
Topics: Blood Platelets; Dipyridamole; Drug Therapy, Combination; Heart Valve Prosthesis; Humans; Platelet A | 1988 |
Ticlopidine inhibits platelet thrombus formation studied in a flowing system.
Topics: Administration, Oral; Adult; Animals; Cell Communication; Endothelium; Female; Humans; In Vitro Tech | 1987 |
Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Line; Female; Humans; In Vitro Techniques; Male; | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; D | 1985 |
Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats.
Topics: Animals; Anticoagulants; Aspirin; Capillaries; Dipyridamole; Gastric Mucosa; Male; Platelet Aggregat | 1985 |
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.
Topics: Animals; Anticoagulants; Blood Platelets; Cell Survival; In Vitro Techniques; Male; Neuraminidase; P | 1985 |
[Antithrombogenic therapy based on the study of the changes in platelet aggregability and blood coagulability in the early period after prosthetic valve replacement].
Topics: Adult; Anticoagulants; Blood Coagulation; Dipyridamole; Female; Heart Valve Diseases; Heart Valve Pr | 1985 |
[Prevention of thrombosis of a blood vessel prosthesis using the anti-aggregation drug ticlid].
Topics: Blood Vessel Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thrombosis; Ti | 1985 |